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NG2 cells are regarded as the fourth major type of glial cells in the central 
nervous system (CNS), besides astrocytes, microglia and oligodendrocytes. 
They were previously considered as oligodendrocyte progenitor cells (OPCs) 
and can differentiate into oligodendrocytes and help axon regeneration in 
demyelination diseases. However, the NG2 cells are present with substantial 
quantity and evenly distributed in the brain parenchyma. In addition, active 
responses of NG2 cells have been observed in pathological conditions. These 
observations suggest that NG2 cells may not act only as OPCs. NG2 cells in 
the adult CNS may have other functions which are yet to be elucidated. 
Therefore, the aims of this study were to investigate the responses of NG2 
cells and their possible functions under the inflammation condition. In 
addition, the potential mechanism of how NG2 cells become activated was 
also investigated. 
In the current study, a neuroinflammatory model was established by 
intracerebral injection of lipopolysaccharide (LPS). Results showed that after 
focal injection of LPS (10µl, 1mg/ml) into the Sprague-Dawley rats, NG2
+
 
cells became rapidly activated at 1 day, 3 and 5 days. Firstly, NG2
+
 cells 
presented morphological changes. The cell bodies became larger and the cell 
processes thicker and shorter. Secondly, the number of NG2
+
 cells gradually 
increased at the injury site, but, BrdU proliferation analysis showed that hardly 
any NG2
+ 




 cells appeared and 
gradually increased in numbers. The results suggested that some microglia 
were induced to express NG2 protein, which may contribute to the increase in 
the number of NG2
+
 cells. Therefore, it would be more scientifically proper to 
use NG2 expressing cells in the CNS to describe the NG2
+
 cells, which are in 









 cells), i.e., 
NG2 positive microglia or induced NG2 microglia.  
Since the reaction pattern of NG2 expressing cells in response to 
neuroinflammation were similar to microglia, the functions of NG2 expressing 
cells were investigated from two aspects: phagocytosis and cytokine-
 ii 
 
chemokine expression. The phagocytic capability of NG2 expressing cells was 
investigated by injection of latex beads at the same site of LPS injection. The 




 macrophages at different time points after LPS injection. 
However, no NG2
+
 cells engulfed latex beads, suggesting that neither 
constitutive NG2 cells nor induced NG2 microglia play a phagocytic role in 
response to neuroinflammatory stimulation. In other words, although it is not 




) are the same in function as 









activated microglia did turn off their phagocytic function when they were 
induced to express NG2 proteins.   





 cells expressed IL-1β at 3 days after LPS injection, 
but not IL-6, IL-10, and lix even at other different time points. Therefore, NG2 
expressing cells were different in cytokine expression in comparison to 
microglia. Based on cell morphologies, only NG2
+
 cells with an amoeboid 
phenotype but not those NG2
+
 cells with multiple branches were positive to 
the anti-IL-1β antibody, suggesting that activated NG2+ cells themselves 
might function differentially in the cytokine network in the brain immunity 





 cells presented an amoeboid morphology, some activated 
microglia might alter their function in cytokine expression when they were 
induced to express NG2 proteins.   
In addition to exploration of functions of NG2 expressing cells, the 
mechanism of their activation was also investigated in the current study. 
Results showed that after application of minocycline, a potent inhibitor for 
microglial activation, responses of NG2 expressing cells were attenuated, 
evident as retardation in change in cell morphology and increase in NG2
+
 cell 
number. Therefore, the current result as well as anti-CD11b antibody blocking 
activation of NG2 expressing cells previously observed in this lab suggests 
that the activation of NG2 expressing cells may be an event downstream to 
microglial activation in the neuroinflammatory model. 
 iii 
 
Although exact function of NG2 expressing cells in the brain remains to be 
elucidated, the alteration in NG2 expression in neuroinflammation at least 
reflects certain cellular functional modification during neuropathogenesis. The 
current study showed that a direct exogenous injection of TGF-β1 led to a 
profound increase in the number of NG2 expressing cells compared with LPS 
treatment. Additionally, TGF-β1 induced an earlier induction of NG2 protein 





 cells. These responses of NG2 expressing cells to TGF-β1 were 
inhibited using neutralized TGF-β1 antibody through the Smad2/3 signalling 
pathway. For these reasons, the activation of NG2 expressing cells may be 
concluded as an event downstream to microglial activation which may be 
mediated by TGF-β1 secreted from activated microglia in the 
neuroinflammatory model. 
In conclusion, the findings in this study have extended current knowledge 
about NG2 expressing cells. In response to neuroinflammation, reactive 
microglia might release TGF-β1 to activate constitutive NG2 cells and at the 
same time to induce expression of NG2 protein in some microglia, resulting in  
activated NG2 expressing cells presenting changes in morphology, increase in 
number, and differential expression in certain cytokines. While gaining NG2 
proteins, activated microglia could eventually lose their phagocytic capability. 
This gaining-losing phenomenon could eventually hint at the possibility, 
through an alteration of non-neuronal cell function, to modify the cell niche to 





 cells might therefore be a new therapeutic target in treatment of 
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Inflammation is a type of tissue response to various harmful stimuli, such as 
pathogens, damaged cells, or irritants. In the CNS, inflammation could be 
involved in both acute neurodegenerative conditions, including cerebral 
ischaemia and traumatic brain injury, and chronic neurodegenerative diseases 
such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). As the major 
non-neuronal cells in the CNS, glial cells play an active role in various 
neuropathologies. The glial cells, generating a lot of inflammatory mediators 
including pro-inflammatory and anti-inflammatory cytokines, complement 
proteins, neurotrophins and growth factors, could mediate inflammatory 
responses in the brain and may serve protective or destructive roles for their 
surrounding neurons (Raivich et al. 1999). Therefore, exploring the functions 
of glial cells may be of significant importance in understanding 
neuropathogenesis and discovering effective therapeutic intervention for 
various CNS injuries and diseases. 
In the adult CNS, it was conventionally thought there were four types of glial 
cells, namely astrocytes, microglia, oligodendrocytes, and ependymal cells. 
Under pathological conditions, microglia and astrocytes are the non-neuronal 
cells to actively respond to pathological stimuli. Microglia as the “macrophage” 
in the CNS are the first one to show reactive responses and the major cell to be 
implicated in the inflammation (Nakamura 2002). They become activated and 
rapidly show alterations in many aspects:  the size of cell bodies increases, cell 
processes become shorter, morphology transforms from ramified resting into 
amoeboid shape and numerous inflammatory molecules such as cytokines are 
released (Hanisch 2002). If there is any cell death, a further transformation 
into phagocytic cells occurs, which remove cellular debris, entering the state 
of phagocytosis (Moller et al. 1996; Streit and Kreutzberg 1988). Another glial 
cell type, astrocytes could also release neurotrophic factors, cytokines and 
nitric oxide which further influence the neurons (Chen and Swanson 2003). 
However, the activated astrocytes may be harmful because they may increase 
the expression of glial fibrillary acidic protein (GFAP) to form glial scars, 
which prohibit axonal regeneration. 
In addition to these traditional glial cells in the brain, in early 1980’s, a new 





which was not co-stained with markers of microglia, astrocytes and 
oligodendrocytes in normal brain, indicating that the NG2 cells belong to a 
distinct cell type (Nishiyama et al. 2009; Peters 2004). They make up 5-10% 
of all glial cells and are ubiquitously distributed in the gray and white matter 
(Horner et al. 2002). Several receptors have been found on NG2 cells such as 
2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) 
subtype of glutamate receptor, γ-aminobutyric acid (GABA) receptor (Trotter 
et al. 2010) and platelet-derived growth factor α receptor (PDGFαR) (Horner 
et al. 2002). The NG2 cells become activated under pathological conditions 
and their responses are similar to the immune responses of microglia (Wang 
and He 2009). Although many studies have been carried out on NG2 cells, 
their functions are still not clear at present and debatable. Therefore, 
investigating functions of NG2 cells under the brain inflammation is important 
to gain more knowledge on NG2 cells and it may possibly provide a new 
direction in the CNS disease therapy. 
In the subsequent sections, some background information about glial cells will 
be reviewed, then basic knowledge about NG2 cells will be introduced and 
their possible functions in several aspects including remyelination, axonal 
growth, interaction with neurons and neuroinflammation will be discussed in 
detail. 
1.1 Neuroinflammation 
Inflammation, the reaction of living tissues to various harmful stimulations, 
can be classified as either acute or chronic inflammation. Acute inflammation 
causes an immediate and early response to harmful stimuli and is a basic 
defensive response. Chronic inflammation means long-term inflammation and 
can be persistent for several weeks or months (Streit et al. 2004). In peripheral 
tissues, inflammation normally shows classic features such as swelling, 
redness, body temperature increase and often accompanied by pain. Given 
more mechanistic definitions, inflammation includes invasion of circulating 
immune cells from blood and production of inflammatory mediators. In the 
CNS, the brain was regarded as an “immune privileged” organ and not 





However, more studies have reported that the brain respond to infections or 
inflammation through innate immune responses and adaptive immune 
responses (Bailey et al. 2006). The responses of the brain differ from the 
peripheral tissues. Thus, the term neuroinflammation was used to define the 
inflammation occurring in the brain, which has typical characteristics 
including synthesis of inflammatory mediators, complement activation, major 
histocompatibility complex (MHC) expression, invasion of immune cells and 
activation of local glial cells (Lucas et al. 2006).  
1.1.1 Acute neuroinflammation 
Acute neuroinflammation is usually seen in acute CNS injuries including 
cerebral ischaemia, brain trauma and epilepsy. In acute neuroinflammation, 
microglia and astrocytes respond rapidly and secrete inflammatory mediators 
to mediate the development of neuropathogenesis. The most common 
inflammatory mediators which play a role in acute CNS injuries and diseases 
are TNF-α, IL-1β, IL-6, complement system and free radicals 
Tumour necrosis factor-α (TNF-α) is commonly considered as a pro-
inflammatory cytokine which promotes the inflammation process during the 
acute phase of CNS inflammation. However, it may have both protective and 
harmful effects on neurons depending on the TNF-signalling pathway 
mediated by its two receptors TNFRI or TNFRII (Fontaine et al. 2002; Yang 
et al. 2002). TNFRII plays a neuroprotective role upon injuries (Shen et al. 
1997; Veroni et al. 2010). However, activation of TNFRI may initiate signals 
resulting in the apoptosis process (Camelo et al. 2000; Condorelli et al. 2000). 
Interleukin-1β (IL-1β) is also regarded as a pro-inflammatory cytokine and has 
neurotoxic effects. In a traumatic brain injury model, cerebral edema and 
tissue loss were reduced through administration of a neutralising anti-IL-1β 
antibody (Clausen et al. 2011). Unlike TNF-α and IL-1β, IL-6 is more likely to 
be beneficial to CNS cells. In an experimental ischaemic model, injection of 
IL-6 was demonstrated to reduce the ischaemic damage and inhibit neuronal 
death (Matsuda et al. 1996). The complement system is composed of about 30 
fluid-phase and cell membrane associated small proteins. Activation of 





mediators and enhance the tissue injury (Mollnes and Fosse 1994; Mollnes et 
al. 2002). Nitric oxide (NO) is an important free radical to influence survival 
of neurons. NO is generated by three nitric oxide synthase (NOS) enzymes: 
endothelial NOS, neuronal NOS and inducible NOS. During ischaemic 
damage, NO produced by endothelial NOS is protective, while NO produced 
by neuronal NOS and iNOS is harmful (Parmentier et al. 1999).  
1.1.2 Chronic neuroinflammation 
Chronic neuroinflammation is usually observed in chronic CNS diseases 
including Multiple sclerosis (MS), AD, PD and other chronic conditions. It is 
more complex than the acute injuries. The development and progression of the 
diseases are influenced by multifactors such as aging, environmental factors 
and genetic background (Campbell 2004). Many inflammatory mediators are 
expressed in chronic neuroinflammation and thus influence the progression of 
the diseases. MS is characterised by damage of myelin sheaths surrounding 
axons and loss of neuronal functions because of the invasion and activation of 
T cells and macrophages to the CNS. Many inflammatory mediators are 
involved in MS. In experimental allergic encephalomyelitis (EAE), an 
autoimmune animal model of MS, anti-inflammatory cytokines such as IL-10 
(Rott et al. 1994) or TGF-β1 (Stevens et al. 1994) are shown to inhibit or 
prevent EAE. In addition, neutralization of TNF-α with antibodies (Selmaj et 
al. 1991a) and neutralization of IL-1 with soluble receptors (Jacobs et al. 1991) 
could also suppress EAE. AD is characterized by the progressive failure to 
form new memories and access to the existing ones because of the neuronal 
damage in the hippocampus and amygdala. The hallmark of this disease is 
accumulation of amyloid plaques and neurofibrillary tangles which are not 
only toxic to neurons (Yankner 1989; Yankner et al. 1990), but also can lead 
to neuronal damage through neurotoxins released by activated microglia 
(Combs et al. 2000; Qin et al. 2002). 
It is clear that in either acute or chronic neuroinflammation, glial cells will 





1.2 Glial cells in the central nervous system 
In the CNS, glial cells are traditionally described as of the following four types: 
microglia, astrocytes, oligodendrocytes and ependymal cells. Recently, in the 
past thirty years, a new population of non-neuronal cells, NG2 cells, came into 
sight as another distinct type of glial cells in the CNS (Krawczyk and 
Jaworska-Adamu 2010; Peters 2004). They are ubiquitously distributed in the 
brain grey and white matter (Dawson et al. 2003; Trotter et al. 2010). In the 
adult brain, NG2 cells have been morphologically characterized by multi-
branched processes with small cell bodies and do not overlap with other glial 
cell markers (Wang and He 2009). Therefore, NG2 cells have been regarded 
as a distinct type of glial cells in the CNS. 
1.2.1 Microglia 
Microglia compose 10–20% of the total glial population in the CNS. They are 
the first and main form of active immune defence in the CNS. These cells are 
widely accepted to be bone marrow derived monocyte-lineaged cells which 
infiltrate into the brain parenchyma during early embryonic stage and then 
develop along with brain maturation (Cuadros and Navascues 1998). They are 
functionally related to peripheral tissue macrophages and other cells of the 
monocyte lineage. However, they are distinct from those tissue macrophages 
because of their relatively quiescent phenotype and tight regulation by the 
CNS microenvironment. 
In the normal adult brain, microglia are in ramified phenotype, which has 
many fine perpendicular processes extending from a few long prolongations. 
They serve as sensor cells in the brain which detect abnormalities or changes 
in the environment of the brain (Kreutzberg 1996). When the brain is injured, 
affected by infections, or suffering from certain diseases, microglia 
morphologically transform from ramified shape into amoeboid phenotype with 
retracted processes and enlarged cell bodies. They may also increase in cell 
number at the affected site. After activation, microglia express many protein 
mediators including pro-inflammatory cytokines like TNF-α and IL-1β, anti-





chemokines, growth factors, reactive oxygen and nitrogen species, lipid 
mediators and other factors (Nakajima and Kohsaka 2004). They may also 
migrate to the impaired region and phagocytose cell debris if cell death occurs. 
In this active state, microglia can either exert damaging effects or protective 
effects on neighbouring cells through production of cytokines and trophic 
factors. The neurotoxic activity of microglia has been demonstrated in Chao’s 
study that activated microglia reduce the neuronal cell survival in the co-
culture system (Chao et al. 1992). In addition, activated microglia may also 
lead to death of oligodendrocytes (Merrill and Zimmerman 1991). However, 
microglia may have neuroprotective role through elimination of glutamate 
(Lopez-Redondo et al. 2000) and secretion of neurotrophic molecules like 
TGF-β1 at the axotomized facial nucleus (Kiefer et al. 1993). Therefore, 
microglial cells, as immune cells in the brain may secrete both neuroprotective 
and neurotoxic molecules. It is important to balance its effect during brain 
injuries or diseases. 
1.2.2 Astrocytes 
Astrocytes are the most numerous glial cell type in the CNS and are estimated 
to comprise about 20-25% or even up to 50% of total cells in some brain areas 
(Hansson 1988; Montgomery 1994). They derive their name from their star-
like appearance. Expression of GFAP, the major protein of astrocyte 
intermediate filaments, is commonly used as a specific antigen marker for the 
immunohistochemical identification of astrocytes (Norton et al. 1992). In the 
CNS, there are two types of astrocytes: fibrous and protoplasmic types 
according to the differences in their cellular morphologies and anatomical 
locations (Newlands et al. 1984). The fibrous astrocytes are usually located in 
the white matter with relatively few organelles but long unbranched cellular 
processes. The protoplasmic astrocytes are found in the grey matter with a 
larger quantity of organelles and many finely branched tertiary processes 
(Sofroniew and Vinters 2010). Both astrocyte subtypes make extensive 
contacts with blood vessels and are one of the components of the blood brain 





and Bergmann glia in the cerebellum, which appear similar to the 
protoplasmic astrocytes in the antigenic phenotype (Barres 2008).  
In the normal CNS, astrocytes perform several functions: providing nutrition 





buffering and water transport; recycling neurotransmitter substance including 
glutamate uptake and glutamate release (Kimelberg and Nedergaard 2010).  
During the developmental stage, astrocytes are found to form the molecular 
boundaries to guide the migration of developing axons (Powell and Geller 
1999). In addition, astrocytes are essential for the formation and function of 
developing synapse. Christopherson et al. (2005) reported that astrocytes 
release a large matrix-associated protein called thrombospondin, which 
induces synaptogenesis (Christopherson et al. 2005).  
Astrocytes make extensive contacts with blood vessels and are especially 
important in formation of the blood brain barrier and contribute to the 
regulation of the local CNS blood flow. Studies have shown that they produce 
and release many molecular mediators such as prostaglandins (PGE) and NO 
to regulate the blood flow (Gordon et al. 2007; Iadecola and Nedergaard 2007). 
In response to CNS injuries like trauma, ischemia, infection or other 
neurodegenerative diseases, reactive astrogliosis may occur. Although reactive 
astrogliosis is beneficial in that it encapsulates infections and seals a damaged 
blood brain barrier, it may be harmful in other ways such as increasing the 
expression of GFAP to form glial scars, which prohibit severed CNS axonal 
regeneration (Silver and Miller 2004). In addition to formation of glia scar, 
they may also release trophic factors, cytokines and nitric oxide which further 
influence neurons (Chen and Swanson 2003).  
1.2.3 Oligodendrocytes 
Oligodendrocytes arise from the OPCs during development. After birth, the 
OPCs migrate from the ventricular zone and develop into oligodendrocytes 
through a series of intermediate steps: at the beginning OPCs express A2B5 





subsequently enter into pro-oligodendrocyte stage to express the immature 
oligodendrocyte antigen O4 but gradually lose expression of NG2 and 
PDGFαR (Bansal and Pfeiffer 1992; Pfeiffer et al. 1993), followed by 
galactocerebroside (GalC) expression and finally myelin basic protein (MBP) 
to become mature oligodendrocytes (Nishiyama et al. 2009). 
The oligodendrocytes present in the CNS are divided into two phenotypes: 
myelinating and nonmyelinating oligodendrocytes, both functionally 
interlocked with neurons (Szuchet et al. 2001). Myelinating cells associate 
with axons and ensheathe them with myelin, which is composed of 80% lipid 
and 20% protein and belongs to an electrically insulting material. Axons were 
organized into segments surrounded by the myelin, separated by bare regions 
named nodes of Ranvier (Poliak and Peles 2003). Myelination enables 
saltatory propagation of action potentials occurring at the node of Ranvier, 
thus increases transmission speed of impulses. Nonmyelinating 
oligodendrocytes adhere either to the neuronal somata or blood vessels 
(Szuchet et al. 2001).  
The main function of oligodendrocytes is to provide physical support to 
neurons, ensheathe neuronal process to form myelinated axons and replace 
myelin when parts of the myelin sheath are lost (Baumann and Pham-Dinh 
2001). However, in MS, oligodendrocytes are destroyed thus leading to the 
compromising of repair process. 
1.2.4 Ependymal cells 
Ependyma is a thin epithelial membrane lining ventricles of  the brain and the 
central canal of the spinal cord, extending from lateral ventricles to the filum 
terminale (Del Bigio 2010). It is composed of ependymal cells, which is a type 
of glial cells in the CNS. Morphologically, ependymal cells are in a cuboidal 
to columnar shape with a round nucleus and inconspicuous nucleolus and 
covered in a layer of cilia. In brain ventricles, a subpopulation of modified 
ependymal cells together with capillaries forms the choroid plexus, which 






1.2.5 NG2 cells 
NG2 cells, firstly reported in the 1980’s, are regarded as a distinct type of glial 
cells in the CNS. They compose 5-8% of all cells in the adult CNS and can be 
identified by the antibody against a chondroitin sulfate proteoglycan (CSPG) 
named NG2, and are evenly distributed in the grey and white matter (Dawson 
et al. 2003; Trotter et al. 2010). However, the properties of NG2 cells are not 
fully studied and their functions in the CNS still remain to be elucidated.  
In the following section, more current knowledge about the NG2 protein and 
NG2 cell behaviour and their possible functions will be reviewed. 
1.3 Biology of NG2 cells 
1.3.1 NG2 protein  
NG2 derives its name from the rat species (Nishiyama et al. 1991; Stallcup 
1981). Its homologues have been discovered in human as melanoma 
chondroitin sulfate proteoglycan-CSPG4 (Harper et al. 1984), in mouse as 
AN2 (Schneider et al. 2001; Stegmuller et al. 2002), in Drosophila as 
CG10275 and in Caenorhabditis elegans (C.elegans) as C48E7.6.P (Celniker 
et al. 2002). The high level of conservation suggests that NG2 may mediate 
important cellular functions. 
1.3.1.1 The antigen marker for the cell type 
NG2 protein is an antigen marker to label NG2 cells. It belongs to the CSPG 
family. NG2 was first identified as a cell surface antigen of neural tumor-
derived cell lines with glial and neuronal properties (Wilson et al. 1981). 
Firstly, Stallcup and cohn (1976) classified the neural tumor-derived cell line 





conductance. The antisera was then raised in the rabbit by injection of whole 
cells either from neuron-like (N) cell or glia-like (G) cell group (Stallcup and 
Cohn 1976). After absorption of neuron-like cell antiserum with glia-like cell 
groups and vice versa, neuron-specific surface antigen N1, N2 and N3 and 
glia-specific surface antigen G1 and G2 were identified. Wilson et al. (1981) 





glial properties (Wilson et al. 1981). Identification of NG2 as a CSPG was 
reported in the subsequent study showing NG2 was composed of a well-
defined 300kDa band and a high molecular weight (MW) smear (Stallcup et al. 
1983). The primary structure of the NG2 including complete cDNA and 
primary amino acid sequences was then established by Nishiyama’s lab 
(Nishiyama et al. 1991).  
1.3.1.2 The structure and distribution of NG2 protein 
NG2 is a transmembrane protein with a large extracellular N-terminal domain 
containing disulfide bridges and an intracellular C-terminal PDZ binding motif 
(Stallcup 2002).  It is encoded by a single gene with multiple exons coding for 
2327 amino acids (330 kDa). The ectodomain (2,224 amino acids) is further 
divided into three subdomains. Domain 1 contains two LNC-domains 
(Laminin-Neurexin-Sex Hormone binding globulin) in the extreme N-terminal, 
which is stabilized in a globular conformation by intramolecular disulfide 
bonding. The central domain 2 contains both the type V and VI collagen-
binding site (Burg et al. 1997; Tillet et al. 1997) and a single chondroitin 
sulfate chain at serine-999 (Nishiyama et al. 1991; Stallcup and Dahlin-Huppe 
2001). Domain 3 contains sites for proteolytic cleavage (Nishiyama et al. 1995) 
near the transmembrane domain (25 amino acids). The intracellular domain 
(76 amino acids) is shorter compared with the outside part. It includes a C-
terminal type I PDZ (Postsynaptic density 95/Discs Large/Zonula-occludens-1) 
recognition motif, a proline-rich segment and several potential sites for 
threonine phosphorylation. The interactions of NG2 with extracellular and 
intracellular ligands may play an important role in both cell proliferation and 







Figure 1.1 Structure of NG2 protein  
The NG2 protein is a transmembrane protein with two LNS-domains at the 
end of N-terminal, a collagen binding domain, a chondroitin sulfate chain, a 
short transmembrane domain and a small C-terminal PDZ binding motif. This 
figure is modified from Trotter J (2010). Brain Res Rev 63(1-2):72-82. 
 
In the mouse CNS, NG2 homolog AN2 expression begins at embryonic day 
(E)13/E14, peaks between postnatal day (P) 8 to 12 and gradually decreases 
thereafter (Niehaus et al. 1999). NG2 is mainly expressed in oligodendrocyte 
progenitor cells and pericytes in the developing CNS. A subpopulation of NG2 
cells is present in the adult brain, which is a distinct population with a 
phenotype different from OPCs (Karram et al. 2005). In the peripheral nervous 
system (PNS), the mouse NG2 homolog AN2 is present on immature Schwann 
cells (Schneider et al. 2001) and fibroblast-like cells (Morgenstern et al. 2003). 
Outside the nervous system, NG2 is expressed in many immature cell types 
including developing mesenchymal cells in cartilage, immature smooth 
muscle cells, pericytes in the developing vasculature, epidermal stem cells and 





1.3.1.3 Protein interactions of NG2  
Several extracellular partners of NG2 have been identified. Those are 
extracellular matrix components including collagen type V and VI, growth 
factors such as platelet-derived growth factor (PDGF) and basic fibroblast 
growth factor (bFGF) (Goretzki et al. 1999), Membrane-Type-3 Matrix 
Metalloproteinase (MT3-MMP), Plasminogen, galectin 3 and platelet-derived 
growth factor alpha receptor (PDGFαR) (Trotter et al. 2010). In these 
extracellular partners, the interaction among PDGF, PDGFαR and NG2 is 
important to influence the proliferation ability of NG2 cells. Nishiyama et al. 
(1996b) showed that blocking of NG2 with anti-NG2 antibody could both 
reduce the expression of PDGFαR and inhibit the proliferation of OPCs in 
response to PDGF treatment. Since the complex formed by the NG2 and 
PDGFαR was confirmed by the co-immunoprecipitation, it is possible to 
assume that the interaction between NG2 and PDGFαR may lead to OPCs 
responding effectively to the mitogenic stimulus of PDGF (Nishiyama et al. 
1996b). Similarly, Kucharova and stallcup (2010) demonstrated that NG2 
proteoglycan could promote proliferation of OPCs (Kucharova and Stallcup 
2010). In their study, the number of OPCs decreased in the developing white 
matter of NG2 null mouse compared with the wild type, because of the 
downregulation in proliferation of OPCs attributed to the impairment of PDGF 
and bFGF signalling in the NG2 null mouse (Kucharova and Stallcup 2010). 
As a whole, the above studies have shown that the NG2 protein could play a 
role in regulation of cell proliferation.  
Besides the extracellular partners of NG2 protein, several binding partners of 
the intracellular C-terminal PDZ domain-binding motif, Multi-PDZ Domain-
binding motif (MUPP1), Glutamate receptor interaction protein (GRIP) and 
syntenin-1 have also been reported (Barritt et al. 2000; Chatterjee et al. 2008; 
Stegmuller et al. 2003). MUPP1 is a protein with 13 PDZ modules, interacting 
with NG2, and may possibly serve as a multivalent scaffold to link NG2 with 
key structural and/or signalling components in the cytoplasm (Barritt et al. 
2000). However, the functional importance is yet to be determined. The latter 
two intracellular partners, GRIP and syntenin-1, are found to regulate the 





al. 2010). First, GRIP could form a complex with AMPA receptors and NG2 
on the surface of NG2 cells (Stegmuller et al. 2003). When glutamate is 
released by neighbouring neurons, it is possible that NG2 could cluster glial 
AMPA receptors towards the site of neuronal glutamate release through the 
interaction with GRIP (Bergles et al. 2000). It has been found that glutamate 
increases the activation of AMPA receptors expressed on NG2 cells (Hamilton 
et al. 2009). This may imply synapse communication between NG2 cells and 
neurons (Trotter et al. 2010). In addition, the interaction between syntenin-1 
and NG2 protein can influence the migration of NG2 cells to axons prior to 
myelination. In Chatterjee’s study, the association of syntenin-1 and NG2 was 
first verified by immunostaining and co-immunoprecipitation studies and then 
the formed complex by syntenin-1 and NG2 was further proved by co-capping 
assay. Subsequently, downregulation of syntenin-1 in NG2 cells resulted in 
reduction of their migration ability as the same effect as anti-NG2 blockage. 
This study suggests that the migration of NG2 cells is mediated through the 
interaction between syntenin-1 and NG2 (Chatterjee et al. 2008).  
1.3.2 Identification of NG2 cells  
1.3.2.1 Morphology of NG2 cells 
NG2 cells can be characterised by immunohistochemistry study using anti-
NG2 antibody. The morphology of NG2 cells is different between the 
immature CNS and adult CNS. 
In the developing CNS, they are regarded as OPCs which are small rounded 
cells displaying bipolar or tripolar morphology (Chen et al. 2007). In the 
presence of growth factors, PDGF and bFGF, OPCs are maintained at the 
progenitor stage and do not differentiate into oligodendrocytes with a complex 
network of processes (McKinnon et al. 1993). 
In the adult CNS, morphologies of NG2 cells may vary from region to region 
in the CNS, depending on the distinct cytoarchitectural properties of the brain 
region (Dawson et al. 2003). In the grey matter, such as cerebral cortex and 
hippocampus, NG2 cells are in a stellate morphology with many long and fine 





cells bodies. This structure may be helpful in the communication between 
NG2 cells and neurons. In the white matter such as corpus callosum, NG2 
cells have elongated cell bodies and long processes parallel to the myelinated 
axons. Therefore, NG2 cells in the normal adult brain are morphologically 
different from OPCs in the immature state. 
1.3.2.2 NG2 cells in the developing central nervous system 
In the rat CNS, NG2 cells are first found in the developing ventral spinal cord 
adjacent to the floor plate at E14 and appear in the hindbrain and within the 
basal forebrain by E16 and E17 (Nishiyama et al. 1996a). NG2 cells reach to 
the maximum quantity in the cerebral cortex at P3, cerebellum at P10 and in 
the spinal cord before birth. The distribution and number of NG2 cells were 
quite similar to the PDGFαR mRNA expressing cells (Pringle et al. 1992). 
From E17 to adulthood, the co-expression of NG2 and PDGFαR has been 
observed, suggesting the role of NG2 cells as OPCs (Nishiyama et al. 1996a).  
During the developmental stage, NG2 cells have a precursor nature, which 
retain the ability to divide. The first indication that NG2 cells might be OPCs 
came from Stallcup’s lab. They found that NG2 was expressed in 
oligodendrocyte-type-2 astrocyte (O-2A) cells, which differentiated into 
astrocytes in the presence of serum and became GalC
+
 oligodendrocytes in 
serum-free defined medium (Levine and Stallcup 1987; Stallcup and Beasley 
1987). Subsequent studies revealed that the temporal and spatial distribution 
of NG2 cells were more closely matched to the developing oligodendrocytes 
rather than astrocytes, suggesting the role of NG2 cells as OPCs (Fulton et al. 
1992; LeVine and Goldman 1988). Further in vivo experiment has shown that 
NG2 cells expressed PDGFαR, which is an accepted marker of OPCs 
(Nishiyama et al. 1996a). Therefore, these findings strongly suggest that NG2 
cells belong to oligodendroglial progenitors during the development stage.  
1.3.2.3 NG2 cells in the mature central nervous system 
In the adult CNS, NG2 cell has a highly complex morphology with an 
irregularly shaped cell body and multiple fine and long processes and could 





From the immunohistochemistry study, NG2 cells do not express other glial 
cell markers, for instance, OX42 for microglia, GFAP for astrocytes and 2', 3'-
Cyclic-nucleotide 3'-phosphodiesterase (CNPase) for oligodendrocytes in the 
normal physiological condition. Therefore, NG2 cells are antigenically 
different from other glial cells in the normal adult CNS.  
In the normal adult CNS, a small subpopulation of NG2 cells still expresses 
PDGFαR (Stelzer et al. 2010; Wilson et al. 2006) and retains the ability of 
proliferation at a low level, suggesting some of these NG2 cells may still 
belong to OPCs. However, NG2 cells differ from the cells at the 
developmental stage in many properties as morphology, migration and cell-
cycle length (Wolswijk and Noble 1989; Wolswijk et al. 1990). In addition, 
NG2 cells closely contact neurons at synapses (Bergles et al. 2000; Lin and 
Bergles 2004) and nodes of Ranvier (Butt et al. 1999; Butt et al. 2002). In 
some brain injury models or diseases, NG2 cells are shown to change cell 
morphology, upregulate NG2 protein expression and increase cell number 
(Dehn et al. 2006; Jones et al. 2002).  
All of these properties suggest that the function of NG2 cells in the adult CNS 
seems to be different from the developing CNS. They belong to a 
heterogeneous population with a subpopulation of cells functioning as OPCs 
and other cells with undefined roles at the adult stage (Bouslama-Oueghlani et 
al. 2005; Keirstead et al. 1998; Nishiyama et al. 2002) . 
1.3.3 The function of NG2 cells 
Due to the complex properties, the exact function of NG2 cells in the adult 
CNS is still not clear. Only several features of the cells have been reported so 
far. Firstly, they are evenly distributed in the grey and white matter (Dawson 
et al. 2003; Trotter et al. 2010). Secondly, they are the major cycling cells 
within the adult CNS (Dawson et al. 2000; Horner et al. 2002). Thirdly, they 
closely contact with neuronal cell bodies and dendrites (Butt et al. 2005). 
Fourthly, they form synapses with neurons and receive synaptic input from 
neurons (Bergles et al. 2000; Lin and Bergles 2004). Lastly and interestingly, 





2008b; Kitamura et al. 2010; Tanaka et al. 2001). At present, most studies are 
carried out from several aspects to investigate the functions of NG2 cells: 
oligodendrocyte lineage, myelinated disease, axonal growth, synapse with 
neurons and neuroinflammation conditions. 
1.3.3.1 NG2 cells may not only serve as oligodendrocyte progenitor cell in 
the adult central nervous system 
At the beginning, NG2 cells were regarded as OPCs in the CNS as they could 
differentiate into oligodendrocytes. Stallcup and colleagues (1987) 
demonstrated that NG2 protein was expressed in A2B5
+
 precursor cells 
(Levine and Stallcup 1987; Stallcup and Beasley 1987). After differentiation, 
these precursor cells lost NG2 expression and began to express the antigens of 
mature oligodendrocytes. Since the differentiation process of A2B5
+ 
precursor 
cells was similar with the OPCs, NG2 cells were regarded as OPCs in their 
view. Subsequently, the above finding was further supported by the 
observance of co-expression of NG2 protein and PDGFαR, a marker for OPC 
in the developing CNS (Nishiyama et al. 1996a; Pringle and Richardson 1993). 
However, the view of NG2 cells as OPCs in the adult brain is questionable. 
Firstly, the morphology of NG2 cells is highly complex, which cannot be 
easily classified as oligodendrocyte progenitor cells (Reynolds and Hardy 
1997). Secondly, in the adult brain, only a subpopulation of NG2 cells still 
expresses the OPC marker PDGFαR (Stelzer et al. 2010; Wilson et al. 2006). 
Thirdly, NG2 cells in the normal adult CNS do not overlap with any 
expression of markers known to be specific for other glial cell types (Dawson 
et al. 2000), suggesting that they are a unique type of glial cells in the adult 
brain. Therefore, NG2 cells cannot be merely considered as the OPCs in the 
adult brain and NG2 cells may possess other roles in the normal as well as 
pathological brain.  
1.3.3.2 The role of NG2 cells in remyelination 
Demyelination describes the loss of myelin from axons. It may be resulted 
from either damage of myelin sheath itself or myelin generated cells as 
oligodendrocytes in the CNS  (Love 2006). Since oligodendrocytes play an 





oligodendrocytes within a region of demyelination are able to divide and play 
a role in the remyelination. However, many independent studies showed that 
surviving oligodendrocytes did not contribute to remyelination because of 
extremely low proliferation ability (Carroll et al. 1998; Keirstead and 
Blakemore 1997; Redwine and Armstrong 1998). Therefore, it is unlikely that 
oligodendrocytes play a major role in the repair of demyelinated lesions.  
At present, the consensus function of NG2 cells is that they contribute to 
myelin maintenance and generation of new oligodendrocytes following 
demyelination (Reynolds et al. 2002; Watanabe et al. 2002). In the normal 
adult CNS, NG2 cells retain the proliferation ability as in the development 
period but the proliferation is slow at this stage (Horner et al. 2000; Levine et 
al. 1993). However, enhanced proliferation could be observed in experimental 
demyelination diseases such as genetic myelination defects (Wu et al. 2000) as 
well as other types of chemically and immunologically induced demyelination 
lesions (Keirstead et al. 1998; Watanabe et al. 2002). Since NG2 cells retain 
their proliferative ability in the adult CNS and could proliferate in response to 
a variety of pathological conditions, it is reasonable to make connection 
between NG2 cells and oligodendrocytes. It is of great potential that NG2 cells 
play a major role in remyelination according to differentiation into 
oligodendrocytes. This view has been demonstrated by many studies. 
Watanabe et al. (2002) established a chemically induced demyelination lesion 





cells were proliferating and exclusively located at the 
periphery of the lesion site, while subsequently migrated into the lesion centre. 






gradually decreased with time, concomitant 
with the appearance of BrdU
+
 oligodendrocytes (Watanabe et al. 2002). 
Reynolds et al. (2002) demonstrated NG2 cells responded to demyelination, 
showed by the reactive responses and increase in cell number. In addition, 
CNPase, the oligodendrocyte marker, began to be expressed on NG2 cells in 
the lesion area (Reynolds et al. 2002). Therefore, it suggests that NG2 cells 
may play a role in demyelination diseases. 
In MS, the repeated episodes of myelin destruction eventually result in the 





differentiate into oligodendrocytes during the remyelination stage, it is useful 
if the mechanism of controlling the differentiation process of NG2 cells is 
known. Although the signals that stimulate NG2 cells to re-enter the cell cycle 
following demyelination is not clear at present, several possibilities have been 
suggested. Firstly, the rapid proliferative responses of NG2 cells are only 
observed when inflammation is accompanied by demyelination or more 
substantial tissue destruction, whilst signals from inflammation cells such as 
astrocytes and microglia/macrophages alone are not sufficient to stimulate 
them to re-enter the cell cycle (Di Bello et al. 1999). In addition, it is also 
possible that the proliferation of NG2 cells is initiated by signaling from the 
exposed axon or tissue debris (Franklin 2002). Therefore, the stimulation of 
proliferation of NG2 cells is possibly initiated by a combination of signals 
from the demyelinated axons, reactive astrocytes and microglia/ macrophages.  
1.3.3.3 The role of NG2 cells in axonal growth 
Many CSPGs are known to inhibit the growth of axons (Bovolenta and 
Fernaud-Espinosa 2000). The NG2 protein is composed of a core glycoprotein 
of 300kDa and a single chondroitin sulfate chain, which belongs to the family 
of CSPG (Nishiyama et al. 1991; Stallcup 2002). Therefore, the question of 
whether NG2 protein also inhibits axonal growth is raised here. A series of 
studies have proved that purified NG2 is inhibitory to growing axons (Dou and 
Levine 1994; Ughrin et al. 2003). Dou and Levine (1994) has found that 
neurons did not attach to the NG2-coated surface unless adhesive molecules 
such poly-L-lysine and laminin were employed together and the extent of 
neurite growth reduced by 40-45% after adding NG2 in the substrate. Further 
experiments proved the inhibitory activity came from the core protein but not 
the covalently attached chondroitin sulfate proteoglycan chains (Dou and 
Levine 1994). Ughrin et al. (2003) further divided extracellular domain of 
NG2 core protein into three parts: an extreme N-terminal domain I, a central 
domain II containing glycosaminoglycan (GAG) side chain and a 
juxtamembrane domain III. Their studies demonstrated the independent 
inhibitory effects of domain I and III on neurite growth whilst domain II only 





Because NG2 is a widely used antigen marker expressed on the surface of 
NG2 cells, how about the influence of NG2 cells on axonal growth? Do they 
also present the inhibitory effects to the neurite growth? The answer is still in 
great debate. Some studies have shown the inhibitory effect of NG2 cells on 
axonal growth (Chen et al. 2002a; Chen et al. 2002b). Chen et al. (2002) found 
that NG2 cells inhibited the neurite outgrowth and this effect of growth 
inhibition could be rescued by treatment with polyclonal antibodies against 
NG2 (Chen et al. 2002a; Chen et al. 2002b).  
However, several studies demonstrated that NG2 cells did not show inhibitory 
effects on neurite growth, which was not influenced by the expression of NG2 
protein on their surface (de Castro et al. 2005; Yang et al. 2006). In the in vitro 
study, NG2 cells were permissive of axonal growth in culture, regardless of 
the levels of NG2 protein expression. Actually, they were a favorable substrate 
for axonal growth cones and could promote the axonal growth (Yang et al. 
2006). The same phenomenon has also been found in an in vivo study. In a 
NG2-knockout mice model, the extent of axonal growth after spinal cord 
transection was significant lower compared with wild-type mice, suggesting 
the stimulatory role of NG2 in axonal growth (de Castro et al. 2005).  
In short, whether NG2 cells play the inhibitory or stimulatory role to the 
axonal growth still need to be further investigated.  
1.3.3.4 The role of Neuron-NG2 cell synapse 
Under physiological condition, NG2 cells possess close relationship with 
neurons (Karadottir et al. 2008; Kukley et al. 2007; Lin and Bergles 2002). 
The cell bodies of NG2 cells are very close to neurons in many brain regions 
such as brain cortex, hippocampus and cerebellum (Trotter et al. 2010). NG2 
cells are found to express both AMPA receptors and GABA receptors (Trotter 
et al. 2010). Direct glutamatergic synapses between neurons and NG2 cells 
have been first described in hippocampal slides from both young postnatal and 
adult mice (Bergles et al. 2000). This synaptic communication is not unique to 
the hippocampus and could also be observed in other anatomical regions such 
as cortex (Chittajallu et al. 2004; Kukley et al. 2008), brainstem (Muller et al. 





Additionally, GABAergic synapses between NG2 cells and neurons are 
observed in the hippocampus (Lin and Bergles 2004), dentate gyrus (Mangin 
et al. 2008) and cortex (Tanaka et al. 2009b). N-methyl-D-aspartate (NMDA) 
receptors are also present on NG2 cells and play a role in regulation of NG2 
cells migration (Wang et al. 1996) and damage from ischemic injury 
(Karadottir et al. 2005). They contact with nodes of Ranvier in the white 
matter of CNS (Butt et al. 1999; Butt et al. 2002). Therefore, NG2 cells are 
involved in the formation of glia-neuron synapses and play a role in the 
modulation of synaptic activity. 
The demonstration of synapses between neurons and NG2 cells breaks the 
traditional paradigm that synapse is a sole property of neurons in the CNS. 
Even astrocytes closely connect with the presynaptic terminal and 
postsynaptic terminal of neurons in some brain regions to form tripartite 
synapses (Halassa et al. 2007) and are functionally involved in synaptic 
transduction, the direct synaptic contact with neurons is unique to NG2 cells.  
The synapses formed between neurons and NG2 cells may regulate the 
proliferation, migration and differentiation of NG2 cells in the developing 
stage (Gallo et al. 2008). As per the major proliferation cells in the developing 
and adult brain, studies have demonstrated that NG2 cells still connected to 
neurons through formed glutamatergic and GABAergic synapses while 
dividing (Kukley et al. 2008; Tanaka et al. 2009b). Glutamate is shown to 
inhibit proliferation of NG2 cells through blocking K
+
 channel activity (Gallo 
et al. 1996; Yuan et al. 1998). Therefore, it may be possible that the 
proliferation of NG2 cells is regulated through synapses formed with neurons. 
NG2 cells are able to migrate in both the postnatal and adult brain (Etxeberria 
et al. 2010; Levison and Goldman 1993). They are shown to contact 
glutamatergic synapse while migrating (Kukley et al. 2008). Since glutamate 
has been demonstrated to stimulate migration of NG2 cells through 
integrin/myelin proteolipid protein complexes (Gudz et al. 2006), it may be 
possible that migration of NG2 cells may be regulated through formed NG2-
neuronal synapses. Glutamate inhibits the differentiation process of NG2 cells 





that the neuron-NG2 synapse could regulate the differentiation of NG2 cells 
into oligodendrocytes. 
NG2 cells may also influence neuronal activities. It has been reported that 
NG2 cells produced extracellular matrix (ECM) molecules such as versican, 
neurocan and phosphacan, which could stabilize synapses and interact with 
neuronal intracellular cytoskeleton anchoring ion channels and 
neurotransmitter receptors at the synapse (Butt et al. 2005).  
1.3.3.5 Involvement of NG2 cells in neuroinflammation 
Neuroinflammation，a specialized immune reaction taking place in the CNS，
is involved in various injuries, acute and chronic CNS disorders (Fuster-
Matanzo et al. 2013). Although all the cells in the brain, including neurons, 
microglia, astrocytes and oligodendrocytes, participate in inflammatory 
responses, neuroinflammation is primarily resulted from the activation of 
microglia and astrocytes (Latov et al. 1979; Streit et al. 1999). Both microglia 
and astrocytes generate inflammatory mediators to regulate inflammatory 
responses while microglia play the major role in cytokine and chemokine 
production (Lee et al. 1993). However, the role of NG2 cells in 
neuroinflammation is not clear at present. 
1.3.3.5.1 Cell responses in neuroinflammation 
1.3.3.5.1.1 Microglia reaction 
In response to pathological conditions or diseases, microglia become activated,  
shown by morphological transformation from ramified resting to amoeboid 
phenotypes (Nakamura 2002). Moreover, they may also produce numerous 
protein mediators such as pro-inflammatory, anti-inflammatory cytokines and 
chemokines to regulate the inflammatory response (Kraft and Harry 2011). 
(i) Different stages of microglia activation 
Microglia have different phenotypes in the normal and pathological conditions. 
In the normal adult CNS, microglia are at a resting state with long and 
ramified processes (Raivich et al. 1999; Streit et al. 1999). However, in recent 





act as sensor cells to detect abnormalities or changes in the CNS environment 
(Kreutzberg 1996). They actively search for and read signals as well as the 
possible changes in those signals in the brain environment. They scan their 
territory through fine processes. The expression of receptors for a plethora of 
molecules helps microglia to sense signalling signs from even minor alteration 
caused by disturbed structural and functional integrity in the brain 
environment. Moreover, neurons could also deliver signals to help microglia 
in surveillance mode (Hanisch and Kettenmann 2007). 
Upon a threat to the structural and function integrity of the CNS, a 
transformation from resting microglia to activated state will occur. After 
activation, microglia may undergo differential responsive phenotypes 
throughout the pathologic process. Early microglial activation is observed 
within the first 24 hrs, belonging to stage I (state of alert). At this stage, a 
rapid transformation from the highly ramified resting state to a more stout and 
deramified form occurs after neural injury (Kreutzberg 1996). These alerted 
microglia may move and contact with the damaged structures like injured 
neurons or degenerating neurite terminals, further entering stage II (state of 
homing). If without further cell death, microglia gradually decrease cell 
number, lose the activation markers and return to the resting state. However, if 
neuronal cell death occurs, microglia will transform into phagocytic cells to 
remove neural debris (Moller et al. 1996; Streit and Kreutzberg 1988) or 
disconnected axons and myelin (Bauer et al. 1995; McGeer et al. 1993). The 
massive expression of most activation markers plays a role in adhesion and 
internalization of cell debris at stage III3a, state of phagocytosis. The process 
of phagocytosis affects their direct cellular environment which leads to the 
activation of the adjacent non-phagocytic microglia (stage III3b, stage of 
bystander activation). There are specific molecular markers for different 






Figure 1.2 Molecular markers of microglial activation at different stages 
This table is modified from Raivich G (1999). Brain Res Brain Res Rev 
30(1):77-105.  
 
In many injury models, such as stab wounds (Levine 1994) and kainate 
excitotoxicity (Ong and Levine 1999), microglia are observed to express NG2. 
At present, several studies have directly reported the properties of NG2
+
 
microglia/macrophage-like cells in CNS inflammation. Gao et al. (2010) 
showed that NG2 can mediate the expression of inflammatory cytokines but 
not the chemokine expression in primary microglia (Gao et al. 2010). 
Similarly, in an NG2 knockout mouse model, the migration ability of 
microglia was reduced and the cytokine expression was changed from pro-
inflammatory to anti-inflammatory phenotype (Kucharova et al. 2011). 




 cells in a middle cerebral artery 
occlusion (MCAO) rat model and demonstrated that they expressed various 




 cells may possibly play a 
beneficial role in the ischemic brain (Smirkin et al. 2010). However, the role 
of NG2 protein in microglia and how NG2 protein regulates microglial 
function remains unclear and need to be further investigated.  
(ii) Phagocytosis 
Phagocytosis is a cellular process of engulfment and degradation of invading 





are major professional phagocytes, while astrocytes display phagocytosis with 
delay and less efficiency (Magnus et al. 2002; Parnaik et al. 2000).  
The process of microglial phagocytosis is composed of three steps: recognition, 
engulfment and degradation (Sierra et al. 2013). Firstly, microglia recognize 
targets through numerous receptors including Toll-like receptors (TLRs) and 
phosphatidylserine (PS) receptors which either tether or internalize the target 
(Underhill and Goodridge 2012). Secondly, engulfment receptors including 
integrin receptors like complement receptor 3 (CR3) and Ig superfamily 
receptors like Fc receptors help promote engulfment (Sierra et al. 2013; 
Underhill and Goodridge 2012). Lastly, the phagosome matures. The matured 
phagosomes contain numerous kinds of proteins like hydrolases for digestion 
and proton pumps for degradation of phagocytosed targets (Garin et al. 2001). 
Microglia exhibit phagocytosis in response to brain injuries or diseases. The 
accumulation of amyloid-β (Aβ) protein is the major cause of AD. Microglia 
have been found to phagocytose Aβ by both in vitro (Ard et al. 1996; 
Frackowiak et al. 1992) and in vivo studies (Lewandowska et al. 1999; Weldon 
et al. 1998). Microglia may also phagocytose dead neurons (Fricker et al. 2012) 
and axon debris (Tanaka et al. 2009a) upon stimulation. However, 
phagocytosis may also lead to inflammation which may further lead to 
neuronal cell death (Neher et al. 2011). Therefore, it is important to control 
and balance the phagocytic activity of microglia. However, it is not known 
what is a sign and mechanism of controlling microglial phagocytosis. 
(iii) Cytokine and chemokine release 
In response to various stimuli like brain trauma, infections and 
neurodegenerative diseases, activated microglia have been demonstrated to 
produce numerous cytokines as TNF-α, IL-1, IL-6 and chemokines like MCP-
1 and MIP-1 (Hanisch 2002). By virtue of cytokines, activated microglia may 
possibly coordinate responses of other types of glial cells such as astrocytes 
and oligodendrocytes.  
Several studies have shown the effects of cytokines on astrocytes. TNF-α is 





Selmaj et al. 1990). IL-1 secreted from amoeboid microglia increased 
proliferation of astrocytes in the developing mammalian brain (Giulian et al. 
1988b). Exogenous injection of IL-1 into cerebral cortex further confirmed its 
effects on promotion of astrogliosis (Giulian et al. 1988a). Application of IL-
10, an anti-inflammatory cytokine, attenuated astrocytic activity following 
corticectomy in the mouse brain and this effect may possibly be achieved 
through inhibition of the production of cytokines secreted by microglia or 
microphages (Balasingam and Yong 1996). Therefore, microglia may play a 
role in orchestrating activation of astrocytes through secreted cytokines. 
Oligodendrocytes also show responses to various cytokines. However, they 
may be sensitive and vulnerable to cytokines. Loss of oligodendrocytes may 
result in demyelination diseases such MS. TNF-α is verified to be toxic to 
oligodendrocytes and leads to demyelination (Kita et al. 2000; Renno et al. 
1995). The effect of IL-1 differs from TNF-α and it is not toxic to 
oligodendrocyte lineage cells. It inhibits the  proliferation of OPCs at the late 
progenitor stage, while promotes the survival of differentiated 
oligodendrocytes (Vela et al. 2002). Moreover, IL-2 is shown to promote the 
proliferation of oligodendrocytes (Otero and Merrill 1997).  
Putting together, it suggests that microglia may influence the activities of other 
glial cells including astrocytes and oligodendrocytes. Therefore, it may also 
have potential to mediate the responses of NG2 cells during the pathological 
process. However, currently, there are no studies to clearly investigate the 
interaction between microglial activation and NG2 cells in in vivo. 
1.3.3.5.1.2 Astrocyte reaction 
Besides microglia in response to the pathological brain, astrocytes may also 
become activated (Norton et al. 1992). Reactive astrocytes are shown by their 
enlarged size, thicker processes, upregulated staining of GFAP and increase in 
proliferation (Norenberg 1994; Ridet et al. 1997).  
Astrocytes may play a protective role in the CNS lesions due to release of 
neurotrophic factors (Ip et al. 1993; Nieto-Sampedro et al. 1982). However, 





inhibit axonal regeneration (Liuzzi and Lasek 1987). Glial scar itself may have 
two opposite effects: on the one hand, it separates the lesions area where there 
has been a robust inflammatory response to prevent further damage to 
unaffected neural tissue; on the other hand, the formation of glial scar may 
exert a negative influence on axonal regeneration (Rolls et al. 2009). In a stab 
injury model, glial scar was not formed after ablation of reactive astrocytes in 
the transgenetic mice and at the same time increase in neurite outgrowth has 
been observed (Bush et al. 1999). However, it resulted in the deterioration of 
the injuries shown by the significant increase in leukocyte infiltration, failure 
of blood brain barrier and more profound neuronal cell death (Bush et al. 
1999).  
Astrocytes are also shown to generate cytokines in response to different 
neurodegenerative disorders. In AD, reactive astrocytes expressed pro-
inflammatory cytokines and chemokines as the pathogenesis of AD (Li et al. 
2011). In an in vitro study, astrocytes showed significant increase in both 
mRNA and protein expression of several pro-inflammatory cytokines and 
chemokines like TNF-α and IL-1β in response to LPS stimulation (van 
Neerven et al. 2010). However, compared with microglia, astrocytes showed 
less cytokine production in response to LPS stimulation and expressed 
cytokines at a later stage of injury or disease progress. 
1.3.3.5.1.3 NG2 cell reaction 
Under the neuroinflammation, NG2 cells are found to be activated by 
hypertrophy of cell bodies, increase in cell number and upregulation in 
expression of NG2 protein (Claus et al. 2013; Dehn et al. 2006; Hampton et al. 
2004). In addition, NG2 cells were observed to enwrap motor neurons in the 
facial nucleus after facial nerve axotomy, suggesting close interaction with 
impaired neurons (Zhu et al. 2010). NG2 cells were shown to sense and 
respond to the axonal alterations in a NFL-/- mice model (with the disruption 
of neurofilament light subunit) (Wu et al. 2008a).  
During the development, NG2 cells are seen to generate a subpopulation of 
protoplasmic astrocytes in the grey matter of the ventral forebrain and spinal 





model, NG2 cells were observed to increase their proliferation and generate 
reactive astrocytes (Alonso 2005). More studies have shown that astrocytic 
differentiation was related to the translocation of olig2 into cytoplasm, while 
the expression of olig2 in the nucleus repressed neuronal and astrocytic gene 
expression and maintained the oligodendrocyte lineage (Cassiani-Ingoni et al. 
2006; Magnus et al. 2007; Zhao et al. 2009). However, although some reactive 
astrocytes may be generated from NG2 cells, the main source of astrogliosis 
may still be resident astrocytes (Komitova et al. 2011). 
Although the reactive NG2 cells have been widely observed in many 
pathological models or diseases, what their functions should be and how they 
become activated remains unknown.  
1.3.3.5.2 Cytokine-chemokine network in neuroinflammation 
Cytokines are glycoproteins with low molecular weight. They initiate a 
signalling pathway upon binding with their corresponding receptors and act 
either in an autocrine or paracrine way (John et al. 2003). They play a major 
role in initiation, propagation and regulation of immune and inflammatory 
responses (Benveniste 1992). In the CNS, cytokines are mainly produced by 
microglia (Lee et al. 1993). Usually, cytokines are classified into two types 
according to their effects: pro-inflammatory cytokines and an-inflammatory 
cytokines.   
1.3.3.5.2.1 Pro-inflammatory cytokines 
Pro-inflammatory cytokines include TNF-α, IL-1β, interleukin-2 (IL-2),  
interferon-γ (IFN-γ) and other cytokines, which promote inflammation 
responses in the pathological CNS (Sredni-Kenigsbuch 2002).  
(i) TNF-α 
TNF-α is generated either as a 26kDa membrane-bound protein or a 17kDa 
soluble form cleaved by TACE metalloprotease (Idriss and Naismith 2000). It 
initiates a signalling pathway through binding with its two distinct receptors: 
TNFR1 (p55 receptor) and TNFR2 (p75 receptor) (Benveniste and Benos 





protein (Grell et al. 1998) and is expressed in many cell types. However, 
TNFR2 has higher affinity to the membrane-bound form and a lesser extent to 
soluble TNF-α (Grell et al. 1998) and is only expressed by neuronal cells and 
glial cells (Tartaglia and Goeddel 1992).  
TNFR1 is associated with activation of apoptotic process either through 
nuclear factor-κB (NF-κB) signalling pathway or directly through activation of 
caspase pathway (Smith et al. 2012). Specifically, upon binding with TNF-α, 
the intracellular domain of TNFR1 first interacts with TNF receptor-associated 
death domain adaptor protein (TRADD) to form a complex (Gururaja et al. 
2007). The composed complex then recruits tumour necrosis factor receptor-
associated factor 2 (TRAF2) and receptor interacting protein (RIP) and 
initiates downstream cascade to activate NF-κB pathway or p38 MAPK 
pathway. It may also activate JNK pathway through the sequential recruitment 
of MAP/ERK kinase kinase 1 (MEKK1) and MAPK kinase 7 (MKK7) (Smith 
et al. 2012). Additionally, the sequential recruitment of FAS-associated death 
domain (FADD) and caspase-8 into the composed complex leads to the 
activation of caspase-3 and finally induces apoptosis (Aggarwal 2003; Chen 
and Goeddel 2002).  
TNFR2 is more related to the anti-apoptosis pathway. Upon binding with 
TNF-α, TNFR2 is able to directly combine with TRAF1/TRAF2 to form a 
protein complex which further recruits RIP to initiate either p38 MAPK and 
NF-κB pathway (Smith et al. 2012). At present, the TNFR2 signalling 
pathway is less understood. 
TNF-α belongs to the pro-inflammatory cytokine and could act upon other cell 
types in CNS including astrocytes, oligodendrocytes and neurons. TNF-α 
induces reactive astrogliosis (Selmaj et al. 1990), while it is toxic to both 
oligodendrocytes (Louis et al. 1993) and neurons (Downen et al. 1999).  
(ii) IL-1β 
IL-1β, as a major pro-inflammatory cytokine, is induced in response to various 
injuries or insults. It is synthesized in the precursor form with a MW of 31kDa 





which is usually in a soluble and secreted form (Netea et al. 2010). IL-1β has 
three receptors: IL1-RI, IL1-RII and IL-1 receptor accessory protein (IL-
1RAcP). Because IL-1RII lacks an intracellular signalling domain, it acts as a 
decoy receptor and does not take part in the IL-1β signalling (Bourke et al. 
2003).  
IL-1β initiates its signalling pathway through binding with its two functional 
receptors, IL-1RI and IL-1RAcP, and then recruits myeloid differentiation 
response gene 88 (MyD88) and tumour necrosis factor receptor-associated 
factor 6 (TRAF6) leading to the activation of downstream MAPK cascade 
including p38, JNK and ERK1/2 (Weber et al. 2010). 
Activated microglia and invading immune cells are the main source of IL-1β 
after infection, stroke, traumatic injury and other kinds of stimulation (Hanisch 
2002). IL-1β is widely demonstrated to lead to neuronal cell death under 
different CNS disorders (Allan and Rothwell 2001; Allan et al. 2005; Touzani 
et al. 1999). Exogenous administration of IL-1 significantly exacerbates 
neuronal damage elicited by excitotoxic insult (Lawrence et al. 1998), whilst 
inhibition of IL-1 with its neutralising antibody reduces the ischaemic brain 
damage (Touzani et al. 1999). Although IL-1β is toxic to neurons, it does not 
lead to the cell death of both OPCs and oligodendrocytes. It inhibits the 
proliferation of OPCs and promotes their differentiation (Vela et al. 2002). IL-
1β promotes the early reactive astrogliosis in response to corticectomy (Herx 
and Yong 2001). In addition, astrogliosis is delayed in response to penetrating 
brain injury in the IL1-RI null mice compared with wild type (Lin et al. 2006). 
1.3.3.5.2.2 Anti-inflammatory cytokines 
Anti-inflammatory cytokines include IL-10, TGF-β1, IL-4, IL-5 and other 
cytokines, which attenuate inflammation and play a protective role in the 
pathological CNS (Sredni-Kenigsbuch 2002). 
(i) IL-10 
IL-10 is a cytokine with potent anti-inflammatory property and 
neuroprotective role. Through binding with its two receptors, IL-10RI and IL-





Specifically, IL-10 first binds with IL-10RI and IL-10RII to activate Janus 
tyrosine kinase, JAK1 and Tyk2 and subsequently transcription factor STAT3, 
which further induces transcription of many functional genes in anti-
inflammatory actions (Donnelly et al. 1999).  
IL-10 has been found to be neuroprotective in glutamate induced cerebellar 
granule cell death (Bachis et al. 2001). IL-10 also promotes neuronal recovery 
in a traumatic brain injury model, partially through reductions in 
proinflammatory cytokine synthesis (Knoblach and Faden 1998). IL-10 is 
observed to protect oligodendrocytes against cytotoxicity induced by LPS and 
IFN-γ (Molina-Holgado et al. 2001). IL-10 can inhibit the inflammatory 
mediators secreted by microglia (Hu et al. 1999; Kremlev and Palmer 2005). 
(ii) Transforming growth factor beta (TGF-βs) 
TGF-βs belong to the TGF-β superfamily which includes bone morphogenic 
factors (BMPs), growth and differentiation factors (GDFs), anti-Mϋllerian 
hormone, activins and inhibins (Burt and Law 1994). These proteins in TGF-β 
superfamily share some structural homology but possess separate receptors 
and have different functions (Miyazawa et al. 2002). TGF-βs are found to play 
a role in regulation of proliferation, differentiation and survival of different 
cell types (Lawrence 1996; Massague 1987). Other than these roles as growth 
factors, they also belong to a type of cytokine which plays a role in immunity, 
cancer and diabetes (Clark and Coker 1998).  
(a) Subtypes of TGF-βs  
TGF-βs have three mammalian isoforms: TGF-β1, TGF-β2 and TGF-β3. 
These subtypes are encoded by separate genes but the peptide structures of the 
three members of the TGF-βs family are highly similar and the processing and 
activation mechanisms are also quite similar (Roberts 1998). At the initial 
stage, TGF-β1 precursor (390 amino acids) is composed of a 29 amino acid N-
terminal signal peptide, a 249 amino acid pro-region (latency associated 
peptide or LAP) and a 112 amino acid C-terminal mature peptide. After 
cleavage in the Golgi apparatus, a small latent TGF-β1 complex (100kDa) is 





After that, the small latent TGF-β1 complex is covalently bound to a third 
component, latent TGF-β binding proteins (LTBPs), to form a large latent 
TGF-β1 complex (235–260kDa) in the extracellular space (Dobolyi et al. 
2012). Free active TGF-β1 can be released from the large latent TGF-β1 
complex by many factors including enzymes and pH. In normal serum and 
plasma, free active TGF-β1 exists in a lower concentration and latent TGF-β1 
has a higher concentration. It is the free active TGF-β1 which binds to the 
TGF-β1 receptors and exerts biological functions.  
Among three types of TGF-βs isoforms, TGF-β1 has a unique role in response 
to injury and disease. An upregulation of TGF-β1 was found in response to 
neuropathologies, such as traumatic brain injury (Lenzlinger et al. 2001), 
experimental brain ischemia (Lehrmann et al. 1995), EAE animal model 
(Kiefer et al. 1998) and MS (Beck et al. 1991). TGF-β1 has been demonstrated 
to have neuroprotective effects in different brain lesions: anti-inflammatory 
action, anti-apoptotic action, anti-excitotoxicity and formation of scar 
formation which prevents further neuronal damage (Dobolyi et al. 2012). 
(b) Signaling pathway of TGF-β1 
TGF-β1 have three receptors: TGF receptor type I (TβRI), TGF receptor type 
II (TβRII) and TGF receptor type III (TβRIII) (Dobolyi et al. 2012). Three 
types could be distinguished by their structural and functional properties 
(Derynck and Feng 1997). TβRIII (250-350kDa) is the largest binding protein 
among three receptors. It is a transmembrane proteoglycan with a large 
extracellular domain and a 43 amino acid residue cytoplasmic domain, which 
lacks an obvious signalling motif. Therefore, it could not lead to TGF-β1 
signalling transduction but appears to increase the binding affinity of TβRI 
and TβRII. TβRII (70-85kDa) and TβRI (53kDa) receptors are single-pass 
transmembrane proteins including a serine/threonine kinase domain on the 
cytosolic side of the plasma membrane and are the major TGF-β1 signalling 
mediators. TGF-β1 signals are transduced through the binding of active TGF-
β1 to TβRII at the beginning and sequentially activate TβRI through 
phosphorylation by TβRII. The activated TβRI then initiates Smad-mediated 





Smad signalling pathway is mediated through a series of Smad proteins. 
Briefly, TβRI phosphorylates Smad2 and Smad3. The receptor-activated 
Sma2/3 complex binds with Smad4 to form trimmers and then translocates 
into the nucleus, where it binds transcription factors and causes the 
transcription of DNA. TGF-β1 may also use non-Smad signalling pathways 
which activate ERK, p38 and JNK MAPK kinases, the small GTPases Rho 
and the PI3 kinase-AKT-TOR (Kang et al. 2009).   
 
Figure 1.3 TGF-β1 signaling pathways: Smad and non-Smad signaling 
pathways 
Active TGF-β1 binds with TβRII and TβRI. The TβRI upon phosphorylation 
by TβRII then initiates Smad and non-Smad signaling pathways. This figure is 
modified from Kang (2009). Trends Cell Biol 19(8):385-94.  
 
(c) TGF-β1 and chondroitin sulfate proteoglycan (CSPG) 
CSPGs are proteoglycans consisting of a core protein with covalently attached 
sulfated GAG side chain and differ in their core protein (Morgenstern et al. 
2002). Numerous CSPGs are expressed in the CNS. Among them, brevican, 





important roles in the CNS through interactions of their core proteins and/or 
chondroitin sulphate (CS) chains with cell adhesion molecules, ECM 
molecules and growth factors (Aono and Oohira 2006; Morgenstern et al. 
2002). When the CNS is injured, the expression of CSPGs is upregulated in 
the glial scars around the damage site and they are found to inhibit axon 
regeneration (Fawcett and Asher 1999; Matsui and Oohira 2004; Rhodes and 
Fawcett 2004).  
TGF-β1 is widely considered as a central mediator which plays a role in 
initiating formation of glial scar and deposition of CSPGs. It can induce many 
of the genes which encode CSPG core proteins or enzymes which regulate 
GAG chain synthesis (Smith and Strunz 2005; Wang et al. 2008). Several 
studies have provided in vivo evidence that TGF-β1 regulates the deposition of 
CSPG in the brain lesions (Asher et al. 2000; Dobbertin et al. 2003). In 
Logan’s study, the matrix deposition and fibrogenic scar was significantly 
reduced after inhibition of TGF-β1 with neutralizing antibody (Logan et al. 
1994). Moon and Fawcett (2001) also found that the CNS scar formation 
could be reduced after application with a combination of antibodies against 
TGF-β1 and TGF-β2 (Moon and Fawcett 2001). Application of decorin, a 
small proteoglycan, could attenuate the glial scar and decrease the expression 
of CSPG in the lesion site potentially through the reduction in effects of TGF-
β1 (Davies et al. 2004).  
NG2 proteoglycan, belonging to CSPG family, is widely found to be 
upregulated in the glial scar and has an inhibitory effect on axonal growth 
(Levine 1994; Tan et al. 2006). Studies have shown that the expression pattern 
of NG2
 
in the injury site seems to be consistent with production of TGF-β1.  
In Tang’s study, NG2 was profoundly upregulated at 24 hrs after spinal cord 
injury, peaked at 8 days and decreased gradually until 6 months (Tang et al. 
2003). It is correlated with another study which described the mRNA of TGF-
β1 significantly elevated at 24 hrs and peaked at 7 days and gradually declined 
thereafter in the same injury model (McTigue et al. 2000). Studies have 
described that TGF-β1 increases enzymes required for GAG side chains 
synthesis like chondroitin synthase-1 (CS synthase-1) (Susarla et al. 2011; Yin 





protein. In Moransard’s study, TGF-β was shown to induce both expression 
and secretion of NG2 protein in macrophages and OPCs, but the mechanism 
has been not investigated (Moransard et al. 2011). Further studies may be 
carried out in order to fully understand the specific mechanism. 
TGF-β1 is regarded as an anti-inflammatory cytokine and plays a 
neuroprotective role in neuropathologies. In the normal CNS, TGF-β1 is 
expressed at a low level but upregulated, along with its receptors, TβRI and 
TβRII, in the injured rat spinal cord (McTigue et al. 2000). It is expressed by 
several kinds of cells in the brain like microglia, astrocytes and neurons 
around the injury site (Knuckey et al. 1996; Lehrmann et al. 1998; McTigue et 
al. 2000). TGF-β1 has been found to modulate the properties of microglia in 
many aspects. Firstly, it inhibits proliferation of microglia (Jones et al. 1998). 
When applying TGF-β1 to the microglia-astrocyte co-culture system in which 
microglia were on the top of astrocyte monolayer, the proliferation of ramified 
microglia was inhibited. However, this inhibition was aborted after blockage 
of TGF-β1 activity with neutralized TGF-β1 antibody (Jones et al. 1998). 
Secondly, it may trigger Aβ peptide clearance by microglia (Wyss-Coray et al. 
2001). Wyss et al. (2001) established an aged transgenic mice AD model with 
human amyloid precursor protein (hAPP) expression and increase in TGF-β1 
production by astrocytes. Their results showed that the formation and 
accumulation of parenchymal amyloid plaques was reduced in the hAPP/TGF-
β1 transgenic mouse model compared with hAPP mice. This reduction of 
accumulated Aβ was associated with the widespread activation of microglia. 
The in vitro experiment further confirmed the effects of Aβ clearance by 
microglia after stimulation with recombinant TGF-β1(Wyss-Coray et al. 2001). 
Therefore, TGF-β1 may possibly regulate the activities of microglia. 
However, it is important to notice that TGF-β1 may regulate the activation of 
microglia/macrophages in two directions (Ashcroft 1999). At the early stages, 
TGF-β1 attracts microglia to migrate and infiltrate the inflammatory areas, 
mediates cytokine production and promotes inflammation; later, TGF-β1 
exerts its anti-inflammatory effects on microglia including downregulation in 
the expression of cytokines in activated microglia (Lodge and Sriram 1996; 





production released by microglia (Ryu et al. 2012). This dual function is 
possible regulated by several factors: the local concentration of TGF-β1, the 
delivery methods, and the encountered cell type (Ashcroft 1999).  
In short, TGF-β1 can induce production of CSPG and it may possibly exert 
some effects on NG2, a kind of CSPG. It could also mediate the properties of 
microglia in bidirectional ways. Therefore, TGF-β1 may possibly mediate the 
responses of NG2 cells as well as microglia. 
1.4 Aims of Study 
As mentioned in the above literature review, it is normally considered that 
NG2 cells are OPCs in the adult brain, which could differentiate into 
oligodendrocytes. However, NG2 cells, ubiquitously distributed in both grey 
and white matter, exist in such a large numbers without expression of CD9 
which is relevant to oligodendrogenesis. Therefore, they may not merely play 
a role as OPCs in the CNS and can be presumed to have some other uncertain 
functions.  
1. Under pathological conditions, NG2 cells showed reactive responses: 
enlargement of cell bodies, upregulation of NG2 protein expression 
and increase in the cell number. Their responses seem to be similar to 
reaction of some immune cells in the brain. Therefore, it is 
hypothesized that NG2 cells may possess some functions similar to 
microglia such as phagocytosis and cytokine secretion.  
 
2. In some injury models or neurodegenerative diseases, the co-
localization between NG2 and OX42 has been observed. At present, 
most researches support the view that microglia are induced to express 
NG2 protein. It has been reported that NG2 protein could mediate 
expression of inflammatory cytokines but not chemokines in primary 
microglia in response to LPS stimulation (Gao et al. 2010). In addition, 
Iba1
+
 microglia with NG2 protein expression play a beneficial role 
through secretion of neuroprotective factors in the ischemic brain 
(Smirkin et al. 2010). Therefore, it is hypothesized that NG2 protein 






3. In injury models or diseases, NG2 cells show corresponding reactive 
responses. However, how NG2 cells become activated and why they 
have such responses are still unknown. As mentioned in the literature 
review, NG2 protein, the antigen marker for NG2 cells, belongs to the 
family of CSPG which is increased and deposited after TGF-β1 
stimulation. In addition, TGF-β1 also regulates the properties of 
microglia. Therefore, it is hypothesized that TGF-β1 could regulate the 
responses of NG2 cells and lead to their activation. 
Therefore, the aims of this study were to investigate the responses of NG2 
cells using a brain inflammation model and explore the potential mechanisms 
and functions of their activation. The specific objectives of this research were 
to: 
1. Establish a lipopolysaccharide (LPS) induced rat brain inflammation 
model to study responses of NG2 cells. 
 
2. Investigate whether NG2 cells could be involved in the immune 
defence network according to secretion of cytokines. 
 
3. Explore whether NG2 cells have phagocytic capability during the brain 
inflammation process. 
 
4. Find out whether NG2 protein could mediate the phagocytosis function 
and cytokine expression of microglia. 
 
5. Study the mechanism of how NG2 cells become activated and NG2 
expression is induced in microglia. 
The results of current study may contribute to a better understanding of NG2 
cells. As major non-neuronal cells, NG2 cells are found to be rapidly 
responsive to various neuropathological stimuli. If the functions of NG2 cells 
and the mechanisms of NG2 cell activation are fully understood, this will not 





to look at the position of non-neuronal cells in the CNS cellular network, but 
also provide a better picture for understanding our human brain. This may be 
helpful in providing extra interventions for treatment of injuries or diseases of 
the CNS.  
In the next chapter, experimental methods will be described from four aspects: 
establishment of the brain inflammation model, cytokine secretion, 
phagocytosis assay and possible mechanism of activation of NG2 cells. 
























In summary, the aims of this project were to study the responses of NG2 cells, 
their potential functions, and possible mechanisms involved in NG2 cell 
activation in an in vivo neuroinflammatory model. Neuroinflammation was 
induced by direct focal injection of LPS into the brain cortex. Some 
morphological changes and functional studies of NG2 cells were characterized 
using immunohistochemistry and biochemistry methods. The mechanisms of 
NG2 cell reaction were analysed by evaluating effects of a possible candidate 
molecule, TGF-β1, on NG2 cells. 
2.1 Neuroinflammatory Model 
2.1.1 Animal 
Adult male Sprague-Dawley (SD) rats (250~350g, 6~8 weeks) were used in 
the current study. At least three animals were used for each experimental 
group. All animal work has been carried out in accordance with the guidelines 
of the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publications NO. 85-23, revised 1996) and approved by 
Institutional Animal Care & Use Committee and National University of 
Singapore (IACUC Protocol No. 122/08 and 017/12), Singapore. The animals 
were maintained in a 12-hrs day/night cycle and provided with food and water. 
All efforts were made to relieve the pain and reduce the number of rats used in 
the studies. 
2.1.2 Anaesthesia 
Prior to the surgery, perfusion or collection of tissue samples, SD rats were 
deeply anesthetized with xylazine and ketamine (10 and 75 mg/kg). After 
about 5-10 mins, the foot pad of the rat was pinched with a pair of toothed 
forceps in order to ensure that the animal was under full anaesthesia. All 
procedures involving animals were approved by Institutional Animal Care & 
Use Committee, Singapore. 
2.1.3 LPS focal injection 
In the current study, LPS was intracerebrally injected into the brain cortex to 
establish a neuroinflammatory model. After being deeply anesthetized, the 




animal was placed in a stereotaxic instrument to fix the brain. Then the skull 
was exposed by using a sharp knife to cut the skin. LPS solution (1g/l, 
10g/rat; E. coli serotype 0127:B8, Sigma, USA) was injected at the location 
of 3.0 mm posterior and 2.0 mm lateral to the bregma and 2.0 mm deep to the 
skull surface at the left hemisphere. The injection was completed in 5 mins 
and the needle was kept there for another 5 mins prior to withdrawal from the 
brain. After that, analgesic (buprenorphine, 0.025mg/kg) was subcutaneously 
injected to relieve the pain and then followed with injections twice a day, 
continuous three days. After injection, the animals were put back to the cage 
for recovery. The survival intervals were set as 1 day, 3, and 5 days. In 
addition, animals without treatment were used as normal control; animals with 
intracerebral injection of saline served as LPS treatment control. Tissue 
samples were collected for immunofluorescence study, Real time PCR and 
Western blot analysis. The number of animals used for LPS treatment was 
tabulated in Table 2.1. 
2.2 Treatment for experimental observation 
Different treatments were carried out in the current study: BrdU was used to 
study the proliferation status of NG2 cells; latex beads were injected to study 
the phagocytosis capability of NG2 cells; minocycline treatment, TGF-β1 
injection and TGF-β1 neutralisation assay were employed to explore the 
reactions of NG2 cells. Anti-TβRII neutralisation assay was used to study the 
mechanism of the activation of NG2 cells. The number of SD rats used in each 
experimental group was listed in Table 2.1. 
2.2.1 BrdU intraperitoneal injection 
To observe cell proliferation in the brain cortex after LPS focal injection, 
BrdU (Millipore, USA) was dissolved in 0.9% saline at 10mg/ml. The Brdu 
treatment was performed at each survival time point as 1 day, 3, and 5 days 
after LPS injection. Specifically, rats at each designated time point were 
intraperitoneally (I.P.) injected with BrdU for 2 times at a dosage of 150mg/kg 
for each time. The first injection was given 4hrs before perfusion with a 2-hr 
interval for second injection. Two times of injection were given in total. The 




animals were then perfused 4 hrs after the first injection. Tissue samples were 
collected for immunofluorescence study.  
2.2.2 Latex beads injection 
Latex beads are small particles and have different colours. They are widely 
used in a variety of applications such as electron microscopy, cell counter 
calibration, and phagocytosis experiments. In the current study, latex beads 
were intracerebrally injected into brain cortex to study the phagocytosis 
capability of NG2 cells. 
For observation of phagocytosis, two ways of latex injection were chosen: 1μl 
of red fluorescent latex beads (Sigma, USA) was injected into the brain cortex 
immediately following LPS injection; In order to make sure there were 
available latex beads when NG2
+
/OX42
+ cells appeared, 1μl of latex beads 





cells were in larger quantities. Three survival 
time intervals, 1 day, 3, and 5 days were set in this study. Tissue samples were 
collected for immunofluorescence study.  
2.2.3 Minocycline intraperitoneal injection 
Minocycline, an inhibitor for microglial activation, was purchased from sigma 
and dissolved in sterile water at 25mg/ml yielding a clear, yellow to amber 
solution. If not completely dissolved, the solution was sonicated to ensure 
complete solubilization. The minocycline-LPS-treated group received I.P. 
injection with minocycline 12 hrs before and immediately after LPS 
intracerebral injection and then once a day until sacrifice. This treatment 
protocol was based on those studies in which the inhibition of microglia 
activation was achieved (Fan et al. 2005a; Fan et al. 2005b). The animals with 
I.P. injection of saline served as corresponding control. At designated time 
point, tissue samples contained the injury site were collected for 
immunofluorescence staining, RNA and protein analysis.  
 




2.2.4 TGF-β1 injection 
In order to observe the direct effect of TGF-β1 on the activation of NG2 cells, 
TGF-β1 (Peprotech, USA) was injected at the same site as LPS groups at 
5ng/l, 20ng/rat. The animals were allowed to recover for 1 day, 3 and 5 days 
until being sacrificed. Animals without treatment were used as the normal 
control; animals with intracerebral injection of saline in 0.1% bovine serum 
albumin (BSA) served as the TGF-β1 treatment control. Tissue samples were 
collected for immunofluorescence study. 
2.2.5 Anti-TGF-β1 injection  
On the other hand, anti-TGF-β1 was injected to block the effect of secreted 
TGF-β1 in the LPS injection groups. The LPS injection groups were randomly 
divided into two groups:  one group was injected with anti-TGF-β1 (R&D 
system, USA) at 2g/rat, 0.5mg/ml immediately after LPS injection; another 
group was injected with Phosphate Buffered Saline (PBS) served as control. 
There were three survival time intervals, 1 day, 3, and 5 days. In summary, the 
control groups used for different treatments in the study were made as follows: 
SD rats without treatment were used as normal control; SD rats with 
intracerebral PBS injection served as the control of anti-TGF-β1 injection. 
Tissue samples were collected for immunofluorescence study. 
2.2.6 Anti-TβRII injection 
In order to study the mechanism of how NG2 cells became activated, anti-T 
βRII as the antagonist of TGF-β1 was injected following LPS treatment. The 
LPS injection groups were injected with anti-TβRII (Millipore, USA) at 
2µg/rat, 1mg/ml immediately after LPS injection. Rats without treatment were 
used as normal control and rats with unrelated antiserum injection served as 
anti-TβRII control. At 3 days after treatment, tissue samples were collected for 
both immunofluorescence study and Western blot.  
 
 




Table 2.1 The number of rats sacrificed at different time points after focal 
injection of various molecules (outside the brackets) and their 
corresponding treatment controls (in the brackets) is shown in the table. The 
number of animals treated with BrdU and minocycline is also represented.  
 








LPS injection 27 15 (15) 15 (15) 
Latex beads injection 27   
TGF-β1 injection 9 (9)   
LPS+anti-TGF-β1 9 (9)   
LPS+anti-TβRII 3 (3)  3 (3) 
Normal control 9 9 9 
Brdu treatment 9   
Minocycline treatment 9 (9) 5 (5) 5 (5) 
 
2.3 Immunohistochemistry 
2.3.1 Tissue sampling 
2.3.1.1 Perfusion 
2.3.1.1.1 Fixatives 
I. Phosphate Buffer solution (0.1M PB-1 liter) 
 0.1 M Solution A: (69g NaH2PO4. H2O in 5 litres Deionised H2O)    
±200 ml 
 0.1M Solution B: (178g Na2HPO4.2 H2O in 10 litres Deionised H2O) 
800 ml 




            (Add approximately 1 volume of ‘A’ to 4 volume of ‘B’ and adjust to 
PH 7.4) 
II. 2% paraformaldehyde (PF): 20g PF in 1000ml PB solution 
2% PF preparation 
2% PF was prepared by heating paraformaldehyde powder in PB solution at 
about 60 ºC. After PF powder was totally dissolved, the conical flask was 
immediately put into ice to cool down. All fixatives used in the present study 
were freshly prepared before use. 
2.3.1.1.2 Perfusion procedure 
Two reservoirs were used in this perfusion procedure: one containing Ringer’s 
solution and the other containing Fixative. Each reservoir was connected to a 
long polythene tube with an air trap interposed between them. A 19G winged 
needle (Terum Co., Japan), serving as cannula, was connected to the tube.  
Ringer’s solution and 2% PF were poured separately into each Ringer’s bottle 
and Fixative bottle. Those two bottles were then hanged at about one meter up 
and all air bubbles were removed from the tubes, which connected the two 
reservoirs. After anesthetized the animals with xylazine and ketamine, they 
were fixed on the wax board with 24G needles. A snip at the centre of thorax 
down to the middle of abdomen was made. An incision was made through the 
skin and muscles of the anterior abdominal wall and then extended bilaterally 
along the margins.  The thoracic cavity was fully opened up to expose the 
heart. Care should be taken during this process not to damage the lungs. 
Perfusion was initiated whereby the needle connected to the ringer’s bottle 
was inserted into the left ventricle and immediately followed by a cut on the 
right atrium to let out the blood, and subsequently the perfusate. A total of 200 
ml of Ringer’s solution was used to flush the vascular system until the lungs 
and liver became clear of blood. A total of about 400 ml of the cold fixative (2% 
PF) was then administered for nearly half an hour. 
 




2.3.1.2 Preparation of gelatine coated slides 
Materials 
1.5% gelatin solution (filtration before use) 
 Gelatin 9g 
 Distilled water 600ml 
Heat until dissolved and then cool down before adding: 
 Chromium potassium sulphate 0.9g 
 
Procedure 
Slides were first soaked in the absolute ethanol for 2 mins and dried in the 
fume hood at room temperature. The dried slides were then immersed into the 
gelatin solution for 1 min and dried overnight at room temperature. After dry, 
the gelatinized slides were put back into slide boxes and kept in an oven at 
37ºC until use. 
2.3.1.3 Preparation of frozen sections 
Materials 
0.75% gelatin solution (100ml, for picking sections onto gelatinized slides) 
 Gelatin 0.75g 
 Distilled water 80ml 
Heat until dissolved, then adding: 
 1x PBS (PH 7.4) 20ml 
 
Procedure 
After perfusion, the brains were collected and then postfixed with the same 
fixative-2% PF for additional 2 hrs. The tissue samples were subsequently 
equilibrated in 20% sucrose prepared with 0.1 M PB solution and kept 
overnight at 4°C. After the tissues sank to the bottom, they were ready for 
cryostat. Briefly, the specimens were firstly attached onto a metal chuck using 
shandon embedding matrix (Thermo scientific, USA) and then rapidly frozen 
by quenching in the liquid nitrogen up and down for several times. Cautions 
should be taken to prevent over frozen. Each frozen brain was sectioned into 
30μm coronal sections using a cryostat (Leica CM 3050, Germany). The 




sections were subsequently picked onto gelatin coated slides with 0.75% 
gelatin solution, allowed to dry at room temperature for nearly 2 hrs and 
finally stored in -20°C until immunohistochemistry study. 
2.3.2 Procedures of Immunofluorescence staining 
2.3.2.1 Buffers and solutions 
I. 0.1 M PBS (PH7.4) 
 NaCl 8g 
 KCl 0.2g 
 Na2HPO4 1.44g 
 KH2PO4 0.24g 
 Distilled water 900ml 
      (Adjusted to PH 7.4 with 1N HCl and topped up to 1,000 ml with distilled 
water) 
 
II. PBS containing 0.1% Triton-X 100 (PBS-TX) 
 1x PBS 1000ml 
 Triton-X 100 1ml  
 
III. 5% Normal goat serum 
 Normal goat serum 5µl 
 1x PBS 95µl 
 
2.3.2.2 Antibodies 
Table 2.2 Antibodies 
Primary antibody 
(source) 
Antibody dilution Company 
NG2 (rabbit) 1:100 Millipore 
NG2 (mouse) 1:100 Abcam 
OX42 (mouse) 1:100 Santa Cruz 
ED1 (mouse) 1:100 Santa Cruz 
GFAP (mouse) 1:200 Millipore 
CNPase (mouse) 1:400 Millipore 
PDGFαR (rabbit) 1:200 Cell signalling 
BrdU (mouse) 1:200 Millipore 




IL-1β (rabbit) 1:100 Abcam 
TGF-β1 (rabbit) 1:100 Abcam 
IL-10 (rabbit) 1:100 Abcam 
IL-6 (rabbit) 1:100 Abcam 
Lix (rabbit) 1:100 Peprotech 
iNOS (rabbit) 1:100 Abcam 
TβRI (rabbit) 1:50 Santa Cruz 




Antibody dilution Company 
Goat anti-mouse Fluor 488 1:200 Invitrogen 
Goat anti-rabbit Fluor 594 1:200 Invitrogen 
Goat anti-mouse Fluor 594 1:200 Invitrogen 
Goat anti-rabbit Fluor 488 1:200 Invitrogen 
 
2.3.2.3 Staining procedure 
Sections from different treatment groups including LPS injection, TGF-β1 
injection, LPS+anti-TGF-β1 injection, LPS+anti-TβRII and LPS+minocycline 
treatment, were used for double immunofluorescence staining. Specifically, 
the slides were washed with 1x PBS-TX for 3 times, each time 10 mins. Then 
the sections were blocked with 5% goat serum prepared in 1x PBS-TX for 1 hr 
at room temperature and subsequently incubated with primary antibodies 
(listed in Table 2.2) at 4ºC overnight. Next day, the sections were washed 
with 1x PBS for 3 times of 10 mins each and then incubated with secondary 
antibodies for 1 hr at room temperature. After washed with 1x PBS for 3 times 
of 10 mins each, the slides were incubated with DAPI solution which stained 
the nucleus for 3 mins. The sections were then washed with 1x PBS for 3 
times of 5 mins each, before mounted with nonfluorescent mounting medium 
(DAKO, Denmark) and photos were taken with a Laser-Scanning confocal 
Microscopy (Olympus FluoViewTM  FV1000, Japan). 




2.4 Real-time Polymerase Chain Reaction (RT-PCR) 
2.4.1 Tissue sampling for mRNA expression 
2.4.1.1 Tissue from LPS injection group 
After rats were under deep anaesthesia, the brain tissues containing LPS 
injection area were taken out and put into a small tube with RNA later (Qiagen, 
Germany) which could inhibit the RNA degrade and then stored in -80ºC 
fridge until use. The survival intervals were 6 hrs, 12 hrs, 1 day, 3, and 5 days. 
In addition, animals without treatment were used as normal control; animals 
with intracerebral injection of saline served as LPS treatment control.  
2.4.1.2 Tissue from minocycline treatment group 
Brain tissues including injection area from LPS+minocycline treatment groups 
were collected and stored in -80ºC fridge until use. The survival intervals were 
3 days after LPS injection. Animals with I.P. injection of saline served as 
minocycline treatment control.  
2.4.2 RNA extraction procedure with RNeasy Microarray Tissue Mini Kit  
After aspirating the RNA later solution, the tissue samples (not more than 
100mg) were homogenized in 1ml of Qiazol reagent using a tissue 
homogenizer (Sigma, USA). If foaming occurs during the homogenization, the 
homogenate were put at room temperature for 2-3 mins until the foam 
subsided. After homogenization, the tubes containing the homogenate were all 
further incubated at room temperature for 5 mins in order to promote the 
complete dissociation of nucleoprotein complexes. 200µl chloroform was then 
added. The tubes were securely capped, shaken vigorously for 15s and then 
put at room temperature for 2-3 mins to settle down. The mixtures were 
centrifuged at 12,000 x g for 15 mins at 4ºC. After centrifugation, the sample 
was separated into 3 phases: an upper, colourless, aqueous phase containing 
RNA; a white interphase; and a lower, red, organic phase. Absolutely, the 
upper, aqueous phase containing the RNA (approximately 600µl) was 
transferred to a new tube. Then 1 equal volume (about 600µl) of 70% ethanol 
was added into the tube and mixed thoroughly by pipetting up and down. 




700µl of the sample were transferred to an RNeasy Mini spin column placed 
in a 2 ml collection tube and centrifuged for 30s at 13,000 rpm at room 
temperature. The flow-through was discarded. The remainder of the sample 
was repeated with centrifugation. After that, 700µl buffer RW1 was added into 
the RNeasy spin column and centrifuged for 30s at 13,000rpm, followed by 
adding 500µl buffer RPE and centrifuged for 30s at 13,000rpm to wash the 
membrane. The flow-through was discarded. The column was washed again 
with 500µl buffer and centrifuged for 2 mins at 13,000rpm. This long 
centrifugation step was to dry the spin column membrane and remove the 
ethanol which may interfere with downstream reactions. The RNeasy spin 
column was then placed in a new 2 ml collection tube and centrifuged at full 
speed for 1 min to eliminate any possible carryover of buffer RPE. Finally, 
RNA was eluted in 30µl RNase-free water. The concentration and purity of 
the extracted RNA were evaluated by spectrophotometric absorbance reading 
at 260nm and 280nm (Nanodrop, Thermo scientific, USA). 
2.4.3 cDNA synthesis 
Two μg of RNA sample was mixed with 1μl oligo (dT) 15 primer (Promega, 
USA) and RNase free water to make a final volume of 10μl. After incubation 
at 70°C for 5 mins, the tubes containing the mixture solution were 
immediately transferred onto ice to cool down for 5 mins.  
Another mixture was prepared as follow: 4μl M-MLV Reverse Transcriptase 
5x Buffer (Promega, USA); 1μl dNTP Mix (Promega, USA); 0.5μl RNase 
inhibitor (Promega, USA) and topped up with RNase free water to make a 
final volume of 9 µl. The mixture solution was then transferred into the tube 
containing RNA sample and incubated at 37°C for 10 mins. After this step, 
1μl M-MLV Reverse Transcriptase (Promega, USA) was added to the tube, 
evenly mixed by pipetting up and down and then incubated at 42°C for 1 hr, 
followed by 5-min incubation at 90°C. The resultant cDNA was then further 
diluted for 10 times with RNase free water and stored at -20°C until use. 
 
 




2.4.4 Real Time qRT-PCR 
The qRT-PCR was performed using an ABI real-time PCR instrument 
(Invitrogen, USA) setting as the default program for 40 cycles of denaturation 
at 95ºC for 1s and annealing at 60 ºC for 20s. The reaction mixture (10µl) was 
composed of 3µl RNAase free water, 5µl of fast SYBR master mix 
(Invitrogen, USA), 0.5µl of forward primer, 0.5µl of reverse primer and 1µl of 
10 times diluted cDNA. The Ct values was obtained from the software and 
then the fold change was calculated with the 2
-ΔΔCT
 method (Livak and 
Schmittgen 2001), normalized by the level of GAPDH expression in each 
individual sample. The formula was as follows: 
Fold change= 2
^
 [(CTcontrol gene-CTcontrol GAPDH)-(CTtarget gene-CTtarget GAPDH)] 
Table 2.3 Primers of Quantitative Real Time PCR 
 
Rat Primers 





IL-1β TCGTTGCTTGTCTCTCCT TGATGACGACCTGCTAGTGTG 
 
TGF-β1 ATACGCCTGAGTGGCTGTCT GTTTGGGACTGATCCCATTG 
 
IL-10 ATCCAGAGGGTCTTCAGCTTC ACCAGCTGGACAACATACTGC 
 
















2.5 Western Blot 
2.5.1 Tissue sampling for protein expression 
Tissue samples were collected at different time intervals from different 
treatments including LPS injection, LPS+minocycline injection and LPS+anti-
TβRII treatment and used for the protein analysis. The survival time points for 
LPS treatment were set as 6 hrs, 12 hrs, 1 day, 3 and 5 day. Animals without 
any treatment served as normal control and animals with intracerebral 
injection of saline served as LPS treatment control. The study time point for 
LPS+minocycline was set as 3 days. Their corresponding controls included 
normal control, I.P. injection of saline control and intracerebral injection of 
saline control. The controls of LPS+anti-TβRII treatment included normal 
control and intracerebral injection of unrelated antiserum control. The survival 
time point was made at 3 days. 
2.5.2 Protein extraction 
Materials and reagents: 
 T-PER tissue protein extraction reagent (Thermo, USA) 
 
 Halt protease inhibitor cocktail (Thermo, USA) 
 
 Halt phosphatase inhibitor cocktail (Thermo, USA) 
 EDTA solution 100x (Thermo, USA) 
 Protein assay  dye reagent concentrate (Bio-Rad, USA) 
 
 Protein assay standard lyophilized BSA (Bio-Rad, USA) 
 
 30% Acrylamide/Bis solution 29.5:1 (Bio-Rad, USA) 
 
 Ammonium persulfate (Bio-Rad, USA) 
 
 N,N’-methylene bisacrylamide N,N,N,N-Tetramethylenediamine 
(TEMED) (Bio-Rad, USA) 
 
 1.5 M Tris-HCl Buffer pH 8.8 
 
 1.0 M Tris-HCl Buffer pH 6.8  
 




 10% (W/V) SDS solution (Bio-Rad, USA) 
 
 10% Tween 20 (Bio-Rad, USA) 
 
 Glycine, Electrophoresis purity reagent (Bio-Rad, USA) 
 
 1x SDS/Glycine Electrophoresis Buffer: 
Tris 3.03g 
            SDS 1g 
            Glycine 14.4 g 
           Distilled water 1000ml 
 
 Transfer Buffer: 
            Tris3.03g 
            Glycine 14.4 g 
            Methanol 200 ml  
            Distilled water 800 ml 
 
 1x TBS-Tween 
NaCl 8g 
Tris 2.42g  
Tween-20 10ml 
Distilled water 900ml 
(Adjusted to PH 7.6 with 4N HCl and topped up to 1,000 ml with 
distilled water) 
 
 Immun-Blot PVDF Membrane 20X20 cm (Bio-Rad, USA) 
 
 Blotting grade Blocker Non-Fat Dry Milk (Bio-Rad, USA) 
 
 Supersignal® West Dura Extended Duration Substrate (Substrate A 
and B) (Thermo, USA) 
 
 CL-XPosureTM Film 18X24 cm Clear Blue X-Ray film (Thermo, 
USA) 
 
 RestoreTM Western Blot Stripping Buffer (Thermo, USA) 
 
Table 2.4 Antibodies: 
Primary antibody 
(Source) 
Antibody Dilution Company 
TNF-α (rabbit) 1:4000 Millipore 
IL-1β (rabbit) 1:2000 Abcam 
TGF-β1 (rabbit) 1:500 Abcam 
IL-10 (rabbit) 1:2000 Abcam 




CNPase (mouse) 1:1000 Millipore 
Iba1 (rabbit) 1:500 Wako 
GFAP (mouse) 1:2000 Millipore 
Total Smad2/3 (rabbit) 1:1000 Cell signalling 
p-Smad2/3 (rabbit) 1:1000 Cell signalling 




Antibody Dilution Company 
Goat anti-mouse HRP 1:10,000 Pierce 
Goat anti-rabbit HRP 1:2000 Pierce 
 
Procedures: 
The tissues with the injection area were used in this study to extract total 
protein. After weighing the tissue samples, the volume of T-PER reagent was 
calculated according to the ration of 1g of tissue to 20ml T-PER reagent. The 
final lysis buffer was composed of T-PER reagent (Thermo, USA), Halt 
protease inhibitor cocktail (Thermo, USA) or Halt phosphatase inhibitor 
cocktail (only for phosphatase protein, Thermo, USA) and EDTA solution 
100x (Thermo, USA). The tissue samples were then homogenized in the lysis 
buffer and centrifuged at 14,000g for 20 min. The supernatant was transferred 
to small new tubes while the residue was discarded. 10µl of supernatant was 
set aside for protein concentration analysis. The remaining supernatant was 
mixed with 6x loading dye and then denatured with the heat blocker at 95ºC 
for 10 mins. The mixture was then aliquoted into small tubes and stored at -
20ºC until use. 
2.5.3 Protein concentration analysis  
A standard curve for protein concentration was made using Bio-Rad BSA 
(1.6mg/ml). Serial dilutions were made with distilled water into 0.4, 0.2, 0.1, 
0.05mg/ml in wells of 96-well plates. After that, the standard protein was 
made by adding 10µl of each serial diluted concentration into 200µl of Bio-
Rad Protein Assay (1:5 dilution). As for the tissue samples, 5µl of each sample 




was added to 95µl of distilled water to obtain a 20x dilution. 10µl of each 
diluted sample was then added to 200µl of Protein Assay. Each standard and 
samples were repeated with 3 times. The mixture was incubated at room 
temperature for 5 mins and then the absorbance was measured at 595m by the 
GENios multiplate reader (Tecan, Switzerland).  
2.5.4 Preparation of sodium dodecyl sulphate polyacrylamide gel 
Resolving Gel (10ml) 
                                                    8%                              12% 
H2O                                            4.6 ml                        3.3 ml 
30% acrylamide/bis mix            2.7 ml                        4.0 ml 
1.5 M Tris (pH 8.8)                   2.5 ml                        2.5 ml 
10% SDS                                   0.1 ml                        0.1 ml 
10% ammonium persulfate       0.1 ml                         0.1 ml 
TEMED                                    0.006 ml                      0.004 ml 
 
 
The 8% gel was used for detecting NG2, p-Smad2/3, total Smad2/3 and 12% 
gel was used for the other proteins. After preparing above mixture, the 
resolving gel was slowly added into the gap of two pieces of glass plates 
immediately after adding TEMED. Then 100% ethanol was added to the top 
of the resolving gel in order to get rid of any bubbles and keep smooth of the 
gel surface. The gels were then kept at room temperature for 30 mins until it 
solidified. 
5% stacking gel (5ml) 
H2O                                         3.4 ml 
30% acrylamide/bis mix         0.83 ml 
1.0 M Tris (PH 6.8)                 0.63 ml 
10% SDS                                 0.05 ml 
10% ammonium persulfate     0.05 ml 
TEMED                                   0.005 ml 
 
The ethanol was discarded and the stacking gel was injected slowly into the 
gap. A 10-well or 15-well comb was then inserted into the stacking gel. The 
gel was kept at room temperature for 30 mins until it became solid. 
 





The combs were carefully removed from the gels and then the glass plates 
containing the gels were transferred into a Mini Protean 2D-gel 
Electrophoresis tank (Bio-Rad, USA). In each lane, 90µg (for p-Smad2/3) or 
20µg (for other left proteins) of denatured protein for each tissue sample was 
added. 5µl Precision Plus Protein Dual Colour Standard (Thermo, USA) was 
used as the marker to identify the size of protein bands. The electrophoresis 
was started at 80V for 20 mins and then changed to 100V for 100 mins.   
2.5.6 Semi-dry transfer of protein 
Before semi-dry transfer, four filter papers (for two gels) were soaked into the 
transfer buffer for 20 mins. Two pcs of Immun-Blot PVDF Membranes (Bio-
Rad) were incubated in methanol for 10s and then put into transfer buffer for 
15 mins. The gels were separated from the glass plates and kept into transfer 
buffer. From the plate of the semi-dry transfer machine, 1 filter paper on the 
bottom, 1 membrane, 1 gel, 1 filter paper were placed in sequence and then the 
completed gels were transferred at 20V for 2 hrs (for NG2) and 50 mins (for 
other proteins). 
2.5.7 Immunoblotting 
The PVDF membranes were blocked with 5% milk in 0.1% TBS-Tween on a 
shaker at room temperature for 1 hr and then washed with 0.1% TBS-Tween 
twice. The primary antibodies in 0.1% TBS-Tween were added and incubated 
on a shaker at 4ºC overnight.  Next day, membranes were washed with 0.1% 
TBS-Tween for 3 times of 15 mins each on a shaker at room temperature. 
Corresponding HRP-secondary antibodies were then applied for 1 hr on a 
shaker at room temperature. 
The membranes were washed with 0.1% TBS-Tween for 3 times of 15 mins 
each. The substrate mixture which composed of equal volume of substrate A 
and B (Supersignal West Dura Extended Duration Substrate) was added on the 
membranes and incubated for 5 mins in dark before X-ray film exposure. 




If necessary, the membranes could be stripped to stain other antibodies. 
Briefly, the membranes were washed with 1x TBS for 3 times of 10 mins each 
and then stripped by incubating with Restore
TM
 Western Blot Stripping Buffer 
(Thermo Scientific, USA) for 20 mins. After further washing with 0.1% TBS-
Tween for 3 times of 15 mins each, the membranes were blocked with 5% 
milk and incubated with other target primary antibodies. 
2.6 In vivo Functional analysis of NG2 cells 
2.6.1 BrdU proliferation assay 
In order to study the proliferation ability of NG2 cells, BrdU assay was carried 
out in the current study. Specifically, the sections from the animals with BrdU 
treatment were washed with 1x PBS for 3 times of 10 mins each. Then 
sections were incubated in 2M HCl for 30 mins at 37 C to denature DNA. 
After blocking with 5% goat serum in 1x PBS-TX at room temperature for 1 
hr, the sections were then incubated with mouse anti-BrdU (1:200, millipore, 
USA) and rabbit anti-NG2 (1:100, Millipore, USA) or rabbit anti-Iba1 (1:500, 
Wako, Japan) overnight at room temperature. The following steps could refer 
to the immunofluorescence staining procedure. Images were captured with a 
confocal Microscopy (Olympus FluoViewTM  FV1000, Japan). 
2.6.2 Phagocytosis assay 
The latex beads (L9279, sigma, USA) used in this study are in amine-modified 
forms. The average bead size is 0.1µm. They are fluorescent in red, with the 
excitation at 575nm and emission at 610nm, thus could be observed under the 
confocal microscope. 
In order to observe the phagocytosis of NG2 cells, microglia and macrophages, 
the sections including latex bead injection site were single stained with 
corresponding antigen markers, anti-NG2, OX42, or ED1 antibody. For the 
triple labelling, the sections were co-stained with antibodies against NG2 and 
OX42. For single antibody staining, goat anti-rabbit Alexa-488 (for rabbit 
source) or goat anti-mouse Alexa-488 (for mouse source) was employed. For 
triple labelling sections, corresponding secondary antibodies were goat anti-




rabbit Alexa-596 (detecting anti-NG2) and goat anti-mouse Alexa-405 
(detecting anti-OX42). After immunofluorescent staining, slides were stored at 
4ºC fridge until observation. When taking picture with the confocal 
microscope (Olympus FluoViewTM FV1000, Japan), NG2 was view in FITC 
channel (green), OX42 in DAPI channel (blue) and latex beads at Cy3 channel 
(red). 
2.6.3 Detection of selected cytokine expressions in the normal control and 
LPS focal injury brain tissue 
In order to detect whether NG2 cells could express cytokines, several 
antibodies of typical pro-inflammatory cytokines and anti-inflammatory 
cytokines were co-stained with anti-NG2, a marker of NG2 cells. 
First, slides were washed with 1x PBS-TX for 3 times, with 10 mins for each 
time. Then the sections were blocked with 5% goat serum for 1 hr and then 
incubated with primary antibodies of rabbit source: IL-1β (Abcam, UK), IL-10 
(Abcam, UK), TGF-β1 (R&D systems, USA), IL-6 (Abcam, UK), Lix 
(Peprotech, USA) and iNOS (Abcam, UK), which co-stained with either 
mouse NG2 (Millipore, USA) or mouse OX42 (Santa Cruz, USA) at room 
temperature overnight. In addition, in order to detect the cellular expression of 
IL-10, it was co-stained with GFAP (Millipore, USA), an antigen marker of 
astrocyte. Next day, after washing with 1x PBS for 3 times, each time of 10 
mins, the sections were then incubated with goat anti-rabbit Alexa-596 
(Invitrogen, USA) and goat anti-mouse Alexa-488 (Invitrogen, USA) for 1 hr 
at room temperature. After staining with DAPI solution for 3 mins, the 
sections were mounted with nonfluorescent mounting medium (DAKO, 
Denmark) and images were captured with a confocal microscope (Olympus 
FluoViewTM FV1000, Japan). 
2.7 Statistical analysis 
All the experiments were repeated at least in triplicate for statistical purpose, 
and where appropriate, the data were presented as mean and standard 
deviation (SD). The Student’s t-test was used when comparing only two 




groups. One-way ANOVA was used to compare with more than three groups. 




























 cells including the constitutive NG2 cells and microglia with 
induced NG2 expression do not have phagocytic ability 
3.1 Establishment of LPS induced neuroinflammation model 
3.1.1 Activation of glial cells towards LPS focal injury 
After LPS focal administration at 1µg/µl, 10µg/rat, it induced strong 
microglial activation around the needle track and lesion centre indicated by the 
asterisks at 1 day (Figure 3.1A), 3 (Figure 3.1B) and 5 days (Figure 3.1C). 
Furthermore, the brain pathology was confirmed at 1 day post injection 
according to immunofluorescence staining with OX42 labelled microglia, 
GFAP labelled astrocytes, CNPase labelled oligodendrocytes, and NG2 
labelled NG2
+
 cells (Figure 3.1D-I).  
Ramified resting microglia in the normal cortex (Figure 3.1D) were 
transformed into amoeboid activated phenotype 1 day post injection (Figure 
3.1E), which served as key symbols for brain pathology induced by LPS 
administration.  At the same time, astrocytic hypertrophy (Figure 3.1G) and 
increase in expression of CNPase in the cell bodies of oligodendrocytes 
(Figure 3.1I) were also observed. After LPS challenge, the sizes of NG2
+
 cell 
bodies increased (Figure 3.1E, G and I) compared to those in the normal 
cortex (Figure 3.1D, F and H). Additionally, NG2 positive staining became 
more intense in comparison with those in the normal side. No double labelling 
of GFAP or CNPase with NG2 in either normal brain cortex (Figure 3.1F and 
H) or impaired brain cortex at 1 day after LPS injection (Figure 3.1G and I) 
was observed. However, it seems that there was colocalization between NG2 






Figure 3.1 Activation of glial cells towards LPS focal injury 
The injection centres indicating by the asterisks are seen at different time 
points post LPS treatment (A, B and C). Microglia (OX42, green) are 
transformed from ramified resting in normal cortex (D) into amoeboid 
activated phenotype (E). The cell bodies of astrocytes (GFAP, green) become 
hypertrophied (G) compared with those in the normal state (F). Additionally, 





staining in their cell bodies in response to the LPS stimulation (I). At 1 day 
after LPS challenge, the sizes of NG2
+
 (red) cell bodies increase (E, G and I) 
in comparison to those in the normal cortex (D, F and H). Bar: 100μm in 
Figure A-C and 10μm in the left figures. 
3.1.2 Cytokines expression 
In the LPS focal injection model, mRNA expression levels of inflammatory 
cytokines like TNF-α and IL-1β increased at the early time points and then 
gradually decreased (Figure 3.2). For the TNF-α, the mRNA expression 
peaked at 6 hrs after LPS injection and then gradually decreased at least till 5 
days after LPS treatment. For the IL-1β, the mRNA level increased at 6 hrs, 
peaked at 12 hrs after LPS injection and then gradually declined at least till 5 
days post injection. These results suggested again that the LPS induced 
inflammation model was successfully established, indicated by the 




Figure 3.2 mRNA expression of TNF-α and IL-1β after LPS focal injection 
The mRNA expression levels of TNF-α and IL-1β were studied up to 5 days 
after injection of LPS by RT-PCR. (A). TNF-α expression is significantly 
upregulated at 6 hrs after injection and then gradually decreases. (B). IL-1β 
expression is significantly upregulated at 6 and 12 hrs after LPS injection. Its 
expression peaks at 12 hrs and then gradually decreases until 5 days. The 
quantitative analyses were done by normalising the values to GAPDH. Bar 





After LPS focal injection, protein expression levels of TNF-α and IL-1β 
increased at early time points and then gradually decreased (Figure 3.3), 
which was consistent with the changes of mRNA expression levels (Figure 
3.2). The expression of TNF-α increased at 6 hrs and 12 hrs and then gradually 
decreased (Figure 3.3A). The protein of IL-1β increased at 6 hrs, peaked at 12 
hrs after LPS injection and then gradually decreased at 5 days after LPS 
injection (Figure 3.3B).  
 
 
Figure 3.3 Protein expression of TNF-α and IL-1β after LPS focal injection 
Proteins from different time points after LPS injection were extracted and 
immunoblotted. Western blot analyses comparing the expression profile of 
TNF-α and IL-1β. 20µg of protein was loaded into each lane. Signals for β-









3.2 Activation of NG2
+ 
cells 
After successful establishment of the LPS induced inflammation model, the 
responses of NG2
+ 
cells were examined from two aspects: the morphological 
change and the number alteration of NG2
+
 cells. 
3.2.1 Morphological change of NG2
+
 cells 
After LPS focal injection into the brain cortex, the morphology of the fourth 
major glial cells, NG2
+ 
cells, in the impaired brain cortex showed some 
changes (Figure 3.4), indicated by arrows, the size of cell bodies became 
larger, the cell processes thicker, and immunostaining of NG2 stronger, which 
is consistent with other findings in stab wound injury model (Yokoyama et al. 
2006) and cerebellum puncture lesion (Levine 1994).  
 
 
Figure 3.4 Morphological changes of NG2
+ 
cells after LPS focal injection 
Immunofluorescence staining of NG2
+ 
cells with anti-NG2 (red) and nuclei 
with DAPI (blue). At 1 day (B, F), 3 (C, G) and 5 days (D, H) after LPS 
injection, NG2
+ 
cells show obvious morphological changes compared with the 








3.2.2 Increase of NG2
+ 
cell number 
The number of NG2
+ 
cells was obtained according to counting the DAPI-
stained nuclei and anti-NG2 stained cell bodies at different time intervals from 
triplicate groups. Only the complete cells with a cell body and nucleus would 
be counted. The results showed that the number of NG2
+ 
cells in LPS 
administrated group gradually increased and peaked at day 5 post-operation 
compared with the normal control group (Figure 3.5).  
 
                         
Figure 3.5 Increase in the number of NG2
+ 
cells in LPS focal injected brain at 
different time points 
Quantification of the number of NG2
+
 cells (per counting area). The number 
of NG2
+
 cells significantly increases in the LPS treatment group and peaks at 
5 days post-injection in comparison to normal control group. Bar graphs 
















 cells did not stain with anti-BrdU antibody 
As shown in Figure 3.6, BrdU (red) was detected with anti-BrdU which 
labelled the newly synthesized DNA in the nucleus of replicating cells staying 
at the S phase of cell cycle. Therefore BrdU
+
 cells indicate proliferating cells 
in the brain cortex. BrdU was incorporated into the Iba1 labelled microglia 
(green) at 1 day (Figure 3.6D), 3 (Figure 3.6E) and 5 days (Figure 3.6F) 
after LPS injection, suggesting microglia were the proliferating cells. However, 
the red nuclei (BrdU) were not co-localized with the nuclei of NG2
+ 
cells 
(green) at different time points (Figure 3.6A, B and C), indicating that NG2
+ 





cells are not co-stained with anti-BrdU antibody 
Confocal images showing the expression of BrdU with NG2
+ 
cells and 
microglia. The BrdU (red) is positively incorporated by the Iba1
 
labelled 
microglia (green, D, E and F), whilst not colocalized with the nuclei of NG2
+ 






3.4 No decrease in the number of oligodendrocytes 
As shown in the above results, NG2
+ 
cells were not proliferating in response to 
the inflammation induced by LPS. It is widely considered that one of the 
functions of NG2
 
cells is to act as OPCs, which may differentiate into 
oligodendrocytes in demyelination. Therefore, the responses of oligo-
dendrocytes were observed in this study. Western blot results (Figure 3.7A) 
showed that the amount of CNPase, an antigen marker of oligodendrocytes, 
was not changed at any time point after LPS injection compared with normal 
control group. β actin was used an internal control here. Moreover, the cell 
number of CNPase
 
labelled oligodendrocytes was also not altered in LPS 























Figure 3.7 The protein expression of CNPase and the number of CNPase
+
 cells 
(A) Western blot shows no obvious changes in expression of CNPase at 
different time intervals after LPS injection compared to the normal control 
group. (B) There are also no significant changes in the number of CNPase
+ 
cells after LPS focal injection. Bar graphs represent mean±SD from three 
independent experiments (Average counting area: 0.1 mm
2
, Significance was 





3.5 Identification of NG2
+
 cells 
3.5.1 Colocalization of NG2 and OX42 immunostaining 
In the cortex of the normal adult rat brain (Figure 3.8A, B and C), there was 
seldom any colocalization between NG2 (red) and OX42 (green). However, in 
this LPS induced neuroinflammation model, the colocalization appeared in the 





 double stained cells were more evident at 3 (Figure 3.8E) 
and 5 days (Figure 3.8F). In the Figure 3.8G, the serial scanning of the brain 
section with double staining of anti-NG2 (red) and anti-OX42 (green) 
antibodies at 5 days after LPS injection showed the colocalization (yellow) of 
the double staining existed in the cell at the crossing point of the two yellow 
lines. These two yellow lines presented two serial scanning plans (narrow 
picture panels on the right and bottom) through the entire thickness of the 
brain section with the double labelling of anti-NG2 and anti-OX42. 
These double labelling cells could also be observed in other models such as 
facial nerve axotomy model (Zhu et al. 2010) and stab wound injury model 
(Yokoyama et al. 2006). According to the results in the Section 3.3 in the 
current study, the number of NG2
+ 
cells increased at the observed time points 





cells have been found in the current study, it may 
be possible that microglia might be induced to express NG2 protein and join 
the pool of NG2
+ 





















Figure 3.8 Double immunofluorescence labelling of NG2 and OX42 at 1 day, 
3 and 5 days after LPS injection 
Confocal images showing the immunostaining between NG2 (red) and OX42 
(green) in the normal cortex (A, B and C) and LPS focal injected cortex (D, E 
and F). At 1 day after LPS injection (D), few double labelling between NG2 
and OX42 could be observed. More significant colocalization is observed at 3 
and 5 days after LPS injection (yellow, E and F). The confocal Z stack image 
(G) shows double staining of antibody against NG2 (red) and OX42 (green) 
after serial scanning through entire thickness of the brain section. The cross 
point of two yellow lines indicates a double labelling cell (yellow). The two 
green lines in narrow picture panels on the right and bottom indicate the cells 

















 cells was obtained through counting the cells 
with yellow cell bodies and DAPI stained blue nuclei in the 40x magnification 





cells in LPS administrated group gradually increased and peaked at day 5 post-




 cells to total OX42
+
 
cells also gradually increased from nearly 7% at 1 day to about 40% at 5 days 


















cells at 1 
day, 3 and 5 days after LPS injection 




 cells increases gradually as the inflammation 





 cells to total OX42
+
 cells also significantly increases and peaks 
at 5 days post LPS injection. Bar graphs represent mean±SD from three 





3.5.3 No colocalization of NG2 and ED1 staining 
3.5.3.1 No colocalization of NG2 and ED1 staining at 1 day, 3 and 5 days 
after LPS treatment 
Some studies have reported that NG2 protein is also expressed in macrophages 
besides activated microglia in the transient MCAO rat model (Smirkin et al. 
2010) and excitotoxic hippocampal lesion model (Bu et al. 2001). In order to 
find out whether NG2 protein could be induced in macrophages in the current 
model, anti-NG2 was co-stained with the anti-ED1, an antigen marker of 
phagocytic macrophages. As shown in Figure 3.10, ED1
+
 cells appeared in 
the vicinity of the injection site 1 day after LPS injection (Figure 3.10D). The 
intensity of ED1 immunostaining became stronger at 3 and 5 days after LPS 
injection (Figure 3.10E and F). However, there was seldom any double 
labelling between NG2 and ED1 positive cells both in the normal cortex 
(Figure 3.10A, B and C) and the LPS-injected cortex (Figure 3.10D, E and 
F). Therefore, the current results may suggest that ED1
+
 macrophages were 
not induced to express NG2 protein as some activated microglia in this LPS 











Figure 3.10 No colocalization between NG2 and OX42 at 1 day, 3 and 5 days 
after LPS injection 
Double immunofluorescence staining of antibodies against NG2 (red) and 
ED1 (green) in normal cortex (A, B and C) and LPS focal injected cortex (D,  
E and F) at 1 day (A, D), 3(B, E), and 5(C, F) days after LPS injection. No 
colocalization between NG2 and ED1 labelling is observed across 1 day, 3 and 













3.5.3.2 No colocalization between NG2 and ED1 at 7 and 14 days after 
LPS injection 
The above results showed that ED1
+
 macrophages did not express NG2 
protein at 1 day, 3 and 5 days after LPS injection. In a previous study, Bu et al. 
2001 reported that after the excitotoxic hippocampal injury, colocalization 
between the NG2 and ED1 was not detected at 7 days after injury, but 
appeared at 14 days post injury (Bu et al. 2001). Since the time point in this 
study only lasted for 5 days post LPS treatment, it was not clear whether ED1
+
 
macrophages could express NG2 protein at a longer survival time point as 
described in Bu’s study. Therefore, the study time points were extended to 7 
and 14 days and then the double labelling between ED1 and NG2 was checked. 




 cells were still present at 7 
days after LPS injection indicated by the arrows (Figure 3.11Aa). However, 
there was still no double labelling between NG2 and ED1 (Figure 3.11Ab). 
Further extending the survival time to 14 days, NG2
+ 
cells have returned to the 





at 14 days (Figure 3.11Bc). However, there were still no NG2 and ED1 



















Figure 3.11 No colocalization between NG2 and ED1 at 7 and 14 days after 
LPS injection 
Double immunofluorescence staining of antibodies against NG2 (red) with 
OX42 (green, Aa and Bc) or ED1 (green, Ab and Bd) in the impaired cortex at 




 cells are 
observed at 7 days post injury, shown by the arrows (Aa). However, there is 
no colocalization between anti-NG2 and ED1 (Ab). Nearly no double labelling 
of antibodies against NG2 and OX42 in the focal injected cortex is observed at 
14 days after LPS injection (Bc). There is still no colocalization between anti-







3.5.4 Immunofluorescence staining of anti-NG2, OX42 and PDGFαR 
antibodies 




 cells, the sections containing the 
injection area were labelled with antibodies against NG2 or OX42 with 
PDGFαR. As shown in the Figure 3.12, cell types including NG2+/ PDGFαR+ 
cells, NG2
-/ PDGFαR+ cells and OX42-/PDGFαR+ cells were observed near 
the injection site at 5 days post LPS stimulation. Some NG2
+
 cells were co-
localized with PDGFαR+ cells in the normal brain tissue (Figure 3.12Bk), 
consistent with the view that a subpopulation of NG2 cells exists as OPCs at 
the adult stage (Dawson et al. 2000; Nishiyama et al. 2002). Under the injury, 
even PDGFαR+ cells were partially co-localized with NG2+ cells (Figure 
3.12Bl), they were always negative to OX42
+





 cells might possibly not come from the PDGFαR labelled 





















Figure 3.12 Immunofluorescence staining with anti-NG2, OX42 and PDGFαR 
antibodies at 5 days after LPS injection 
Confocal images showing the double immunofluorescence staining between 
anti-OX42 and PDGFαR antibodies (A) as well as anti-NG2 and PDGFαR 
antibodies (B). OX42 labelled microglia are not co-localized in both normal 
control group (Ae) and LPS injection (Af). NG2 labelled NG2 cells are double 
stained with PDGFαR labelled OPCs in normal condition (Bk) as well as 











 cells did not engulf latex beads 
3.6.1 Injection of latex beads immediately after LPS 
Fluorescent latex beads are small particles with different sizes and different 
fluorescent colours and could be observed under a normal fluorescent 
microscope or laser confocal microscope, thus widely used in the phagocytosis 
assay. In this study, latex beads with red fluorescent colour were employed to 
study the phagocytosis function of NG2
+ 
cells. They were immediately 
administrated after LPS injection into the same injection site. As shown in 
Figure 3.13, small red dot particles were injected latex beads. Some OX42 
labelled microglia were observed to engulf the latex beads, appearing the 
green cell bodies encircling red latex beads at 1 day (Figure 3.13B), 3 (Figure 
3.13E) and 5 days (Figure 3.13H) post injection. In addition, ED1 labelled 
macrophages (green) were also found to phagocytose injected small latex 
beads (red) at different time points, shown in yellow (Figure 3.13C, F and I). 
These results were consistent with the widely accepted knowledge that 
microglia or macrophages performed the phagocytic function in the CNS. For 
the NG2
+ 
cells, they became activated, with the pronounced increases in size 
of cell bodies while shortness in cell processes. However, the latex beads were 
not contained in the cell bodies of NG2
+ 
cells at 1 day, 3 and 5 days post LPS 
injection (Figure 3.13A, D and G). As per current view, NG2
+ 
cells in this 
study were composed of two kinds of cells: the constitutive NG2
+
 cells and 
microglia with induced expression of NG2 protein. Thus this result may 
demonstrate that the NG2
+
 cells did not have the phagocytic function in this 
LPS induced inflammation model. Specifically, the resident NG2
+ 
cells did not 
present engulfing function. In addition, microglia with induced NG2 protein 
expression may also not have phagocytic function. It is possible that the NG2 











Figure 3.13 Latex beads were not engulfed by NG2
+ 
cells at 1 day, 3 and 5 
days after LPS injection 
 
The latex beads (red) injected brain sections were stained with either anti-NG2 
(green) or anti-OX42 (green) or anit-ED1 (green) antibodies. In the 
surrounding area of the injection site, many OX42 labelled microglia (B, E 
and H) and ED1 labelled macrophages (C, F and I) engulf latex beads shown 
by the green cell bodies encircling red or the yellow cells at different time 
intervals. However, NG2
+ 
cells seldom contain red latex beads in their cell 









3.6.2 Latex beads injection at 3 days after LPS injection 
Since the activation of NG2
+ 





cells became more pronounced from 3 days post injection at later 
inflammation process, it is not clear whether this is the reason that latex beads 
were not phagocytosed by NG2
+ 
cells. Therefore, another plan of latex 
injection was made. Specifically, latex beads were injected 3 days later after 
LPS injection, when NG2
+ 





appeared in large quantity as mentioned in Section 3.5.1. The result showed 
that the latex particles were still mainly inside the cell bodies of OX42
 
labelled 
microglia (Figure 3.14B, E and H) or ED1 labelled macrophages (Figure 
3.14C, F and I). The NG2
+ 
cells composed of resident NG2
+ 
cells and 
microglia with induced NG2 expression still did not engulf red latex beads 
















 cells did not phagocytose latex beads when latex beads 
were injected at 3 days after LPS injection 
 
Latex beads (red) and immunofluorescene staining of NG2, OX42 or ED1 (all 
in green) at 1 day (A, B and C), 3 (D, E and F) and 5 days (G, H and I) after 
Latex injection at 3 days post LPS injection. Near the injection area, a lot of 
OX42
+
 microglia (B, E and H) and ED1
+
 macrophages (C, F and I) contain 
latex beads in their cell bodies, showing by the green cell bodies encircling red 
latex beads or the yellow cells at different time intervals. However, NG2
+ 
cells 
still do not engulf red latex beads in their cell bodies at 1 day (A), 3 (D), and 5 









3.6.3 Triple labelling of NG2, OX42 and Latex beads at three days after 
LPS injection 
In order to further confirm the view of non-phagocytic ability of NG2
+
 cells 
near the injection site, triple labelling between Latex, NG2 and OX42 was 
performed in this study. Results showed OX42 labelled microglia (blue) could 
engulf latex beads, displayed by the blue cell bodies encircling red latex beads 
(Figure 3.15B). In addition, cells with double labelling between NG2 and 
OX42 were also presented, appearing in the white (Figure 3.15D). However, 
the NG2
+
 cells (green) did not contain latex beads inside their cell bodies 





 cells in the white did not contain red latex beads in the 
cell bodies, indicated by the arrows. Other cells stained in the green, except 
the white, represented the constitutive NG2
+ 
cells. They also did not engulf 
latex beads. Therefore, the triple labelling results further confirmed that both 
the constitutive NG2
+ 
cells and microglia with induced NG2 expression did 
not have phagocytic function in this neuroinflammation model. Thus, the 
induced NG2 protein expression in microglia may possibly present the 









          
 
Figure 3.15 Triple labelling of Latex beads (red), NG2 (green) and OX42 
(blue) at 3 days after injection of both LPS and Latex beads 
OX42
+
 microglia contain latex beads inside (B, appearing as blue cell bodies 
encircling red dots). The NG2
+ 
cells still do not engulf latex beads (C). The 





 cells do not engulf latex beads (shown by the arrows 










cells and cytokines and chemokines 
3.7 Cytokines and chemokines expression in NG2
+ 
cells 
In order to investigate whether NG2
+ 
cells could express cytokines and 
chemokines during the inflammation process like microglia, the major 
immune cells in the CNS, anti-NG2 antibody was co-stained with selective 
antibodies which detected corresponding cytokines and chemokines in this 
LPS focal injury model.   
3.7.1 NG2
+ 
cells did not express IL-6 
As shown in Figure 3.16, the expression of IL-6 was less in the normal adult 
brain (Figure 3.16A and E) but increased after LPS treatment at different time 
intervals. IL-6 was observed in OX42 labelled microglia appearing in the 
yellow shown by the arrows at 1 day (Figure 3.16B), 3 (Figure 3.16C) and 5 
days (Figure 3.16D) after LPS injection. However, NG2
+ 
cells were not co-
localized with IL-6 at different time points after LPS injection as shown in 

















Figure 3.16 No colocalization between anti-IL-6 and anti-NG2 antibodies at 
different time points after LPS injection 
Double immuofluorescene staining of antibodies against IL-6 (red) and NG2 
(green) or OX42 (green) in the normal brain cortex (A and E) and LPS focal 
injury cortex. No colocalization between NG2 and IL-6 is observed at 1 day 
(F), 3 (G) and 5 days (H) after LPS injection. IL-6 is localized on OX42 


















cells did not express LPS induced CXC chemokine (lix) 
Lix is an LPS induced chemokine and chemoattractant to neutrophils.  It has 
been shown that microglia and macrophages could upregulate the expression 
of lix upon activation (Albright and Gonzalez-Scarano 2004). Lix was 
previously found to be expressed by NG2
 
cells in vitro through a cytokine 
microarray analysis in our lab (data not published). In this study, whether 
NG2
+ 
cells could express lix was studied in this LPS induced inflammation 
animal model. As shown in Figure 3.17, lix was expressed at a low level in 
the normal condition (Figure 3.17A and E) but increased after LPS 
stimulation. Microglia was able to express lix at 3 days after LPS injection 
(Figure 3.17C), shown in yellow indicated by the arrows. However, NG2
+ 
cells did not express lix at any time points after LPS injection (Figure 3.17F, 





cells did not express lix at different time intervals after LPS 
administration 
Double immunofluorescence labelling between antibodies against lix (red) and 
NG2 (green) or OX42 (green) in the normal brain cortex (A and E) and 
impaired brain cortex at 1 day (B, F), 3 (C, G) and 5 days (D, H) after LPS 









 cells did not express IL-10 
As shown in Figure 3.18, IL-10 (red) was expressed at a low level in the 
normal adult brain tissue (Figure 3.18A and E) but increased at different time 
points after LPS injection. Microglia expressed IL-10 at 3 days after LPS 
injection (Figure 3.18C), shown in the green cell bodies encircling red 
indicated by the arrows. However, NG2
+ 
cells were not observed to express 
IL-10 at 1 day (Figure 3.18F), 3 (Figure 3.18G) and 5 days (Figure 3.18H) 





 cells did not express IL-10 at different time points after LPS 
injection 
Double immunofluorescence staining of antibodies between IL-10 (red) and 
NG2 (green) or OX42 (green) in the normal brain cortex (A and E) and LPS 









In the Figure 3.18, the morphology of some IL-10
+
 cells looked like 
astrocytes at 3 and 5 days after LPS injection. Furthermore, many studies have 
reported that astrocytes expressed IL-10 in the pathological conditions 
(Hulshof et al. 2002; Ledeboer et al. 2002). Therefore, in the current study, the 
cellular localization of IL-10 was further investigated through double labelling 
with anti-GFAP (Figure 3.19). 
Through double staining between anti-IL-10 and anti-GFAP, many co-
localized cells, appearing in yellow, were found at 3 (Figure 3.19C) and 5 
days (Figure 3.19D) after LPS injection. This result suggests that IL-10 was 
mainly expressed in GFAP labelled astrocytes at a later time point in this LPS 
focal injury model. 
 
Figure 3.19 Colocalization between anti-IL-10 and anti-GFAP antibodies after 
LPS treatment 
Colocalization between IL-10 (red) and GFAP (green) is not found both in the 
normal cortex (A) and 1 day (B) after LPS treatment. However, the double 













cells did not express inducible nitric oxide synthase (iNOS) 
The inducible nitric oxide synthase (iNOS) is one of three key enzymes which 
generate nitric oxide (NO). In the brain, microglia and astrocytes are the major 
glial cell types which express iNOS and produce NO in response to the 
neuroinflammation or neurodegenerative diseases (Guo and Bhat 2006; Xu 
and Drew 2006).  The expression of iNOS in microglia could be triggered by 
LPS (Lieb et al. 2003; Possel et al. 2000). In the current LPS model, the 
localization of iNOS was observed using anti-OX42 antibody to label 
microglia and anti-NG2 antibody to label NG2
+ 
cells. Under the normal 
condition (Figure 3.20A and E), iNOS expression was seldom detected but 
upregulated after LPS treatment. Specifically, iNOS was expressed by OX42
+
 
microglia at 1 day (Figure 3.20B), 3 (Figure 3.20C) and 5 days (Figure 
3.20D) after LPS injection, indicated by the arrows. However, NG2
+ 
cells did 
not express iNOS at different time points after LPS administration (Figure 





















Figure 3.20 No colocalization between anti-iNOS and anti-NG2 antibodies 
after LPS injection 
Double labelling between antibodies against iNOS (red) and NG2 (green) or 
OX42 (green) in the normal brain cortex (A, E) and LPS focal injury cortex 


















 cells can express IL-1β 
The results stated previously showed that NG2
+
 cells did not express IL-6, lix, 
IL-10 and iNOS. However, the expression pattern of IL-1β was different from 
those cytokines. As shown in Figure 3.21, the expression of IL-1β was low 
and seldom detected in the normal brain tissue (Figure 3.21A and E) but was 
greatly upregulated after LPS treatment. OX42
+
 microglia (green), as the 
positive control here, expressed IL-1β (red) at 1 day (Figure 3.21B), 3 (Figure 
3.21C) and 5 days (Figure 3.21D) after LPS focal injury and the 
colocalization (yellow) was indicated by the arrows in the picture. For the 
NG2
+ 
cells (green), they did not express IL-1β (red) at 1 day (Figure 3.21F) 
and 5 days (Figure 3.21H) after LPS treatment. However, IL-1β was co-
localized with amoeboid phenotyped NG2
+
 cells (yellow) at 3 days (Figure 
3.21G) after LPS injection as shown by the arrows. This was consistent with 
another study that IL-1β was expressed by the amoeboid phenotyped NG2+ 
cells in a trimethyltin-evoked neuronal apoptosis model (Fiedorowicz et al. 
2008b). According to the morphological observation, these IL-1β+/NG2+ cells 
may possibly belong to the microglia with induced NG2 protein expression. 
Further triple labelling study should be required in order to confirm this 
















Figure 3.21 Double immunofluorescence staining between anti-IL-1β and anti-
NG2 after LPS injection 
Double labelling (yellow, arrows) of antibodies against IL-1β (red) with NG2 
(green) or OX42 (green) in the normal brain cortex (A and E) and LPS focal 
injury cortex at 1 day (B, F), 3 (C, G), and 5 days (D, H). IL-1β is co-localized 
with NG2
+ 















Part III. The activation of NG2
+ 
cells is downstream to microglial 
activation 
3.8 The responses of NG2
+ 
cells after inhibition of microglial activation by 
minocycline in LPS focal injury model  
Minocycline is a tetracycline-type antibiotic and has anti-inflammatory 
functions in the CNS. It is a potent inhibitor of microglial activation and has 
no direct effect on astrocytes and neurons (Amin et al. 1996; Tikka et al. 2001; 
Tikka and Koistinaho 2001). It blocks secretion of the inflammatory cytokines 
through inhibition of p38 MAPK pathway in microglia (Tikka et al. 2001; 
Tikka and Koistinaho 2001; Zhu et al. 2002). In this study, minocycline was 




3.8.1 Attenuation in the expression of LPS-induced cytokines after 
minocycline treatment 
In this LPS injection model, minocycline has been found to attenuate the 
expression of cytokines. Figure 3.22A showed the mRNA expression of 
cytokines at 3 days after LPS plus minocycline treatment. The mRNA 
expression of IL-1β, IL-10 and TGF-β1 significantly declined after 
minocycline treatment compared with only LPS treatment group. Additionally, 
the changes in the protein expressions of cytokines were detected by the 
western blot shown in Figure 3.22B and Figure 3.22C. At 3 days after LPS 
injection, the cytokines including TNF-α, IL-1β, IL-10 and TGF-β1 were 
significantly upregulated in comparison to the normal control group. After 
minocycline treatment, the upregulation of expression of these cytokines was 
significantly inhibited compared with only LPS treatment. This result 
indicated that minocycline could attenuate the LPS induced 
neuroinflammation, which was consistent with other studies that minocycline 
has the anti-inflammatory effects (Sanchez Mejia et al. 2001; Tomas-







Figure 3.22 Inhibition in the expression of LPS-induced cytokines after 
minocycline treatment 
Minocycline was administrated 12 hrs before and immediately after LPS 
microinjection and then followed by daily injection for 3 days. A. The mRNA 
expression of TNF-α, IL-1β, IL-10 and TGF-β1. B. Protein expression of 
cytokines TNF-α, IL-1β, IL-10 and TGF-β1. C. Significant downregulation of 
protein expression after minocycline treatment compared with only LPS 
administration shown by the relative density. N: normal control; LPS: LPS 
treatment; LPS+M: minocycline treatment following LPS injection; S: saline 













3.8.2 Decrease in expression of Iba1 after minocycline treatment 
To assess the effect of minocycline on status of microglial activation, protein 
expression of Iba1, a marker of activated microglia was investigated. Western 
blot bands of Iba1 were shown in the Figure 3.23A and relative density to β 
actin was calculated in the Figure 3.23B. After LPS administration for 3 days, 
the expression of Iba1 significantly increased compared with normal control 
group. However, after minocycline daily treatment for three days, the 
expression of Iba1 significantly decreased compared with only LPS treatment 
group (Figure 3.23B). This result suggests that the activation of microglia was 
suppressed by minocycline treatment.  
 













Figure 3.23 Decrease in protein expression of Iba1 after minocycline treatment 
A. Iba1, a marker for activated microglia, is expressed at a low level in normal 
control group (N). After LPS treatment (LPS), protein expression of Iba1 
significantly increases. However, this effect is inhibited by minocycline 
(LPS+M) at some extent. (S: saline treatment); B. Bar graphs represent 






3.8.3 No direct activation effect on astrocytes after minocycline treatment 
At 3 days after LPS injection, the expression of GFAP significantly increased 
compared with normal control group. However, it did not alter after 
minocycline daily treatment for three days (Figure 3.24). This result suggests 
that the expression of GFAP is not affected by minocycline, which is 
consistent with the findings that minocycline has no direct effect on activation 
of astrocytes (Fan et al. 2005a; Yrjanheikki et al. 1998). 
 
 
Figure 3.24 No alteration in GFAP expression after minocycline treatment 
A. At 3 days after LPS administration (LPS), protein expression of GFAP 
significantly increases compared with normal control group (N). However, 
this effect is not influenced by minocycline treatment (LPS+M). S: saline 







3.8.4 Downregulation in responses of NG2
+
 cells after inhibition of 
microglial activation by minocycline treatment 
In order to investigate the responses of NG2
+ 
cells after minocycline treatment, 
the immunofluorescence staining was carried out to detect the NG2
+
 cells 
(Figure 3.25A, B and C). The double staining of antibodies against NG2 and 
OX42 was carried out at 1 day (Figure 3.25A), 3 (Figure 3.25B) and 5 days 
(Figure 3.25C) after LPS plus minocycline treatment. The responses of OX42 
labelled microglia (green) declined compared with only LPS treatment at 
different time intervals (Figure 3.25Ae, Bk and Cq), suggesting minocycline 
inhibited microglial activation in this LPS focal injury model. Additionally, 
the staining of NG2 (red) became weaker at 1 day (Figure 3.25Ad), 3 (Figure 
3.25Bj) and 5 days (Figure 3.25Cp) after LPS plus minocycline treatment. As 
stated the results before, the colocalization between NG2 and OX42 has been 
observed at 1 day, 3 and 5 days after LPS injection. In addition, both the 
number of NG2
+




 cells increased with the time point. In 





 cells was investigated. As shown in Figure 3.25 Af, Bl and Cr, 




 cells after minocycline treatment compared 
with only LPS treatment. 





                   
Figure 3.25 Double immunofluorescence staining between NG2 and OX42 at 
1 day, 3 and 5 days after LPS plus minocycline treatment 
Expression of NG2 decreases after minocycline treatment at different time 
points (Ad, Bj and Cp) compared with only LPS injection (Aa, Bg and Cm). 
Double labelling (yellow) between NG2 (red) and OX42 (green) could be 
observed at 3 (Bi) and 5 days (Co) after LPS injection. However, the co-
localization decreases at both 3 (Bl) and 5 days (Cr) after minocycline 





3.8.5 Inhibition of the increase in the number of NG2
+ 
cells 
According to the above immunofluorescence staining results, the responses of 
NG2
+ 
cells became weaker after minocycline treatment compared with only 
LPS administration group. Then, the number of NG2
+
 cells (Figure 3.26A) or 
OX42
+
 cells (Figure 3.26B) was quantified through cell counting. After 
minocycline treatment, the number of OX42 labelled microglia was lesser at 1 
day, 3 and 5 days compared with that of only LPS treatment group (Figure 
3.26B). At the same time, the number of NG2
+ 
cells also significantly reduced 
at 1 day, 3 and 5 days after minocycline treatment (Figure 3.26A). 
Minocycline is regarded as a potent inhibitor of microglial activation. The 
current result showed that after inhibition of microglial activation, the 
responses of NG2 expression also decreased. This may suggest that the 
activation of NG2
+ 















                      
 




 cells at 1 day, 3 and 5 days after 
LPS and minocycline treatment 
(A) The number of NG2
+
 cells significantly reduces at different time points 
after minocycline treatment (LPS+M) compared with that of LPS 
microinjection (LPS). (B) The number of OX42
+
 cells becomes less at 1 day, 
and significantly reduces at 3 and 5 days after minocycline treatment. Bar 
graphs represent mean±SD from three independent experiments. Average 












3.8.6 Inhibition of IL-1β expression in NG2+ cells 
As mentioned in the results in Section 3.7, NG2
+ 
cells did not express 
cytokines including IL-6, Lix, IL-10 and iNOS. However they could express 
IL-1β. This result was consistent with Fiedorowicz’s study that NG2+ cells 
with amoeboid phenotype expressed IL-1β in the mice hippocampus after 
trimethyltin intoxication (Fiedorowicz et al. 2008b).  
In this study, minocycline was given multiple daily injections in the LPS 
treatment group until sacrifice in order to inhibit the activation of microglia. 
As shown in Figure 3.27B, IL-1β was expressed by OX42 labelled microglia 
at 1 day (Figure 3.27Bg), 3 (Figure 3.27Bh), and 5 days (Figure 3.27Bi) of 
LPS treatment groups indicated by the arrows. After minocycline treatment, 
although the expression of IL-1β decreased compared with LPS treatment 
group, IL-1β was still observed to be expressed in microglia (Figure 3.27Bj, 
Bk and Bl). IL-1β was also expressed by NG2+ cells at 3 days after LPS 
injection (Figure 3.27Ab, arrows). However, after minocycline treatment, the 
activated responses of NG2
+ 
cells were downregulated (Figure 3.27Ad, Ae 
and Af) and more importantly, the induced expression of IL-1β was inhibited 






                    
Figure 3.27 Immunofluorescence staining of IL-1β with NG2 or OX42 at 1 
day, 3 and 5 days after LPS or LPS plus minocycline treatment 
IL-1β positive labelling (red) is expressed by OX42 labelled microglia (green) 
at different time intervals after LPS treatment (Bg, Bh and Bi), even after 
minocycline treatment (Bj, Bk and Bl). IL-1β staining (red) can be observed in 
NG2
+ 
cells (green) at 3 days after LPS treatment (Ab). However, the 
expression of IL-1β is lost in NG2+ cells after minocycline treatment (Ae). 





Part IV. The activation of NG2
+ 
cells is induced by TGF-β1 secreted by 
microglia 
3.9 Cytokine expression in LPS focal injury model 
After LPS injection, the mRNA and protein expressions of cytokines TNF-α, 
IL-1β, IL-10 and TGF-β1 were investigated (Figure 3.28). Considering TNF-
α and IL-1β were usually generated and peaked at early time points after LPS 
induction (Park et al. 2007), 6 and 12 hrs time points were chosen in this study 
and mRNA and protein samples were collected after treatment. The mRNA 
expression of TNF-α significantly increased and peaked at 6 hrs after LPS 
injection. IL-1β had a similar expression pattern, which significantly increased 
at 6 hrs and peaked at 12 hrs after LPS induction. However, the anti-
inflammatory cytokines such as IL-10 and TGF-β1 were expressed at a higher 
level during the late time points of treatment. IL-10 was expressed highly at 12 
hrs, 1 day and 3 days and TGF-β1 significantly increased at 1 and 3 days and 
still maintained at a high level at 5 days after LPS treatment (Figure 3.28A). 
The changes of these cytokines in protein expression were shown in Figure 




 cells appeared at 1 day 
and significantly increased their cell number at 3 days and peaked at 5 days 




 cells were 
closely consistent with the increase in expression of anti-inflammatory 





 cells may be relevant with the expression of secreted TGF-β1 in 










                                                     
 
Figure 3.28 mRNA and protein expressions of cytokines in LPS induced 
neuroinflammation model 
(A) The mRNA expression of pro-inflammatory cytokines like TNF-α and IL-
1β as well as anti-inflammatory cytokines like TGF-β1 and IL-10 at 6 hrs, 12 
hrs, 1 day, 3 and 5 days after LPS treatment and normal or saline control 
group. (B) Western blot of TNF-α, IL-1β, TGF-β1 and IL-10. N: normal 
control; L: LPS injection; S: saline control. In this experiment, saline 
treatment was used for LPS “control” up to 5 days. Bar graphs represent 








3.10 mRNA expression of TβRI and TβRII in LPS focal injury model 
As mentioned in the Section 3.9, TGF-β1 seems to be more correlated with 
the progression of the inflammation process. Therefore, the signalling pathway 
of TGF-β1 was observed in this study through detecting the cellular 
expression of its receptors. As shown in Figure 3.29, mRNA expression of 
two TGF-β1 receptors, TβRI and TβRII, was detected by Realtime PCR. 
Compared with the normal control group, mRNA expression of TβRI 
significantly increased at 3 and 5 days after LPS injection. Additionally, LPS 
injection group triggered higher expression of TβRI at 3 and 5 days compared 
with saline control group, suggesting the signalling pathway of TGF-β1 was 
active (Figure 3.29A). On the other hand, TβRII was activated after LPS 
administration. The mRNA expression of TβRII in LPS treatment group 
significantly increased at different time intervals compared with normal group 








                
 
 
Figure 3.29 mRNA expression of TβRI and TβRII in LPS focal injury model 
(A) Fold change of TβRI in LPS treatment group, saline control group and 
normal control group across 1 day, 3 and 5 days. (B) Fold change of TβRII in 
different treatments across 1 day, 3 and 5 days. Bar graphs represent mean±SD 







3.11 Cellular localization of TβRI and TβRII in LPS focal injury model 
Result of mRNA expression of TβRI and TβRII showed that TGF-βs 
signalling pathway was activated after LPS treatment. In order to find out 
which cells were the corresponding cells to TGF-β1 activity, anti-TβRI and 
anti-TβRII were co-stained with cell markers of NG2+ cells and microglia. In 
Figure 3.30A, TβRI was expressed at 1 day (Figure 3.30Ab), 3 (Figure 
3.30Ae) and 5 days (Figure 3.30Ah) after LPS treatment. Additionally, it was 
co-localized with anti-OX42, the microglial marker, at different time points 
(Figure 3.30Ac, Af and Ai). As shown in Figure 3.30B, TβRII was also 
expressed at different time intervals after LPS stimulation and co-localized 
with OX42 labelled microglia (Figure 3.30Bl, Bo and Br). This result was 
consistent with another study that activated microglia expressed both TβRI 
















































Figure 3.30 Immunofluorescence staining of anti-TβRI or anti-TβRII with 
anti-OX42 antibody in LPS injection model 
Expression of TβRI (A) and TβRII (B) has been observed at 1 day, 3 and 5 
days after LPS injection. It is co-localized with OX42 labelled microglia 





TβRI and TβRII have been found in neurons (Vivien et al. 1998), astrocytes  
(Ata et al. 1999; Vivien et al. 1998) and microglia (Li et al. 2008) in 
pathological conditions but it is unclear whether NG2
 
cells, the fourth major 
glial type in the CNS, would express them or not. Therefore, NG2 was double 
stained with anti-TβRI (Figure 3.31A) and anti-TβRII in this study (Figure 
3.31B). The results showed the expression of TβRI at 1 day (Figure 3.31Ab), 
3 (Figure 3.31Ae) and 5 days (Figure 3.31Ah) in the impaired cortex. It was 
co-localized with NG2
+
 cells at different time intervals shown by the arrows 
(Figure 3.31A). The expression of TβRII was also detected at 1 day (Figure 
3.31Bk), 3 (Figure 3.31Bn) and 5 days (Figure 3.31Bq) after LPS stimulation 
and expressed by NG2
+ 






































Figure 3.31 Immunofluorescence staining of anti-TβRI or anti-TβRII with 
anti-NG2 antibody in LPS injection model 
Expression of TβRI (A) and TβRII (B) has been detected at different time 
points after LPS treatment. Colocalization between TβRI (red)/TβRII (red) and 






3.12 Cells with TGF-β1 expression in LPS focal injury model 
TGF-β1 is found to be upregulated in astrocytes, microglia and neurons in 
response to injuries (Wu et al. 2007; Wu et al. 2008b). In this LPS focal injury 
model, the cellular localization of TGF-β1 was investigated through the 
double labelling between anti-TGF-β1 and either anti-OX42 or anti-NG2. As 
shown in Figure 3.32, TGF-β1 was expressed at 1 day (Figure 3.32B), 3 
(Figure 3.32E) and 5 days (Figure 3.32H) post LPS injection. OX42 labelled 
microglia became activated and expressed TGF-β1 at 1 day (Figure 3.32C), 3 
(Figure 3.32F) and 5 days (Figure 3.32I). This result was consistent with 
other findings that activated microglia were the primary source of TGF-β1 in a 





















Figure 3.32 Colocalization between anti-TGF-β1 and anti-OX42 antibodies in 
LPS injection model 
 
Expressing of TGF-β1 (red) has been observed at 1 day (B), 3 (E) and 5 days 
(H) after LPS injection. It is expressed by OX42 labelled microglia at 1 day 











cells also express TGF-β1 to play a role in the 
neuropathologies remains unknown. In this study, double labelling between 
anti-TGF-β1 and anti-NG2 was carried out. As shown in Figure 3.33, 
although TGF-β1 was expressed at 1 day (Figure 3.33B), 3 (Figure 3.33E) 
and 5 days (Figure 3.33H) after LPS treatment, NG2
+ 
cells were seldom co-
localized with TGF-β1 at different time intervals (Figure 3.33C, F and I). 
 
 
Figure 3.33 No double labelling of anti-TGF-β1 and anti-NG2 antibodies in 
LPS injection model 
Expressing of TGF-β1 (red) has been observed at 1 day (B), 3 (E) and 5 days 
(H) after LPS injection. However, no co-localization between TGF-β1 (red) 
and NG2
+ 






3.13 Direct TGF-β1 injection induces the activation of NG2+ cells 
3.13.1 Activation of NG2
+ 
cells 
In order to find out the direct effect of TGF-β1 on NG2+ cells, TGF-β1 was 
injected at 5ng/l, total 20ng into the rat brain cortex, the same injection site 
as LPS administration. After TGF-β1 injection, NG2+ cells (Figure 3.34Ad, 
Ae and Af) were more activated compared with saline control group (Figure 
3.34Aa, Ab and Ac) in the low magnification picture (20x magnification). 
Additionally, it seems that much more NG2
+ 
cells assembled at the injury 
point compared with saline control group. The higher magnification picture 
(40x magnification) was shown in Figure 3.34B. In the TGF-β1 treatment 
group, the responses of NG2
+ 
cells (Figure 3.34Bj, Bk and Bl) became more 
intense compared with saline group (Figure 3.34Bg, Bh and Bi). Further 
through quantification of cell number, TGF-β1 treatment induced more 
number of NG2
+ 
cells compared with saline control (Figure 3.34C). 
 
























Figure 3.34 Immunofluorescence staining of NG2 and quantification of NG2
+ 
cell number at 1 day, 3 and 5 days after TGF-β1 treatment compared with 
saline control 
In both lower (A) and higher (B) magnification pictures, the responses of 
NG2
+ 
cells become more intense after TGF-β1 treatment (Ad-Af and Bj-Bl) 
compared with saline control group (Aa-Ac and Bg-Bi). Moreover, the 
number of NG2
+ 
cells after TGF-β1 injection is more significant than that of 
saline control at different time points (C). Bar in Figure A: 100µm and Bar in 
Figure B: 50µm. Bar graphs represent meanSD from three independent 
experiments. Average counting area: 0.1 mm
2










3.13.2 Colocalization between NG2 and OX42 
In the lower magnification picture (20x magnification), it seems that TGF-β1 




 cells (yellow, Figure 
3.35Ae and Af) compared with control group (yellow, Figure 3.35Ab and Ac) 




 cells near 
the injury point in TGF-β1 treatment group compared with saline control 




 cells could also be seen in the 
higher magnification picture (40x magnification, Figure 3.35B). According to 





 cells compared with saline control (Figure 3.35C).This result 




























Figure 3.35 Double labelling of anti-NG2
 





 cell number at 1 day, 3 and 5 days after TGF-
β1 and saline control treatment 
In both lower and higher magnification pictures, the colocalization between 
NG2 (red) and OX42 (green) is more evident in TGF-β1 treatment (Ad-Af and 





 cells after TGF-β1 injection is more significant than 
that of saline control at different time points (C). Bar in Figure A: 100µm and 
Bar in Figure B: 50µm. Bar graphs represent meanSD from three 

















 cells in TGF-β1 treatment 
compared with LPS injection   







also increased in cell numbers at different time 
points after TGF-β1 treatment. In order to compare the effect between TGF-β1 
and LPS injection, the number of total NG2
+




 cells was 
quantified under both treatments (Figure 3.36). As shown in Figure 3.36A, 




 between two 
groups 1 day post injection. However, at 3 days after injection, TGF-β1 led to 




 cells compared with 
LPS. At 5 days after treatment, there was no significant difference. Similar 
changes could also be observed in the number of total NG2
+
 cells (Figure 
3.36B). These results may indicate that direct injection of TGF-β1 may 












Figure 3.36 Comparison of cell number of total NG2
+





cells at 1 day, 3 and 5 days between LPS injection model and TGF-β1 
treatment 
Cell number of total NG2
+




cells significantly increases 
at 3 days after TGF-β1 treatment compared with LPS. There are no significant 
changes in the cell number of total NG2
+




cells at 1 and 
5 days in both groups. Bar graphs represent meanSD from three independent 
experiments. Average counting area: 0.1 mm
2







3.13.4 No colocalization between NG2 and ED1 
In order to find out whether phagocytic cells could be induced to express NG2, 
the immunofluorescence staining between NG2 (red) and ED1 (green) has 
been carried out using the sections at 1 day, 3 and 5 days after TGF-β1 
injection and saline control treatment (Figure 3.37). Similarly to the results of 
LPS injection from previous findings, NG2
+ 
cells (red) were not co-stained 
with ED1 labelled phagocytic cells (green) at different time points after TGF-
β1 treatment, shown in the lower magnification picture (Figure 3.37Ad, Be 
and Bf) as well as higher magnification picture (Figure 3.37Bj, Bk and Bl). 
This result suggests that NG2 was not expressed by the ED1 labelled 








                
Figure 3.37 No colocalization between anti-NG2 and anti-ED1 antibodies at 1 
day, 3 and 5 days in TGF-β1 injection and saline control groups 
(A) There is no colocalization between anti-NG2 (red) and anti-ED1 (green) 
antibodies in the TGF-β1 treatment as well as saline control group in the lower 
magnification picture (20x magnification). (B) In the higher magnification 
picture (40x magnification), still no double labelling of anti-NG2 and anti- 







3.14 Inhibition of TGF-β1 with neutralized antibody 
3.14.1 Responses of NG2
+ 
cells 
According to the results in Section 3.8, the activation of NG2
+ 
cells was 
possibly downstream of microglial activation. In addition, direct injection of 
exogenous TGF-β1 could induce the activation of NG2+ cells and lead to the 




 cells compared with LPS injection group. 
In order to further confirm this view, the neutralized TGF-β1 antibody was 
used to block the effect of endogenous TGF-β1 and then the responses of 
NG2
+ 
cells were observed through immunohistochemistry study (Figure 3.38).  
The active responses of NG2
+ 
cells (red) were attenuated after co-injection of 
LPS and anti-TGF-β1 at 1 day (Figure 3.38D), 3 (Figure 3.38J) and 5 days 
(Figure 3.38P) compared with LPS plus vehicle treatment at 1 day (Figure 
3.38A), 3 (Figure 3.38G), and 5 days (Figure 3.38M). In addition, the 
colocalization between NG2 and OX42 was clearly observed at 1 day (Figure 
3.38C), 3 (Figure 3.38I), and 5 days (Figure 3.38O) after LPS plus vehicle 




 cells at 1 day (Figure 
3.38 F), 3 (Figure 3.38 L) and 5 days (Figure 3.38R) after inhibition of TGF-





































Figure 3.38 Double labelling between anti-NG2 and anti-OX42 antibodies at 1 
day, 3 and 5 days post co-injection of LPS and neutralized TGF-β1 antibody 
LPS could trigger the appearance and increase in the colocalization of NG2 
(red) and OX42 (green) at 1 day (C), 3 (I) and 5 days (O). However, this 
colocalization decreases after blocking the effect of TGF-β1 with neutralising 





The responses of NG2
+ 
cells could be observed more clearly in the lower 
magnification picture (20x magnification, Figure 3.39). Compared with saline 
control group (Figure 3.39 A, B and C), LPS induced the upregulation in 
expression of NG2 at the injury site (Figure 3.39 D, E and F). However, this 
LPS induced NG2 activation could be attenuated after treatment with 
neutralized anti-TGF-β1 antibody (Figure 3.39G, H and I). 
 
Figure 3.39 Immunofluorescence staining of anti-NG2 antibody at 1 day, 3 
and 5 days in different treatments 
After LPS treatment, NG2
+ 
cells become activated and gather around the 
injury point (white dotted line in D, E and F). The responses of NG2
+ 
cells 
seem more intense compared with saline control group (A, B and C). However 
the activation of NG2
+ 
cells is further inhibited through injection of 
neutralized anti-TGF-β1 antibody (G, H and I). White dotted line labels the 

















As shown in Section 3.14.1, the responses of NG2
+ 
cells decreased after 
neutralizing secreted TGF-β1. In order to quantify this data, cell counting of 











 cells was made at different time points. The number of total 
NG2
+ 
cells significantly decreased at 1 day, 3 and 5 days compared with LPS 





 cells also declined at 1 day, 3 days and significantly reduced at 5 
days after application of neutralized anti-TGF-β1 antibody (Figure 3.40B). 









 cells divided by the number of total OX42
+
 cells. As shown in 





 cells decreased at both 1 and 3 days and was significantly 




























 cells as well 




 cells after LPS plus anti-TGF-β1 injection 
(A) The number of NG2
+
 cells compared between LPS plus anti-TGF-β1 





 cells compared between LPS plus anti-TGF-β1 treatment and 





 cells to total OX42
+
 cells. Bar graphs represent meanSD from 











3.15 Inhibition of TGF-β1 signalling pathway with intracerebral injection 
of anti-TβRII  
In this study, the signalling pathway of TGF-β1 was inhibited through 
intracerebral injection of anti-TβRII, which was used as antagonist of the 
combination between TGF-β1 and its receptor TβRII. After that, the 
downstream proteins in the TGF-β1 signalling pathway and then the responses 
of NG2
+ 
cells were observed by the western blot and immunohistochemistry 
study. 
3.15.1 Protein expression of Smad2/3 and p-Smad2/3 
Anti-TβRII is widely used as an antagonist of TGF-β1 to block the TGF-β1 
effective signalling pathway. In this study, anti-TβRII was intracerebrally 
injected to the brain cortex immediately after LPS injection. As shown in 
Figure 3.41, the expression of total Smad2/3 was not changed at 3 days after 
LPS+anti-TβRII treatment compared with either LPS+vehicle injection or 
normal control. The expression of p-Smad2/3 significantly increased after 
LPS+vehicle injection compared with normal control group, suggesting that 
the TGF-β1 signalling pathway was activated upon LPS induced inflammation, 













Figure 3.41 Western blot analyse of the expression of Smad2/3 and p-Smad2/3 
at 3 days after different treatments 
Immunoblotting with antibodies at 3 days post-injection. Smad2/3 shows no 
significant changes between different groups (A and B). P-Smad2/3 
significantly increases after LPS+vehicle treatment compared with normal 
control group, while decreases after inhibition of TGF-β1 signalling pathway 
with anti-TβRII (A and C). Statistical analyses of the protein bands were done 
by normalising the target protein band densities to the β actin internal control 
(B and C). N: normal control; LPS: LPS+vehicle. Bar graphs represent 









3.15.2 Decrease in the colocalization between NG2 and OX42 
After inhibition of TGF-β1 signalling pathway with anti-TβRII injection, the 
responses of NG2
+
 cells were detected by the immunofluorescence staining 
(Figure 3.42). At 3 days after co-injection of LPS and vehicle, colocalization 
between NG2 and OX42 was observed (Figure 3.42A). However, this effect 
was inhibited after anti-TβRII treatment (Figure 3.42C). In addition, it seems 
that the responses of NG2
+
 cells became weaker (Figure 3.42D), shown by 
more processes, compared with vehicle injection control (Figure 3.42B). 
Further through quantification of cell number, it showed that the number of 
NG2
+





in the anti-TβRII treatment group. The percentage of NG2+/OX42+ cells to 
total OX42
+
 cells also decreased (Figure 3.42E). Together with above results 
showing the downregulation of p-Smad2/3, it may suggest that the activation 
of NG2
+






























Figure 3.42 Decrease in the colocalization between NG2 and OX42 after 
application of anti-TβRII antibody    
Confocal images showing the colocalization between NG2 (red) and OX42 
(green) at 3 days after co-injection of LPS and vehicle (A), whilst this 












 cells to total OX42
+ 
cells shown in E. Bar graphs represent 




































NG2 cells were first reported in the 1980’s and regarded as the fourth major 
type of glial cells in the CNS, besides astrocytes, microglia and 
oligodendrocytes. They compose 5-8% of all glial cells in CNS and are evenly 
distributed in the grey and white matter.  
Collective data show that the functions of NG2 cells seem to depend on their 
developmental stages. In the immature state, NG2 cells are widely regarded as 
OPCs. From embryonic day 17 (E17), NG2 cells are found throughout basal 
forebrain, hind brain and spinal cord and co-localized with PDGFαR+ cells, an 
antigen marker of OPCs (Nishiyama et al. 1996a). The in vitro studies further 
provided evidence to confirm the role of NG2 cells as OPCs in the immature 
CNS. The PDGFαR+ cells, purified from E17 rat spinal cord, were colocalized 
with NG2 and A2B5 and differentiated into GalC
+
 oligodendrocytes in the 
presence of low-serum medium without growth factors (Hall et al. 1996). 
Furthermore, Diers-Fenger et al. (2001) isolated AN2/NG2 cells from the 
early postnatal mouse brain and observed that they differentiated into MAG
+
 
(myelin-associated glycoprotein) oligodendrocytes in the low-serum medium 
(Diers-Fenger et al. 2001). All these studies have confirmed that NG2 cells in 
the developmental stage may indeed belong to the oligodendrocyte lineage and 
may give rise to the oligodendrocytes (Polito and Reynolds 2005).  
In the adult CNS, a subpopulation of NG2 cells is the major cycling cells and 
viewed as the OPCs, which are labelled by O4 or PDGFαR as described by 
some studies (Horner et al. 2000; Levison et al. 1999; Reynolds and Hardy 
1997). However, the only function of NG2 cells as OPCs in adult CNS is in 
great debate. The reasons are as follows: Firstly, NG2 cells are ubiquitously 
distributed in the grey and white matter. Their distribution is not related to the 
density of myelinated axon tracts, which are mainly located in the white 
matter and myelinated by oligodendrocytes. Secondly, the morphology of 
NG2 cells at the mature stage is different from OPCs. Specifically, OPCs have 
small cell somata with bipolar or short and unbranched processes, while NG2 
cells have long multibranched processes extending from the cell bodies (Berry 
et al. 2002). Thirdly, NG2 cells are found to closely contact neurons at 
synapses and nodes of Ranvier (Butt et al. 1999). Fourthly, in many brain 





increase in cell number and alterations in cell morphology. Therefore, NG2 
cells do not mainly perform as OPCs and may present other functions in the 
CNS. However, the functions of NG2 cells remain unknown and need to be 
explored.  
NG2 cells respond to the stimuli or insult with rapid activation including 
upregulation of NG2 protein expression and increase in cell numbers. 
Furthermore,  the colocalization between NG2 and OX42 has been observed in 
some injury models or diseases such as stab wounds (Levine 1994), kainate 
excitotoxicity (Ong and Levine 1999) and Parkinson’s disease (Kitamura et al. 
2010). These observations may indicate a possible close relationship between 
NG2 cells and microglia. Therefore, this study have investigated the functions 
of NG2 cells in cytokine expression and phagocytosis capability, which are the 
well-known  roles of microglia and aimed to find out the possible mechanism 




The previous study of our lab proposed that NG2
+
 cells may be composed of 
two parts: the constitutive NG2 cells and a subpopulation of microglia with 
induced expression of NG2 protein (Zhu et al. 2010). The current study further 
provided data to suggest that the NG2 expressing cells should be a better term 
to describe NG2
+
 cells observed in neuropathological conditions.  
4.1.1 Activation of NG2 cells in the LPS induced neuroinflammation 
model 
Since neuroinflammation is involved in CNS injuries or diseases, the 
responses of NG2 cells in the neuroinflammation may be representative for the 
injury or disease cases. In the current study, a neuroinflammation model was 
established by intracerebral injection of LPS. LPS is a component of the cell 
wall of gram-negative bacteria and commonly used as an inducer to generate 
inflammation in the host. It first binds to the toll-like receptor (TLR4) and co-
receptor MD2 and further initiates the downstream signalling pathway through 





In this study, LPS was injected at 1μg/μl, total 10μg/rat. 10μl seems to be a big 
volume and may possibly create a big cavity in the brain cortex. However, as 
shown in Figure 3.1A, this volume did not induce such case at 1 day post LPS 
injection and only the needle track has been observed. The injected solution 
may gradually diffuse into the brain tissue. At 3 and 5 days post injection 
(Figure 3.1B and C), a big cavity has been seen with a diameter about 200μm, 
which was possibly due to the effect of LPS. According to the literature review, 
the dose of intracerebral injected LPS differs from 0.2μg to 10μg and the 
volume varies from 1μl to 10μl. Several studies have used the injection 
volume of LPS at 10μl, the same injection volume as the current study, 
inducing well activation effects on microglia (Montero-Menei et al. 1996; 
Montero-Menei et al. 1994; Sun et al. 2008). As consistent with the current 
data, a big cavity was also not formed at the early days post injection. After 
LPS injection, total 30 coronal sections with 30μm of sickness from each rat 
were taken from the area containing the lesion centre (about 900μm from 
rostral to caudal) for the immunohistochemical study. This collected part of 
brain contained the most intense glial reactivity. For mRNA and protein 
analysis, around 3 x 3 x 3 mm tissue piece was dissected out from the 
operation side containing the lesion centre. All the immunostaining pictures 
were taken at the distance around 30μm to 300μm from the edge of lesion 
centre. 
LPS is a strong stimulator to activate microglia and upregulates expression of 
numerous inflammatory cytokines (Li et al. 2007), nitric oxide and free 
radicals (Gao et al. 2002; Horvath et al. 2008). Similarly, in the current study, 
rapid activation of microglia has also been observed, demonstrated by the 
morphological transformation from ramified resting state (Figure 3.1D) to 
amoeboid phenotype (Figure 3.1E), which serves as a key symbol of 
neuroinflammation in the CNS. In addition, the expression of pro-
inflammatory cytokines, such as TNF-α and IL-1β, were profoundly 
upregulated after LPS treatment (Figure 3.2/3.3), which further confirmed the 
successful establishment of neuroinflammatory model. Besides strong 





and oligodendrocytes also showed active responses represented in the 
hypertrophy of cell bodies (Figure 3.1F-I).  
The responses of NG2 cells were further investigated through 
immunofluorescence staining with anti-NG2. As shown by the results, they 
became activated. Firstly, the morphology of NG2
+
 cells showed great 
changes in response to LPS challenge. In the normal adult CNS, NG2
+
 cell has 
a small cell soma, with many long fine multi-branched processes extending 
from cell bodies (Figure 3.4E). However, upon stimulation, the size of their 
cell bodies increased and the branches became thicker and shorter. 
Additionally, the amoeboid phenotype was observed at 1 day, 3 and 5 days 
post LPS injection. This amoeboid phenotype has also been reported in 
another trimethyltin induced dentate granule neuronal cell death model 
(Fiedorowicz et al. 2008a). Secondly, the number of NG2
+
 cells significantly 
increased across different time points after LPS administration compared with 
the normal control (Figure 3.5). This result is consistent with the findings in 
other injury models like anti-GalC induced demyelination model (Keirstead et 
al. 1998) and dorsal rhizotomy model (Zhang et al. 2002). According to above 
results, it seems that NG2
+
 cells may be actively involved in the immune 
system because of their reactive responses to the stimuli.  
4.1.2 Microglia with induced NG2 protein expression may lead to the 
increase in the number of NG2
+
 cells 
As shown by the results, the number of NG2
+
 cells significantly increased 
after LPS stimulation. Compared with the normal control group, there was 
nearly 2 times increase at 1 day, 2.5 times at 3 days, and 3.7 times at 5 days 
post injection. Now, the question is raised that where the increased NG2
+
 cells 
come from. It is possible that the increase in the number of NG2
+
 cells may be 
due to NG2
+
 cell proliferation, NG2
+
 cell migration, or transformation from 





4.1.2.1 Increase in the number of NG2
+
 cells is not due to their 
proliferation 
Cell proliferation may be the most possible source for the increased number of 
NG2
+
 cells since NG2 cells are the major cycling cells in the normal adult 
CNS (Dawson et al. 2003). In the three scored regions including cerebral 
cortex, corpus callosum and hippocampus, NG2
+
 cells are at 70-75% of all the 
proliferating cells labelled by BrdU pulsing for 2 hrs. Moreover, 1-4%  of total 
NG2 cells are at the dividing stage (Dawson et al. 2003). Therefore, because 
of their high proliferation ability, NG2 cells may also have great potential to 
proliferate under pathological conditions. As reported by several studies, NG2 
cells increase their proliferation in demyelination (Di Bello et al. 1999; Levine 
and Reynolds 1999). In the ethidium bromide (EB) induced demyelination 
model (Levine and Reynolds 1999), up to 35.7% ± 2.8% of total NG2 cells in 
the trigeminal nerve and the inferior cerebellar peduncle region of brain stem 
incorporate BrdU at day 2 in a 2 hrs BrdU pulse. The percentage of BrdU
+
 
NG2 cells still last at 10.6% ± 3.6% at 6 day post EB injection. The highly 
proliferative responses of NG2
+
 cells have also been described in the cortical 
stab injury model (Alonso 2005; Hampton et al. 2004). NG2
+
 cells account for 
nearly 35% of all BrdU
+
 cells after 3 hrs BrdU pulse following stab wound 
injury (Alonso 2005). In another cortical stab injury model, the number of 
NG2
+
 cells significantly elevates from 2 days post lesion. NG2
+
 cells account 
for 60% of total BrdU
+
 cells after 4 hrs BrdU pulse with two times treatments 
and 2 hr-interval (Hampton et al. 2004). The difference in the percentage of 
proliferating NG2 cells may be due to the different ways of BrdU treatment. 
All the above studies provide evidences that proliferation may be the most 
possible reason for the increase in the number of NG2
+
 cells in the 
pathological conditions. However, the studies from Levine and Reynolds as 
well as Alonso’s lab showed the active responses and altered morphology of 
NG2
+
 cells. Although the double immunofluorescence staining has not been 
carried out between NG2
+ 
cells and microglia, the possibility of their 
colocalization could not be excluded. Moreover, in the cortical stab injury 
model, Hampton et al. (2004) demonstrated an increase in the colocalization 







 cells may not only come from proliferation of NG2 cells and 
may have other cellular source such as microglia.    
In this study, the proliferation of NG2
+
 cells was investigated by BrdU pulsing 
for 4 hrs with 2-hr interval, total two times injections. As shown in Figure 3.6, 
microglia were co-localized with BrdU
+
 cells indicating they were 
proliferating upon injuries, which was consistent with other findings 
(Hampton et al. 2004; Tatsumi et al. 2005). However, colocalization between 
BrdU and NG2 was not observed in the current study at 1 day, 3 and 5 days 
after LPS stimulation. The most possible fate of proliferating NG2 cells may 
be to differentiate into the oligodendrocytes if there is any loss of 
oligodendrocytes during the pathological process. Therefore, the responses of 
oligodendrocytes were investigated in order to find out the possible reasons of 
non-proliferating NG2 cells in the current model. Western blot result in 
Figure 3.7A showed no alteration in protein expression of CNPase, an antigen 
marker of oligodendrocytes, among different time intervals. Furthermore, the 
number of CNPase
+
 cells counted was not changed (Figure 3.7B). Thus no 
alterations or no intense cell death of oligodendrocytes may be one of the 
reasons that why NG2
+
 cells were not proliferating in the current results.  
Studies have reported that oligodendrocyte lineage cells including OPCs and 
oligodendrocytes were vulnerable to LPS stimulation in the neonatal stage 
(Lehnardt et al. 2002; Pang et al. 2003; Pang et al. 2010). Injection of LPS into 
the white matter of neonatal rats led to hypomyelination and significant loss of 
oligodendrocytes (Lehnardt et al. 2002; Pang et al. 2003). However, 
intracerebral injection of LPS into adult brain does not induce any cell death 
(Nadeau and Rivest 2002). It seems that oligodendrocytes respond differently 
to LPS injection, determined by their developmental stage. Moreover, the loss 
of oligodendrocytes in the neonatal rats after LPS injection may not be totally 
due to the direct effect of LPS. The possibility that loss of OPCs lead to the 
reduction in the number of oligodendrocytes cannot be ruled out. Studies 
further reported that cell death of oligodendrocytes occurring after neonatal 
white matter damage was induced by activated microglia (Pang et al. 2010). 
However, microglia are not always toxic in the injured CNS and may as well 





microglia showed differential effects on OPCs and mature oligodendrocytes: 
reduce OPCs survival but increase survival of oligodendrocytes (Miller et al. 
2007). In fact, the cytotoxicity of microglia depends on the secreted factors (Li 
et al. 2007). Studies have shown that insulin-like growth factor-2 (IGF-2) 
secreted by activated microglia enhances oligodendrocyte survival (Nicholas 
et al. 2002), while TNF-α induces oligodendrocyte toxicity (Zajicek et al. 
1992). In the injured CNS, the combination effects of multiple cytokines and 
other molecules may possibly lead to a dynamic phenotype of microglia. In 
the current intracerebral LPS injection model, it is possible that LPS injection 
does not induce oligodendrocyte cell death due to the differential responses of 
oligodendrocytes in different development stages as well as dual functions of 
activated microglia. Therefore, no significant death of oligodendrocytes and 
no significant increase in the number of CNPase
+
 cells may reasonably 
suggest that NG2
+
 cells did not differentiate into oligodendrocytes. 
Although NG2 cells are evenly distributed in the grey and white matter, they 
may possibly have different phenotypes. Many studies have reported the 
heterogeneous property of NG2 cells. Firstly, the morphology of NG2 cells 
differs in different CNS regions (Dawson et al. 2003). Secondly, in physiology 
studies, NG2 cells in the cerebral cortex are different from the cells in 




 channels and membrane 
properties (Chittajallu et al. 2004). Thirdly, NG2 cells in the subventricular 
zone with higher expression of epidermal growth factor receptor showed 
enhanced migration ability compared with cortical NG2 cells (Aguirre et al. 
2005). Fourthly, in an enhanced yellow fluorescent protein (EYFP)-NG2 
“knock-in” mouse model, only a part of EYFP+ NG2 cells express glutamine 
synthetase both in the developing and adult hippocampus while all EYFP
+ 
NG2 cells could express PDGFαR, olig2 and Sox 10 (Karram et al. 2008). 
Therefore, it is possible that the lack of BrdU
+  
NG2 cells may be due to the 
different environment of brain regions or different stimulations, in which 






4.1.2.2 Increase in the number of NG2
+
 cells is not due to their migration 
Migration of NG2 cells from neighbourhood may lead to the increase in the 
cell number of NG2 cells in the injury site. However, the activation of NG2
+
 
cells was restricted to the area around injection site, while the NG2
+ 
cells in 
the farther adjacent region were not activated, not like microglia with a 
gradient expression shown in Figure 4.1. In addition, the migration ability of 
NG2 cells in the adult CNS has been reduced compared with the developing 
stage (Wolswijk and Noble 1989). Several studies report the poor migration 
ability of NG2 cells when co-cultured with astrocytes, the most possible cell 
type that NG2 cell may encounter in the glial scar (Fok-Seang et al. 1995; 
Schnadelbach et al. 2000). As their poor migratory ability, nearly two times 




at 1 day post LPS injection shown in the 
results may not be due to their migration. 
 
Figure 4.1 Activation of NG2
+
 cells and OX42
+
 microglia at 5 days after LPS 
injection 
A. Activation of NG2
+
 cells is more restricted surrounding the injection site 
but not in the area beyond the white dotted line. B. Reactive responses of 
OX42 labelled microglia are more intense in the injection centre and 
surrounding area but still with reactive responses in the farther region. C. 
Colocalization between anti-NG2 and anti-OX42 antibodies. Bar: 100µm. 
 
4.1.2.3 Colocalization between NG2 and OX42 contributes to the increase 
in the number of NG2
+
 cells 
Besides proliferation and migration of NG2 cells, it may be also possible that 







In the normal adult CNS, NG2
 
cells are a distinct cell type, which are not 
labelled with other glial cell markers like GFAP, CNPase and OX42. In this 
LPS focal injury model, NG2
+
 cells were also not double labelled with either 
GFAP labelled astrocytes or CNPase labelled oligodendrocytes at 1 day post 
LPS stimulation (Figure 3.1). However, NG2
+
 cells were double labelled with 
anti-OX42 antibody at 1 day, 3 and 5 days after LPS injection (Figure 3.8).  




 cells have been reported in lesion 
models like brain knife cut injury (Hampton et al. 2004), stab wound injury 
(Levine 1994; Yokoyama et al. 2006), spinal cord injury (Jones et al. 2002) 





 cells gradually increased and reached to a profound 




 cells to total OX42
+
 cells 
significantly upregulated from nearly 7% at 1 day to about 40% at 5 days after 





cells belong to the microglia/macrophage lineage (Bu et al. 2001; Fiedorowicz 
et al. 2008a; Jones et al. 2002; Matsumoto et al. 2008; Pouly et al. 1999; 
Yokoyama et al. 2006) as well as one study in our lab which also confirms that 
NG2 protein is induced to be expressed on microglia in the facial nerve 
axotomy model (Zhu et al. 2010).  
It is obvious that the blood brain barrier has been damaged upon focal 
injection of LPS. The macrophages in the blood may directly flow to the 
injection area or penetrate from blood vessels where the permeability was 
increased after injury. Studies have reported that macrophages could also 
become NG2 positive upon stimulation like kainic acid induced excitotoxicity 
model (Bu et al. 2001) or in a transient MCAO model (Matsumoto et al. 2008; 
Smirkin et al. 2010). Therefore, it may be possible that macrophages could be 
co-localized with NG2 in this neuroinflammation model. As shown in Figure 
3.10, ED1, a specific antigen marker of macrophages, was expressed at 
different time intervals. However, ED1 labelled macrophages were never 
double labelled with NG2
+
 cells. In Bu’s study, colocalization between NG2 
and ED1 was observed at 14 days post injury, but not at the early time point as 
7 days after injury (Bu et al. 2001). Since the time point in the current study 





not clear whether ED1
+
 macrophages could express NG2 protein at a longer 
survival time point as described in Bu’s study. Therefore, the double labelling 
between ED1 and NG2 was detected by extending the time points to 7 days 




 cells were still present at 7 days. However, there 
was still no double labelling between NG2 and ED1 (Figure 3.11A). Further 
extending the survival time to 14 days, NG2
+ 
cells have returned to the 





subsided at 14 days. However, there were still no NG2 and ED1 double 
labelled cells (Figure 3.11B). Since Iba1 or OX42 may also label a part of 
macrophages, the possibility that macrophages are double labelled with NG2 




 cells cannot be ruled out. In this study, it 
can be only concluded that ED1
+
 macrophages were not induced to express 
NG2 protein. Since ED1 is an antigen maker for phagocytic microglia and 
macrophages, the current finding may suggest that NG2 was possibly not 
expressed by microglia/macrophages with phagocytosis function.  
A subpopulation of NG2 cells in the adult CNS is regarded as OPCs (Horner 





 cells may come from the OPCs and result in the increase 
in cell number. However, this view was not supported by the results shown in 
Figure 3.12, which is similar with another study in our lab: three kinds of cell 
types including NG2
+
/PDGFαR+ cells, NG2+/PDGFαR- cells and OX42+/ 
PDGFαR- cells were also identified in the axotomized facial motor nucleus at 
7 days post-operation. Since PDGFαR+ cells, close to the axotomized motor 





 cells are also negative to PDGFαR, suggesting they are not 
OPCs (Zhu et al. 2010). 





cells came from the part of microglia which were induced to express NG2 
protein. Moreover, the increase in number of NG2
+ 
cells after LPS stimulation 
may be possibly attributed to NG2 positive microglia. In this study, NG2
+ 
cells 
composed two parts in the LPS injury model: the constitutive NG2 cells and 
microglia with induced NG2 protein expression. As reported by Matsumoto et 









 cells in the ischemic core with a MW 
of 300kDa in a whole transmembrane protein and the other belonging to NG2 
glial cells in the contralateral regions with a MW of 290kDa, shedding off the 
extracellular domain (Matsumoto et al. 2008). It may be possible that the 
constitutive NG2 cells and microglia with induced NG2 protein expression in 
this study could be differentiated through the molecular size of NG2 protein. 
In conclusion, a new view was raised in the current study: NG2
+ 
cells in this 
LPS induced neuroinflammation model are named as NG2 expressing cells, 
which were composed of two parts mentioned above and regarded as a 
heterogeneous cell type.  
4.2 NG2 expressing cells do not show phagocytic capability 
Phagocytosis, a Greek-derived term for engulfing, was firstly discovered by 
Ilya Metchnikov in 1882. It is the cellular process of engulfment and 
degradation of invading microorganisms or dead cells by immune cells. In 
mammalian peripheral tissues, phagocytosis is mainly fulfilled by the 
phagocytes including macrophages, neutrophil and dendritic cells as the first 
immune defense (Sierra et al. 2013). In the CNS, phagocytosis is mostly 
performed by microglia as the professional phagocytes while astrocytes 
display phagocytosis with delay and less efficiency (Magnus et al. 2002; 
Parnaik et al. 2000). Phagocytosis is necessary to maintain the homeostasis of 
the brain, which clears off the debris of cells and prevents the overflow of 
cellular components into the brain (Sierra et al. 2013). 
In this study, NG2 expressing cells became rapidly activated shown by the 
enlargement of their cell bodies, shortening of cell processes, upregulation of 
NG2 intensity and increase in cell numbers. The NG2 amoeboid phenotyped 
cells were reported to express IL-1β and interleukin-1 receptor antagonist (IL-
1Ra) and may be involved in mediation of the neuronal death or survival 
following injury (Fiedorowicz et al. 2008b). Since the responses of NG2 
expressing cells are similar to those of microglia in certain extent, the 
phagocytic capability of NG2 expressing cells has been investigated by 





As shown in Figure 3.13, OX42 labelled microglia were fed with latex beads 
shown by green cell bodies encircling the latex beads. In addition, ED1 
labelled macrophages also engulfed latex beads into their cell bodies shown in 
yellow. This result is consistent with the common knowledge that microglia 
/macrophages have phagocytosis function in the development of the CNS 
(Dalmau et al. 2003; Egensperger et al. 1996; Parnaik et al. 2000) and 
pathological CNS (Koenigsknecht and Landreth 2004; Park et al. 2008). 
However, activated NG2 expressing cells did not engulf latex beads at 
different time points after co-injection of LPS and latex, as consistent as the 
absence of latex microspheres in NG2 labelled cells in a stab wound injury 
model (Alonso 2005). As mentioned in Section 4.1, NG2 expressing cells in 
this study were regarded to be composed of two kinds of cells: constitutive 
NG2
+





Therefore, the result in Figure 3.13 suggests that both phenotypes of NG2
+ 
cells did not present phagocytic capability in this LPS focal injury model. This 
phenomenon could be seen more clearly in the picture with triple labelling of 





shown by white did not engulf latex beads at 3 days post LPS plus latex 
injection. Additionally, the constitutive NG2
+
 cells (other cells in the green) 
also did not phagocytose latex beads, which were mainly engulfed by 
microglia/macrophages. 




 cells accumulated in larger quantities 
from 3 days post LPS injection. Therefore, it is possible that the activation of 
constitutive NG2 cells was later than microglia/macrophages. When the NG2 





became more intense, latex beads have already been cleared by microglia or 
macrophages since their phagocytosis process is very fast. In vitro study 
showed that it only took about 1-2 min for microglia to make contact with an 
apoptotic neuron and about 2 hrs to complete clearance of all dead neurons 
(Parnaik et al. 2000). Similarly, in another in vivo study, it took about 1.2-1.5 
hrs for microglial phagocytosis of apoptotic newborn cells in the subgranular 
zone (Sierra et al. 2010). Therefore, it may be reasonable to assume that, if 





available for NG2 expressing cells to phagocytose when they finally became 
highly activated. To exclude this possibility, latex beads were injected three 
days later after LPS injection, when the constitutive NG2 cells were already in 




 cells also existed in larger quantities. 
However, the results showed that microglia and macrophages were still the 
main cell types to engulf latex beads at different time intervals (Figure 3.14). 
NG2
+
 cells still did not engulf latex beads, similar to previous finding (Figure 
3.13). Based on those results, it is appropriate to say that NG2 expressing cells 
do not play a phagocytic role in the LPS induced neuroinflammation model. In 
other words, in this model the constitutive NG2 cells do not have a phagocytic 







 cells). It is of interest to know what the functions might 
be when the cells, especially microglia, have this phenotypic change. 
Microglia, as the professional phagocytes, play beneficial role by engulfing 
cellular debris in the CNS, such as myelin (Hosmane et al. 2012; Tanaka et al. 
2009a), apoptotic neurons (Hanisch and Kettenmann 2007; Peri and Nusslein-
Volhard 2008), Aβ plaques (Paresce et al. 1996; Wang et al. 2011) and 
synapses (Paolicelli et al. 2011; Schafer et al. 2012). However, phagocytosis 
accompanied with inflammation may be harmful and lead to further neuronal 
death in neurodegenerative diseases (Brown and Neher 2010; Neher et al. 
2012; Neher et al. 2011). It is possible that NG2 protein plays a role in 
mediation of the microglial phagocytosis and regulation of its toxicity to other 
cells in the current study. 
In this LPS injection model, OX42
+
 microglia and ED1
+
 macrophages were 
found to phagocytose small latex beads. The phagocytosis process is possibly 
initiated through the combination between LPS and scavenger receptors like 
TLR4 expressed on the surface of microglia/macrophages (Lehnardt et al. 
2002; Noda and Suzumura 2012). Integrin receptors such as CR3 may also 
take part in the phagocytic process. Furthermore, the scavenger receptor CD68 
was also a phagocytosis marker for activated microglia and macrophages. The 
expression of CR3 and CD68 may possibly lead to the phagocytosis of 
microglia/ macrophages. However, this study further found that microglia after 





be due to the controlling effect of NG2 in regulation of microglia phagocytic 
capability. Colocalization between NG2 and OX42 has been found in some 
injury models or neurodegenerative models as well as this LPS induced 
neuroinflammation model. At present, only three studies have directly 
reported the role of NG2
+
 microglia/macrophage-like cells in CNS 
inflammation. The first study showed that primary microglia were induced to 
express NG2 protein after stimulation with LPS as well as microglia in the in 
vivo study following LPS I.P. injection. Further experimental results have 
demonstrated that the induced NG2 protein could mediate the expression of 
inflammatory cytokines like TNF-α, while without alteration of chemokines 
such as monocyte chemoattractant protein-1 (MCP-1) in primary microglia 




 cells may play 
a beneficial role in the ischemic brain lesions through secreting 
neuroprotective factors like bFGF and BMP2 in a MCAO rat model (Smirkin 




 cells in 
the 6-hydroxydopammine-inuced PD model and demonstrated their protective 
role to dopaminergic (DA) neurons through expression of glial cell line-
derived neurotrophic factors (GDNF) (Kitamura et al. 2010). Since microglia 
has diverse molecular markers at different stages (Raivich et al. 1999), NG2 
may also possibly act as a marker indicating the specific functional status of 
activated microglia.  
Phagocytosis may contribute to modulate the inflammatory responses. 
Normally this modulation can be classified into two types according to the 
phagocytic target. Firstly, for removal of microbes, the phagocytic process 
associated with TLRs is pro-inflammatory and secondly, to clear apoptotic 
cells, the phagocytic process initiated by PS receptors is anti-inflammatory 
(Neumann et al. 2009; Ravichandran 2003). It is well known that LPS could 
bind with TLR4 receptors expressed on microglia to induce its phagocytic 
response, which may be relevant to the release of pro-inflammatory cytokines 
and nitric oxide from microglia (Hines et al. 2013; Noda and Suzumura 2012; 
Ribes et al. 2010). In the LPS focal injury model, the phagocytosis could be 
stimulated by the injected LPS and possibly induce strong pro-inflammatory 





system could possess a self-adjustment mechanism to attenuate or restrict 
microglial cytotoxic effects during neuroinflammation. Therefore, induction of 
expression of NG2 protein in microglia may possibly turn off the phagocytosis 
of microglia and reduce overall microglial cytotoxicity in impaired region. If 
this is true, the NG2-induced microglia should reduce production of harmful 
pro-inflammatory cytokines or free radicals in the current neuroinflammatory 
model. 
4.3 NG2 expressing cells might not be involved in the cytokine-chemokine 
network 
4.3.1 NG2 expressing cells do not express IL-6, IL-10, lix and iNOS 
Cytokines are glycoproteins with small molecular weight and act either in a 
paracrine or autocrine way according to interact with their specific receptors. 
They play an important role in regulation of the immune and inflammatory 
responses. In the CNS, although astrocytes could express various cytokines to 
mediate the brain homeostasis (Dong and Benveniste 2001; Lieberman et al. 
1989), microglia appear to be the principal source of pro-inflammatory 
cytokines including TNF-α and IL-1β, anti-inflammatory cytokines like TGF-
β1 and IL-10, NO and glutamate in neuropathological conditions (Aloisi 2001; 
Nakajima and Kohsaka 2004). Since constitutive NG2 cells could become 
activated and some microglia are induced to express NG2 protein upon 
stimulation or diseases, it was wondered that whether NG2 expressing cells 
could also express cytokines to mediate immune responses and whether NG2-
induced microglia and normal activated microglia would be different in 
cytokine expression. Therefore, the cellular expressions of selective pro-
inflammatory cytokines as IL-1β and IL-6, anti-inflammatory cytokines as IL-
10, chemokines as lix and iNOS were investigated in NG2 expressing cells in 
the current study.  
As shown in Section 3.7, OX42
+
 microglia expressed IL-6, IL-10, lix and 
iNOS in the current LPS induced inflammation model, which is consistent 
with the secretion of such factors upon the same LPS or other stimulations 





1999; Vincent et al. 1996). However, NG2
+
 cells did not express such 
cytokines and iNOS. These results suggest that activated NG2 expressing cells 
may exert functions not involving these cytokines and iNOS during 
neuroinflammation, though the exact functions of activated NG2 expressing 
cells is yet to be elucidated. 
4.3.2 NG2 expressing cells with amoeboid morphology express IL-1β 
Although NG2 expressing cells did not express IL-6, IL-10, lix and iNOS in 
the current study, the expression of IL-1β showed difference (Figure 3.21). In 
the normal brain tissue, IL-1β was hardly detected but its expression was 
significantly upregulated after LPS stimulation. The IL-1β+ cells were double 
stained with OX42
+
 microglia after LPS stimulation at 1 day, 3 and 5 days. 
Moreover, some NG2 expressing cells were co-localized with IL-1β at 3 days 
after LPS injection (Figure 3.21G). As indicated by the arrows, those IL-
1β+/NG2+ cells appeared in an amoeboid morphological phenotype. This 
finding is consistent with Fiedorowicz’s study in which NG2+ cells with 
amoeboid type could express IL-1β in a trimethyltin-induced neuronal 
apoptosis model (Fiedorowicz et al. 2008b). Since colocalization between 
NG2 and OX42 has been observed at 3 days post LPS injection, the amoeboid 
phenotyped NG2 expressing cells may represent the microglia with induced 
NG2 protein. The remaining green cells may represent the constitutive NG2 
cells without expression of IL-1β. Further triple labelling should be required to 
confirm this result in the future. 
IL-1β has been found to be involved in neuronal injury in acute damage as 
stroke and neurodegenerative diseases (Allan et al. 2005). Exogenous 
application of IL-1β to the focal ischemic brain could increase the infiltration 
of neutrophils and augment brain damage. Inhibition of endogenous IL-1β 
with either anti-IL-1β or blocker zinc protoporphyrin (ZnPP) could attenuate 
the brain infarction (Yamasaki et al. 1995). In additon, following brain 
ishcemic, double IL-1α/IL-1β knockout mice showed significant decrease in 
neuronal loss and apoptotic cell death (Mizushima et al. 2002). Thus 
endogenous production of IL-1β may be a possible factor which induces 





LPS intracerebral injection could induce the brain inflammation but without 
neurodegeneration (Andersson et al. 1992; Kim et al. 2000; Nadeau and Rivest 
2002). Kim et al. (2000) has reported only neurons in the substantia nigra were 
vulnerable to the inflammatory factors induced by LPS, but not those in the 
hippocampus and cortex (Kim et al. 2000). It may be possible that in the 
current intracerebral LPS injection model, the expression of IL-1β in NG2 
expressing cells may not be relevant to neuronal cell death. Because IL-1β was 
only found in the amoeboid phenotyped NG2
+
 cells but not all NG2
+
 cells, this 
differential expression of IL-1β in NG2+ cells in the current study may at least 
indicate functional alterations in such cells in response to the 
neuroinflammation. It is of interest to further characterize the functional 
changes and its mechanism involved in the activation of NG2 expressing cells 
in the neuropathologies in the future.     
Taken together, above results have shown the differential cytokines expressed 
by NG2 expressing cells in comparison to microglia. Since NG2
+
 cells do not 
express IL-6, IL-10, lix and iNOS, it suggests that cytokines expression may 
not be the main way for them to take part in immune responses. Based on cell 
morphologies, only NG2
+
 cells with an amoeboid phenotype but not those 
with multiple branches were positive to the anti-IL-1β antibody, suggesting 
that activated NG2
+
 cells themselves might function differentially in the 
cytokine network in the brain immunity under the pathological conditions. 




 cells presented an amoeboid 
morphology, some activated microglia might alter their function in cytokine 
expression when they were induced to express NG2 proteins.   
Although the exact roles of the NG2 expressing cells are still unknown, it can 
be confirmed in the current study that, in response to LPS induced 
neuroinflammation, NG2 expressing cells become activated and some 
activated microglia join in the pool of NG2 expressing cells, resulting an 
alteration in expression of cytokines, chemokines, and iNOS in the impaired 





4.4 The possible mechanism of activation of NG2 expressing cells 
NG2 expressing cells have acquired great interest in recent years. They are 
activated in various studies including spinal cord injury (Jones et al. 2002), 
stab would injury (Levine 1994; Yokoyama et al. 2006), peripheral nerve 
injury (Zhu et al, 2010), brain ischemic injury (Matsumoto et al. 2008; 
Smirkin et al. 2010) and neurodegenerative diseases like PD (Kitamura et al. 
2010). However, how NG2 expressing cells become activated still remains 
unknown. In the current project, the possible mechanism has been explored. 
4.4.1 Activation of NG2 expressing cells may be an event downstream to 
microglial activation 
LPS is a component of gram-negative bacterial cell wall and could induce 
inflammation with glial cell activation in the CNS. TLR4, the cellular binding 
receptor of LPS, is necessary to the signal transduction induced by LPS. The 
binding of TLR4 with LPS initiates a MyD88 (myeloid differentiation primary 
response gene 88)-dependent signalling pathway to produce various pro-
inflammatory cytokines and reactive oxygen species (Lu et al. 2008). TLR4 is 
present on monocytes/macrophages and other immune cells in the peripheral 
system (Cole et al. 2010; Hoshino et al. 1999; Kim et al. 2010). In the CNS, 
the cellular expression of TLR4 has been investigated in many studies. 
Lehnardt et al. (2002) reported that TLR4 was expressed by microglia at high 
levels, but not present on astrocytes and OPCs (Lehnardt et al. 2002). An 
opposite study from Taylor’s lab found OPCs expressed TLR4 and other 
interacting proteins such as MyD88, which were necessary for the TLR4 
signalling pathway. However, the expressed TLR4 was not involved in the 
generation of pro-inflammatory cytokines (Taylor et al. 2010). No matter 
whether OPCs express TLR4 or not, both studies have confirmed that LPS 
may not directly influence the reactive responses of NG2 expressing cells.  
NG2 expressing cells are found in close contact with microglia under both 
normal and disease conditions (Nishiyama et al. 1997). In addition, in vitro 
studies have reported that NG2 expressing cells could respond to microglial 





many inflammatory cytokines, nitric oxide and other factors under 
pathological conditions, it is possible that the activation of NG2 expressing 
cells could be mediated through these microglial secreted factors. In this 
study, the effect of microglial activation on NG2 expressing cells has been 
investigated in the following studies. 
Minocycline is a tetracycline derived antibiotic, which has anti-inflammatory 
properties in the CNS that separate from its antimicrobial action. It is a potent 
inhibitor of microglial activation, which blocks the inflammatory cytokines 
secretion through inhibition of p38 MAPK pathway in microglia (Tikka et al. 
2001; Tikka and Koistinaho 2001; Zhu et al. 2002). However, it has no direct 
effect on astrocytes and neurons (Amin et al. 1996; Tikka et al. 2001; Tikka 
and Koistinaho 2001). Therefore, in this study, minocycline was employed to 
block the activation of microglia and then the responses of NG2 expressing 
cells were investigated. 
After minocycline treatment, the activation of microglia was attenuated. On 
one hand, both mRNA and protein expressions of cytokines including IL-1β, 
TGF-β1 and IL-10 decreased (Figure 3.22); on the other hand, western blot 
results indicated that the protein expression of Iba1, an antigen marker for 
activated microglia, was also downregulated (Figure 3.23). This result was 
consistent with other in vitro and in vivo findings, in which anti-inflammation 
effects of minocycline resulted in attenuation in expressions of cytokines and 
antigen marker OX42 in microglia (Bye et al. 2007; Guasti et al. 2009; Krady 
et al. 2005; Tikka et al. 2001; Tikka and Koistinaho 2001; Yrjanheikki et al. 
1999) . 
Subsequent results showed that the responses of NG2
+
 cells also decreased 
following minocycline treatment. The staining intensity of NG2
+
 cells became 
weaker compared with LPS administration group. The colocalization between 
NG2 and OX42 was also attenuated at different time intervals after LPS 
stimulation (Figure 3.25). The number of NG2
+
 cells as well as the number of 
OX42
+
 cells quantified through cell counting (Figure 3.26) significantly 





Minocycline is regarded as a potent inhibitor to microglial activation. Results 
showed after inhibition of microglial activation, the responses of NG2
+ 
cells 
also decreased. However, the current result cannot confirm that the latter is a 
consequence of the former and not partly due to a direct inhibition effect of 
minocycline on activation of NG2
+
 cells. At present, no studies have reported 
a direct effect of minocycline on NG2 cells. The research has been carried out 
on OPCs with contradicting results. In the normal primary OPCs culture, 
minocycline inhibited their proliferation and differentiation with a dose 
dependent manner in Li’s study (Li et al. 2005). However, Zhang et al. (2003) 
reported that minocycline did not influence the cell morphology, proliferation 
and differentiation of OPCs (Zhang et al. 2003). The contrasting results may 
be possibly due to the different rat species and experimental protocols used to 
isolate and culture OPCs. Further in an in vitro ischemic brain injury model, it 
has been shown that minocycline attenuated cell death, improved cell survival 
and restored maturation of OPCs (Schmitz et al. 2012). However, all these 
data were obtained using the OPCs isolated from neonatal rats rather than 
adults. The responses of OPCs in developmental stage may not represent the 
same as in adult NG2 cells.  
In the current LPS induced neuroinflammation model, it cannot rule out the 
possibility that the responses of NG2
+
 cells may be as a result of a direct effect 
of minocycline. However, as shown by a similar study in this lab (Guo 2009, 
Phd thesis), NG2
+
 cells reaction was inhibited after injection of anti-CD11b 
antibody, which specifically blocked the α subunit of complement receptor 
type 3 expressed by microglia/macrophages and inhibited microglia functions 
(Bruck and Friede 1990; Garcia et al. 1996). Therefore, this observation as 
well as current finding suggests that the activation of NG2
+ 
cells was possibly 
downstream to microglial activation. Since the expression of cytokines 
decreased following downregulation of microglial responses, NG2
+ 
cells 







4.4.2 The activation of NG2 expressing cells are possibly stimulated by the 
TGF-β1 secreted from microglia 
4.4.2.1 The expression pattern of TGF-β1 is the most relevant to the 
activation of NG2 expressing cells 
As per above results, the activation of NG2
+ 
cells may be an event 
downstream to microglial activation. It is well known that after CNS injuries, 
the earliest cell responses come from the infiltration of macrophages and 
activation of microglia. Microglia could express a variety of pro-inflammatory 
cytokines and anti-inflammatory cytokines, such as TNF-α, IL-1β, TGF-β1, 
and IL-10, to influence other kinds of cell activities in the CNS. Therefore, 
cytokine expression was examined in this LPS induced inflammation model 
(Figure 3.28). As shown in the results, pro-inflammatory cytokines as TNF-α 
and IL-1β were expressed at a high level at early time points, 6 and 12 hrs 
separately. However, the anti-inflammatory cytokines such as IL-10 and TGF-
β1 were expressed at a higher level during the late time of treatment. IL-10 
was highly expressed at 12 hrs, 1 and 3 days, while TGF-β1 expression 
significantly increased at 1 and 3 days after LPS treatment and still maintained 
a high level at 5 days post LPS injection. It seems that the expression pattern 
of TGF-β1 was more consistent with the appearance of NG2+/OX42+ cells as 
well as activation of NG2
+ 
cells.  
In the next step, the expression of TGF-β1 as well as its receptors was 
investigated in this LPS induced focal injury model. TGF-β1 is a pleiotropic 
cytokine involved in the modulation of cell growth, differentiation, immune 
function and extracellular matrix production (Flanders et al. 1998). It has three 
types of receptors: TβRI, TβRII, and TβRIII, distinguished by their structural 
and functional properties. Both TβRI and TβRII are single-pass 
transmembrane proteins including a serine/threonine kinase domain in their 
intracellular part and play a major role in the mediation of TGF-β1 signalling 
pathway (Miyazono et al. 2001). TβRIII is the largest binding protein among 
the three receptors and has the highest affinity to TGF-β1. However, it lacks 





lead to TGF-β1 signalling transduction but play a role in presenting TGF-β1 to 
TβRII (Derynck and Feng 1997; Lopez-Casillas et al. 1993). 
Because TβRIII does not play a role in TGF-β signalling pathway, the current 
study only focused on the detection of TβRI and TβRII. As shown in Figure 
3.29, the mRNA expression of TβRI significantly increased at 3 and 5 days 
post LPS injection compared with normal control. Similar results could also be 
observed in the expression of TβRII. The cellular localization of TβRI and 
TβRII was further observed by the immunofluorescence staining. TβRI 
(Figure 3.30A) and TβRII (Figure 3.30B) were upregulated across 1 day, 3 
and 5 days after LPS stimulation and expressed by OX42
+
 microglia, while 
were undetectable in the normal brain. This finding was consistent with 
another study that activated microglia increased expression of TβRI and TβRII 
following hypoxia exposure (Li et al. 2008). A small part of NG2
+
 cells was 
co-localized with TβRI (Figure 3.31A) and TβRII (Figure 3.31B). 
After that, the expression of TGF-β1 was studied. As shown by the earlier 
results, the mRNA expression of TGF-β1 increased at the same time intervals 
shown in Figure 3.28. This finding is consistent with other studies that TGF-
β1 is present at a low level under the normal brain, but rapidly increases after 
CNS injuries (McTigue et al. 2000; Pratt and McPherson 1997). The cellular 
localization of TGF-β1 was subsequently detected by the double 
immunofluorescence staining. TGF-β1 has been reported to be upregulated in 
astrocytes, microglia and neurons in response to injuries (Wu et al. 2007; Wu 
et al. 2008b). In this LPS focal injury model, TGF-β1 was expressed by 
OX42
+
 microglia at 1 day, 3 and 5 days after LPS induction (Figure 3.32), 
which was consistent with other findings that activated microglia were the 
primary source of TGF-β1 in a MCAO animal model (Doyle et al. 2010; 
Lehrmann et al. 1998). However, the activated NG2
+ 
cells did not express 
TGF-β1, excluding the autocrine way mediated by TGF-β1 (Figure 3.33). 
As shown by the above results, mRNA of TGF-β1 increased and peaked at 3 
days after LPS stimulation and still maintained at a high level at 5 days, 




 cells. Moreover, the TGF-β1 





TβRI and TβRII. Similarly, in a penetrating CNS injury model, mRNA of 
TGF-β1 peaked between 2-3 days and decreased around 7-14 days (Logan et 
al. 1992). As shown in a facial nerve axotomy model, the mRNA of TGF-β1 
increased at 2 days, peaked at 7 days post facial nerve transection and declined 
thereafter (Kiefer et al. 1993). The pattern of changes in expression of TGF-β1 




 as shown by a 
same model studied in our lab (Zhu et al. 2010). Therefore, it might be 
hypothesized that TGF-β1 may be relevant to the occurrence of NG2+/OX42+ 
in the current study. 
4.4.2.2 Direct exogenous injection of TGF-β1 upregulates reactions of 
NG2 expressing cells 
TGF-β1 has been reported to increase the expression of CSPG and is related to 
the formation of glial scar. It induces many of the genes which encode CSPG 
core proteins or enzymes which regulate GAG chain synthesis (Smith and 
Strunz 2005; Wang et al. 2008). Since NG2 protein belongs to the CSPG 
families, it may be possible that TGF-β1 is a potential stimulator which 
induces the upregulation of NG2 protein during the lesions. 
In order to confirm the effects of TGF-β1 on NG2 cells, TGF-β1 was directly 
administrated into the brain cortex and then responses of NG2 expressing cells 
were observed. After TGF-β1 administration, much more NG2+ cells 
assembled at the injury point compared with saline control group in the low 
magnification picture (Figure 3.34A, 20x magnification). NG2
+ 
cells appeared 
more intense in immunofluorescence staining compared with saline control 
group in the higher magnification picture (Figure 3.34B, 40x magnification). 
In addition, the increase in colocalization between NG2 and OX42 has been 
observed in TGF-β1 treatment group (Figure, 3.35). According to 
quantification of cell number, the number of NG2
+





cells was more significant after TGF-β1 treatment compared with saline 
control (Figure 3.34C and 3.35C). These results suggest that TGF-β1 
injection could trigger more microglia to express NG2 protein. Even saline 
injection is usually used as a control for the treatment, it indeed showed some 
effects on the activation of NG2
+ 





possibly come from both the needle track injury and the saline volume 
occupation. The needle may produce a necrotic area in the injury centre and 
induce reactive glial cells surrounding the area (Norton 1999). Studies have 
shown the active responses of NG2 cells bordering the injury site in need track 
injury models (Andersson et al. 2011; Levine 1994). However, even saline 
injection induced activation of NG2 cells, TGF-β1 indeed led to a stronger 
reaction of NG2
+
 cells shown by the increase in cell number of NG2
+





 cells, confirming the stronger effect of TGF-β1. The current 
data is consistent with another study which reports the activation effect of 
TGF-β1 on NG2 cells (Rhodes et al. 2006). 
In order to compare the effect between TGF-β1 injection and LPS injection, 
the number of total NG2
+




 cells was quantified under 
both treatments (Figure 3.36). The results have shown that both the number of 
total NG2
+




cells significantly increased 
at 3 days after TGF-β1 injection compared with LPS treatment. Therefore, the 
results showed that TGF-β1 did indeed have an effect on induction of NG2+ 





cells in comparison to LPS stimulation.  
Because NG2 protein was also induced to be expressed in macrophages as 
shown by other studies (Bu et al. 2001; Fiedorowicz et al. 2008a; Jones et al. 
2002), it may be possible that macrophages became NG2 positive under TGF-
β1 treatment and led to the increase of NG2+ cells. Therefore, the 
immunofluorescence staining between NG2 and ED1 was carried out using the 
sections at 1 day, 3 and 5 days after TGF-β1 injection or saline control 
treatment (Figure 3.37). Similarly to the results of LPS treatment in the 
current study, NG2
+ 
cells were not co-labelled with ED1
+
 macrophages.  
Taken together, the above results have shown that in the LPS induced 
neuroinflammation model, both TGF-β1 and its receptors TβRI and TβRII 
were upregulated, suggesting TGF-β1 signalling pathway was activated. 
Moreover, TGF-β1 was expressed by OX42+ microglia but not NG2+ cells. 
Since OX42
+
 microglia could express both TβRI and TβRII, TGF-β1 may 





binding with its two receptors. In addition, after application of exogenous 
TGF-β1, it induced more number of NG2+/OX42+ cells at 3 days compared 









cells may be possibly induced by 
the TGF-β1. 
4.4.2.3 Inhibition of endogenous TGF-β1 attenuates responses of NG2 
expressing cells 
In order to further confirm endogenous effects of TGF-β1 on NG2 expressing 
cells, the secreted TGF-β1 in this LPS injection model was blocked with TGF-
β1 neutralizing antibody. As shown in Figure 3.38, the responses of NG2+ 
cells decreased after LPS plus anti-TGF-β1 treatment at 1 day, 3 and 5 days 
compared with LPS plus vehicle control. The responses of NG2
+
 cells could 
be seen more clearly in the lower magnification picture (20x magnification, 
Figure 3.39). Compared with saline control group, LPS induced an 
upregulation in expression of NG2 protein at the injury site. However, this 
LPS induced NG2
+
 cell activation could be attenuated after treatment with 





 cells both declined after inhibition of TGF-β1 effects (Figure 
3.40). Therefore, in this study, the activation of NG2
+ 
cells composed of NG2
+
 
microglia and constitutive NG2 cells may be possibly induced by TGF-β1. 
This result is consistent with another study that the expression of NG2 protein 
in the lesion site is reduced after application of decorin, potentially through the 
reduction in effects of TGF-β1 (Davies et al. 2004).  
4.4.2.4 The possible TGF-β1 reactive pathway to influence NG2 
expressing cells 
4.4.2.4.1 Possible effects of TGF-β1 on NG2+ microglia 
TGF-β1 plays a role in glial scar formation and CSPG deposition (Asher et al. 
2000; Logan et al. 1994). The mechanism about how TGF-β1 induces the 
generation of CSPG has been clearly studied on astrocytes (Susarla et al. 
2011). It has been confirmed that the production of CSPG is Smad dependent 





CSPG core proteins were differentially changed after knocking down Smad2 
or Smad3. Additionally, the enzymes for synthesis and modification of GAG 
side chains were also regulated. The role of Smad proteins in generation of 
CSPG was also confirmed in a stab wound in vivo model (Wang et al. 2007). 
The Smad3 null mice exhibited differences in many aspects: fewer NG2 
expressing cells, microglial cells and astrocytes near the injury site, less 
deposition of ECM like fibronectin and laminin, while the levels of TGF-β1 
were not influenced. Therefore, it confirmed that TGF-β1 may possibly induce 
the production of CSPG through Smad2/3 signalling pathway. In this study, 
microglia expressed TGF-β1 receptors as TβRI and TβRII (Figure 3.30). 
Moreover, microglia were induced to expression NG2 protein after LPS 
treatment and this effect was promoted by the direct injection of TGF-β1. 
Thirdly, the NG2 expression was attenuated in microglia after application of 
neutralized TGF-β1 antibody. Fourthly, the number of NG2+/OX42+ cells 
decreased after treatment of anti-TβRII (Figure 3.42), which specifically 
blocked the TGF-β1 Smad2/3 signalling pathway, shown by the decrease in 
phosphorylation of Sma2/3 (Figure 3.41). It may be speculated that the NG2 
protein expressed on microglia was possibly induced by TGF-β1 through the 
Smad2/3 signalling pathway. 
TGF-β1 shows anti-inflammatory effects on microglia and could inhibit 
microglial cytotoxicity on neurons (Qian et al. 2008)  and oligodendrocytes 
(Merrill and Zimmerman 1991). In brain injury models including stab wound 
injury (Lindholm et al. 1992), facial nerve axotomy (Kiefer et al. 1993) and 
ischemic injury model (Doyle et al. 2010; Lehrmann et al. 1998), activated 
microglia/macrophages were the primary source to express TGF-β1 (Kiefer et 
al. 1995). These studies suggest that the expression of TGF-β1 is closely 
linked to the microglial activation. As shown by a knife-cut injury model, 
microglia were co-localized with keratin sulphate and chondroitin sulphate (a 
side chain of NG2 protein). Further in vitro study demonstrated that the 
expression of above proteins on microglia was induced by TGF-β1 through 
upregulation of the main enzymes required for biosynthesis of keratin sulphate 
and chondroitin sulphate (Yin et al. 2009). Together with above results, it 





through microglia might possibly be one of the ways to regulate the extent of 
microglial activation and prevent severe brain tissue damage in the current 
LPS induced inflammatory model. 
4.4.2.4.2 Possible effects of TGF-β1 on the reactions of constitutive NG2 
cells 
As the view in Section 4.4.2.4.1, TGF-β1 showed effects on induction of NG2 
protein on microglia, while the effect of TGF-β1 on constitutive NG2 cells 
may not be ignored. 
In the current study, the reactive responses of NG2
+ 
cells near the injury site 
seem to be consistent with the expression pattern of TGF-β1. Other studies 
have also reported similar cases. Tang et al. (2003) demonstrated that NG2 
protein significantly upregualted at 24 hrs, peaked at 8 days and decreased 
gradually after spinal cord injury (Tang et al. 2003), which is tightly linked 
with another finding showing elevation of TGF-β1 mRNA at 24 hrs and peak 
at 7 days (McTigue et al. 2000). Therefore, it might be assumed that TGF-β1 
induced the increase of NG2 expression upon injuries. Besides from activated 
microglia, the increase of NG2 expression may come from the proliferation of 
NG2 expressing cells or upregulation in secretion of NG2 protein. Because 
BrdU assay showed NG2 cells were not proliferating in current study, 
upregulation of NG2 protein production may be the most possible source. 
Studies have described that TGF-β1 could increase the enzymes required for 
GAG side chains synthesis like CS synthase-1 (Susarla et al. 2011; Yin et al. 
2009). Moreover, TGF-β induced the increased expression of NG2 protein in 
OPCs without influencing their proliferation in an in vitro study (Moransard et 
al. 2011). Rhodes (2006) also found that intracerebral injection of TGF-β1 
induced the increase in NG2 level and hypertrophy of NG2 cells (Rhodes et al. 
2006). Therefore, TGF-β1 may possible regulate the generation of NG2 
protein and activation responses of NG2 cells.   
In this study, NG2 cells expressed two TGF-β1 receptors: TβRI and TβRII. 
TGF-β1 showed effects on the reactive responses of NG2 cells: direct 
injection induced profound activation of NG2 cells; inhibition with neutralised 





Smad2/3 signalling pathway, the activation of NG2 cells was attenuated. It 
may suggest that the reactive responses of NG2 expressing cells could be 
possibly regulated by the TGF-β1 through Smad2/3 signalling pathway. 
According to all above results, it may be concluded that the activation of NG2 
expressing cells was downstream to microglial activation and possibly induced 
by the secreted TGF-β1 from microglia after LPS induction. Since TGF-β1 
has also been reported to be expressed by neurons (Wu et al. 2007) or 
astrocytes (Krohn 1999), it may not be totally possible to exclude their effects 
towards NG2 expressing cells. Future work will be carried out in this aspect in 
order to rule out this possibility. 
4.5 Clinical Significance 
Although NG2 expressing cells are the fourth major glial cells in the CNS, the 
function of NG2 are not clear at present. They are found to become activated 
in many injury models like spinal cord injury (Jones et al. 2002) and stab 
wound injury (Levine 1994; Yokoyama et al. 2006) and neurodegenerative 
diseases like PD model (Kitamura et al. 2010). Considering their active 
responses towards pathological conditions, they may possibly participate in 






 cells may possibly play a beneficial role in the CNS 





 cells is consistent with the progress of neuroinflammation. 
Furthermore, microglia with induced NG2 protein expression have lost 
phagocytic capability. Thirdly, NG2
+
 microglia may decrease expression of 
cytokines and iNOS. Therefore, NG2 expressing cells may possibly attenuate 
neurotoxic effects induced by activated microglia since excessive 
phagocytosis and cytokine expression may lead to the neuronal death 
(Gibbons and Dragunow 2006; Marin-Teva et al. 2011; Neher et al. 2011). 




 cells secreted neuroprotective 
factors in the pathological conditions (Kitamura et al. 2010; Smirkin et al. 




 cells may become a new 





In summary, NG2 expressing cells become activated upon LPS stimulation 
possibly due to TGF-β1 secreted by microglia. While some activated 
microglia gaining expression of NG2 to join the pool of NG2 expressing cells 
in the impaired brain region, they lost certain functions such as phagocytosis 
and cytokine expression. The alteration in the functions of NG2 induced 
microglia may suggest the important function of NG2 expressing cells in the 
neuropathologies. The current study may broaden the knowledge of NG2 
expressing cells and give a new idea to look through the position of NG2 
expressing cells in the cellular network of the CNS, which may help to create 
new therapeutic targets in treatment of nerve injuries and neurological diseases.  























CONCLUSIONS AND FUTURE STUDIES





This study established a LPS induced rat brain inflammation model to observe 
the responses of NG2 expressing cells during neuroinflammatory process.  
It has been observed that after LPS intracerebral injection into the brain cortex, 
NG2 expressing
 
cells in the impaired brain area became activated. 
Morphologically the size of cell bodies became larger; cell processes became 
shorter and thicker; the immunostaining of NG2 became more intense. This 
study also observed that the number of NG2
 
expressing cells increased at the 
injury site. However, BrdU proliferation analysis showed that NG2
 
expressing 
cells were almost BrdU negative, suggesting that the increase in the number of 
NG2
+
 cells may not be due to the proliferation of constitutive NG2 cells and 
may have other cellular sources. Firstly, these activated NG2 expressing cells 
in the vicinity of LPS injection site may not come from the activated 
astrocytes and oligodendrocytes because colocalization was never observed 
between NG2
+
 cells and GFAP
 
labelled astrocytes or CNPase
 
labelled 
oligodendrocytes. Secondly, colocalization between NG2 and OX42 did not 
appear at the beginning of the injury process but gradually and remarkably 
increased at later time intervals. Therefore, NG2 protein should be 
progressively induced in microglia during neuroinflammation. Thirdly, the 
increased part of NG2
+
 cells did not come from PDGFαR+ cells. In conclusion, 
the increase in the number of NG2
+ 
cells may come from the subpopulation of 
activated microglia with induced NG2 expression. It should be more 
scientifically proper to use NG2 expressing cells in the CNS to describe the 
NG2
+
 cells, which are in fact composed of two parts: the constitutive NG2 
cells and microglia with induced NG2 protein expression, i.e., NG2 positive 
microglia or induced NG2 microglia. 
Cytokine network-signalling is one of the important functional components in 
the brain immunity in normal and injured as well as diseased CNS. It is well 
known that microglia are the major immune cell type in the CNS, patrolling 
the surrounding environment. After activation, microglia produce a variety of 
pro-inflammatory factors, anti-inflammatory factors and free radicals. In the 
current study, activated microglia expressed IL-1β, IL-10, IL-6, lix and iNOS 




to participate in the immune defense. However, NG2 expressing cell did not 
express IL-10, IL-6, lix and iNOS. Only IL-1β was colocalized with NG2 
expressing cells. This suggests that the activated NG2 expressing cells present 
differently in cytokine expression in comparison to microglia. To verify the 
mechanism of the differential cytokines expression in NG2 expressing cells, 
further research is required.  
The clearance of regional microenvironment in the CNS is also crucial in 
keeping a healthy and balanced niche for normal or diseased neurons. It is well 
established that microglia patrol the CNS and remove cellular debris away 
from the brain parenchyma (Neumann et al. 2009). In this study, the 
phagocytic ability of activated NG2 expressing cells was investigated with the 





 macrophages at different time points after LPS 
injection, which is consistent with the well accepted view that activated 
microglia have the phagocytic function in the CNS (Aloisi 2001; Gehrmann et 
al. 1995). However, the activated NG2 expressing cells did not engulf any 
latex beads. Therefore, it suggests that the NG2 expressing cells may not 
directly play the scavenger role in brain immunity. In other words, neither 
constitutive NG2 cells nor induced NG2 microglia play a phagocytic role in 
response to neuroinflammatory stimulation. 
Microglia has been found in close contact with NG2 cells under both normal 
and disease conditions (Nishiyama et al. 1997). In addition, the responses of 
NG2 cells could be influenced by the microglial secreted factors shown by in 
vitro studies (Pang et al. 2010; Wu et al. 2010). Therefore, in this in vivo 
study, the responses of NG2 expressing cells were first studied after inhibition 
of the activation of microglia. Results have shown the attenuation of cytokines 
expression and downregulation in the Iba1 expression, the antigen marker of 
activated microglia, both of which confirmed that minocycline had 
successfully blocked activation of microglia. After inhibition of microglia 
activation, the responses of NG2 expressing cells decreased and the number of 
NG2 expressing cells also declined. This result, plus anti-CD11b antibody 
blocking activation of NG2 expressing cells previously observed in this lab, 




suggests that the activation of NG2 expressing cells may be possibly an event 
downstream to microglial activation. 
In order to find out the possible reason, further experiments were conducted. 
The results showed that the expression pattern of TGF-β1 was the most 




 cells and the responses of activated 
constitutive NG2 cells. Furthermore, based on the literature review that TGF-
β1 is related to the deposition of CSPG, therefore TGF-β1 signalling pathway 
was investigated. Firstly, the expression of TGF-β1 and its receptors TβRI and 
TβRII was upregulated, suggesting the TGF-β1 signalling pathway was active 
in this LPS focal injury model. Furthermore, TGF-β1 was localized in 
microglia but not NG2 cells, suggesting it may influence NG2
+
 microglia and 
constitutive NG2 cells through paracrine pathway. After that, TGF-β1 was 
directly injected into the brain cortex at the same site as LPS injection. Results 
have shown that exogenous injection of TGF-β1 could induce the activation of 
NG2 expressing cells and it has a stronger effect compared with LPS. 
Subsequent results have confirmed the effects of TGF-β1 by its neutralised 
antibody. After that, results showed that the responses of NG2 expressing cells 




 cells decreased after 
treatment with anti-TGF-β1 neutralized antibody through the Smad2/3 
signalling pathway. Therefore, this study confirmed that the activation of both 
NG2
+
 microglia and constitutive NG2 cells may be possibly induced by the 
TGF-β1 secreted by microglia. 
5.2 Future studies 
In order to fully investigate the properties and functions of NG2 expressing 
cells and especially NG2
+
 microglia, further studies could be carried out from 
below aspects: 













from LPS induced inflammation model with laser microdissection techniques. 
 Extract mRNA from the isolated cells and find out whether they could 
express cytokines or neuroprotective factors. 




 Compare whether there are any differences in expression of cytokines 




















 Confirm the expression of two TGF-β1 receptors: TβRI and TβRII. 
 Further study the TGF-β1 signalling pathway to induced NG2 protein 
expression in microglia: Smad2/3 signalling pathway; enzymes 
required for biosynthesis of chondroitin sulphate side chain. 






3. Investigate the function of NG2 expressing cells using the NG2 knockout 
mice in the same LPS focal injury model. 
 Find out if there are any changes on inflammation progress like the 
cytokine expression. 
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